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Thesis summary 
 
Diabetes and its complications, such as hypertension and diabetic cardiomyopathy, increase 
the risk of morbidity and mortality in human populations. Despite decades of research, the 
full aetiology of these complications still remains unclear. Strong evidence suggests there is 
dysfunction in the autonomic neurons system, including abnormal activity in the sympathetic 
nervous system and baroreflex impairment, which may contribute to the development of 
cardiovascular complications in diabetes; however, the mechanisms behind these 
abnormalities in diabetes are not well understood. Autonomic nuclei within the central 
nervous system (CNS) that are involved in the control of sympathetic nerve activity, the 
sensitivity of the baroreflex and the cardiovascular system are the paraventricular nucleus of 
the hypothalamus (PVN), the rostral ventrolateral medulla (RVLM) and the nucleus tractus 
solitarius (NTS). Inflammation and oxidative stress in these centres have been identified to 
contribute to the hyperactivity of the sympathetic nerves and baroreflex dysfunction in other 
diseases, but whether this true in diabetes is not clear. Microglia and astrocytes are the 
resident immune inflammatory cells within the CNS. Once they become activated in response 
to various stimuli, they can release pro-inflammatory molecules and reactive oxygen species; 
however, the role of these cells in the development of diabetic cardiovascular complications 
remains unclear. Drinking 1% NaCl has been shown to have biphasic effects on the 
development of diabetic complications in animals, but whether these effects are mediated via 
influencing brain inflammation has not been investigated. In addition, little is known about 
the influence of antioxidants and high fat feeding on microglial activation in central 
autonomic centres in diabetic animals. Thus, the aim of this thesis was to identify whether 
inflammation occurs in central autonomic centres in different species and models of diabetes 
and to explore the consequences of neuroinflammation in these animals. 
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In chapter 3, the effect of the inhibition of microglia in the PVN on blood pressure and heart 
rate in long-term (8 weeks) STZ-diabetic rats was investigated. Microglia and astrocytes were 
activated in the PVN in STZ diabetic rats. Pro-inflammatory cytokines released from both 
activated microglia and astrocytes have been implicated in spinal neuronal hyperexcitability. 
This suggested that the activation of microglia and astrocytes may be important for mediating 
inflammation in the PVN in diabetic rats, which may cause neuronal hyperactivity and then 
lead to increased sympathetic activity. Minocycline treatment inhibited PVN microglial 
activation but not the activation of astrocytes, suggesting that microglial activation was not 
responsible for astrocyte activation; however, in this study, the consequence of the inhibition 
of microglial activation could not be tested for several reasons, including morbidity and the 
lack of hypertension in STZ diabetic animals. Therefore, an alternative approach to this study 
was justified.  
In most studies on long-term (6-8 weeks) STZ diabetic rats, unchanged or lowered blood 
pressure has been observed, which is consistent with the data presented in chapter 3. 
Drinking 1% NaCl, which may prevent dehydration, causes hypertension in diabetic rats 
within 2 weeks after STZ treatment, but how this occurs and whether brain inflammation 
contributes to this hypertension has not been investigated. Therefore, in chapter 4, we 
investigated the effects of 1% NaCl intake on blood pressure, baroreflex sensitivity and 
inflammation in the PVN, NTS and RVLM in 2-week STZ diabetic rats. In addition, we 
investigated whether the inhibition of microglia in the PVN can prevent hypertension in STZ 
diabetic rats given 1% NaCl. Diabetic rats given saline exhibited hypertension, dysfunction of 
the bradycardic baroreflex and signs of normalised blood volume in comparison with the 
control rats and the diabetic rats that drank water. Diabetic rats that drank 1% NaCl also 
showed increased microglial activation in the PVN, NTS and RVLM. The inhibition of 
activated microglia in the PVN via administering ICV minocycline prevented the 
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hypertension seen in diabetic rats given 1% NaCl, strongly suggesting that microglial 
activation plays an important role in the generation of hypertension in these animals. Despite 
this, the possibility that increased blood volume and/or baroreflex dysfunction are 
mechanisms by which 1% NaCl intake induces hypertension in STZ diabetic rats cannot be 
ruled out.  
While it is clear from these studies that 1% NaCl intake can reduce baroreflex sensitivity in 
2-week STZ diabetic rats, another study reported that the prolonged drinking of 1% NaCl 
causes improvement in ex vivo cardiac function in 6-week STZ diabetic rats. Whether 
treatment with 1% NaCl for longer periods produces similar beneficial effects on the 
baroreflex sensitivity is not known. Therefore, in chapter 5, we aimed to investigate the 
effects of 1% NaCl on the baroreflex sensitivity and to determine whether 1% NaCl intake 
influences inflammation cardiovascular centres in longer term (6 weeks) STZ diabetic rats. 
The diabetic rats showed dysfunction in the barorflex sensitivity. This dysfunction was 
associated with increased microglial activation in the NTS and PVN. Drinking 1% NaCl for 6 
weeks restored the function of bradycardic baroreflex and also reduced the activation of 
microglia and neurons in the NTS in these animals. The data suggest that microglial 
activation in the NTS may be responsible for the baroreflex dysfunction seen in 6-week STZ 
diabetic animals. The data also suggest that drinking 1% NaCl can prevent cardiovascular 
complications through a reduction in microglial activation in longer term STZ diabetic rats.  
In addition to hypertension and the baroreflex dysfunction, cardiomyopathy is a common 
form of diabetic complication and can occur independently of hypertension in diabetes. There 
is evidence that inflammation in the PVN is a potential contributing factor to the development 
of cardiomyopathy in other diseases. In chapters 3 and 5, evidence is provided that 
microglial cells are activated in the PVN in 6-8 STZ diabetic rats, but the role of these cells in 
diabetic cardiomyopathy has not been investigated. Therefore, in chapter 6, we aimed to 
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investigate the structural and functional parameters of the left ventricle in diabetic rats at 6 
weeks following STZ injection and to determine whether the inhibition of microglial 
activation in the PVN could reverse any of the changes observed. Six-week STZ diabetic rats 
showed clear left ventricular dysfunction, including elevated end diastolic pressure, an 
increased internal diameter in the systole and diastole and a decreased E/A ratio when 
compared with the control rats. These animals also displayed marked activation of microglia 
and neurons in the PVN. Inhibition of microglial activation via administering ICV 
minocycline reduced the PVN neuronal activity and significantly normalised the left 
ventricular function. This study suggests that microglial activation in the PVN leads to PVN 
neuronal excitation in STZ diabetic rats. The data also confirm our proposal that microglial 
activation in the PVN plays a critical role in the pathogenesis of diabetic complications.  
Drinking 1% NaCl for 6 weeks in STZ diabetic rats reduces cardiovascular complications, 
but the exact mechanism is still unclear. The data from chapter 6 indicated that microglial 
activation in the PVN contributes to cardiac dysfunction in STZ diabetic rats; however, 
whether the beneficial effects of the prolonged drinking of 1% NaCl on the cardiac function 
are mediated by reducing the inflammatory response is not known. Therefore, in chapter 7, 
we investigated the effects of 1% NaCl on the cardiac function in vivo and whether 1% NaCl 
intake influences microglial activation in 6-week STZ diabetic rats. Drinking 1% NaCl 
restored elevated end diastolic pressure but not the other parameters of the left ventricle in 
these animals. The 1% NaCl intake also reduced the activation of microglia and neurons in 
the NTS and PVN when compared to the STZ diabetic rats given tap water. When the drug 
minocycline was accompanied by prolonged 1% NaCl intake, the STZ diabetic rats showed a 
further improvement in cardiac performance and a reduction in microglial and neuronal 
activation in PVN compared with STZ diabetic rats given saline alone. These results 
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indicated that changes in cardiac function are paralleled by the level of microglial activation 
in the PVN observed in diabetic animals.  
Because the mouse is the most suitable animal model for genetic manipulations, it was 
important to examine whether microglia and neurons are also activated in the PVN in STZ 
diabetic mice as well as the time period of any activation. Hydrogen sulphide (H2S) has been 
shown to inhibit microglial activation in vitro experiments, but the effect of the systemic 
infusion of H2S on PVN function in STZ mice has not been investigated. Therefore, in 
chapter 8, we examined the dose and time dependence of microglial and neuronal activation 
and the effects of H2S in STZ treated mice at 7 weeks. The microglia were activated in the 
PVN in STZ diabetic mice at 16 weeks after STZ injection but not at the 7-week time period 
compared to the control. In diabetic mice treated with a low dose of STZ, the microglia in the 
PVN were not activated at the 10-week time period; however, the PVN neuron activation was 
observed in STZ diabetic mice at all time periods as well as in diabetic mice treated with a 
low dose of STZ, suggesting neuronal activation precedes microglial activity. H2S treatment 
attenuated the increase in neuronal activation in the PVN and prevented dehydration at 7 
weeks following STZ injections. These findings suggest that H2S treatment may play an 
important role in regulating kidney and PVN neuron function in diabetes.  
A high fat diet is a major contributing factor in the pathogenesis of type 2 diabetes, which is 
the most common form of diabetes in humans. Whether PVN inflammation occurs in models 
of type II diabetes requires investigation. Thus, in chapter 8, we also examined the PVN 
inflammation in mice treated with a low dose of STZ and high fat feeding. No significant 
difference was observed in the percentage of microglia activated in the PVN in mice treated 
with STZ and high fat feeding when compared to the control; however, the neuronal 
activation was significantly increased in the PVN in these mice. The addition of a high fat 
diet to the STZ treatment attenuated the increase in neuronal activation in the PVN. These 
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findings suggest that the activation of microglia in the PVN does not occur in all animal 
models of diabetes.  
In conclusion, microglial activation occurs in the PVN in long-term STZ-induced diabetic 
rats and mice but not in a mouse model of type II diabetes. Although the cause is not fully 
known, microglial activation in the PVN plays an important role in the pathogenesis of 
diabetic complications. While 1% NaCl prevents dehydration in short and long-term STZ 
diabetic rats, it has a biphasic effect on diabetic complications. This effect was mediated, at 
least in part, by changes in neuroinflammation. The beneficial effects of hydrogen sulphide 
on PVN function may be mediated via reducing neuroinflammation and/or oxidative stress in 
diabetes. Thus, new therapeutic approaches aimed to target neuroinflammation may be of 
clinical importance in preventing diabetic cardiovascular complications in humans.   
  
  Page | VIII 
 
 
 
Declaration 
 
I certify that, except where due acknowledgement has been made, the work is that of the 
author alone; the work has not been submitted previously, in whole or in part, to qualify for 
any other academic award; the content of the thesis is the result of work that has been carried 
out since the official commencement date of the approved research program; any editorial 
work, paid or unpaid, carried out by a third party is acknowledged; and ethics procedures and 
guidelines have been followed. 
 
 
 
 
 
 
Emad Alahmadi  
December 2015 
 
 
  Page | IX 
 
 
 
TO My father, Khalid Alahmadi
  Page | X 
 
 
 
Acknowledgments 
 
My warmest thanks go to my primary supervisor, Dr Martin Stebbing for the opportunity to 
complete my PhD in his laboratory and for his teaching, guidance, support, encouragement, 
advice and patience throughout my PhD programme.   
I want to express my gratitude to my second supervisor, Prof. Emilio Badoer for his valuable 
directions and technical assistance in surgical procedures.   
I would like to acknowledge all of the members of the neuropharmacology and 
neuroinflammatory research group for their support and motivation, especially Markus and 
Eloise.  
I would also like to thank my friend, Mohammad Makkawi for his kindness and support during 
the stressful times.  
Finally, I deeply thank my parents, Khalid and Hnnan Alahmadi, and dear wife, Nujoud 
Aahmadi, for their support.  
 
  Page | XI 
 
 
 
Table of Contents 
 
Thesis summary ........................................................................................................................ II 
Declaration ............................................................................................................................ VIII 
Acknowledgments..................................................................................................................... X 
Table of Contents ..................................................................................................................... XI 
List of Figures ....................................................................................................................... XVI 
Abbreviations ......................................................................................................................... XX 
Publications and Communications ...................................................................................... XXII 
Chapter One: Literature Review ................................................................................................ 1 
 Overview .......................................................................................................................... 2 1.1
 Diabetes mellitus .............................................................................................................. 5 1.2
 Use of streptozotocin‐induced diabetic models to study complications .................... 6 1.2.1
 Cardiovascular complications in diabetes ........................................................................ 8 1.3
 Microvascular complications ..................................................................................... 8 1.3.1
 Macrovascular complications .................................................................................... 9 1.3.2
 Diabetic cardiomyopathy ......................................................................................... 10 1.3.3
 Blood pressure ......................................................................................................... 11 1.3.4
 Salt-sensitivity of arterial blood pressure in diabetes .............................................. 12 1.3.5
 Diabetic cardiovascular complications: the role of sympathetic nerve activity ...... 14 1.3.6
 Cardiovascular centers in the CNS................................................................................. 17 1.4
 The paraventricular nucleus (PVN) ......................................................................... 17 1.4.1
 Nucleus tractus solitarius (NTS).............................................................................. 20 1.4.2
 Rostral Ventrolateral Medulla (RVLM) .................................................................. 22 1.4.3
 The role of microglia in inflammation of the CNS ........................................................ 23 1.5
 The origin of microglia ............................................................................................ 23 1.5.1
 Morphology and function of microglia ................................................................... 24 1.5.2
 Table of Contents Page | XII 
 
 
 
 Microglial activation: the dual ability of neuroprotection and neurotoxicity .......... 26 1.5.3
 Consequences of microglial activation in the CNS in diabetes ............................... 28 1.5.4
 Astrocytes another cell types involved in neuroinflammation ....................................... 30 1.6
 Astrocytes are key players in CNS immunity ......................................................... 31 1.6.1
 The role of activated astrocytes in pathological conditions .................................... 32 1.6.2
 Inflammation in cardiovascular centres and its role in regulating sympathetic activity 1.7
and the cardiovascular system .............................................................................................. 35 
 Rationale and research questions ................................................................................... 38 1.8
 Project specific aims ................................................................................................ 40 1.8.1
Chapter Two: Materials and Methods ...................................................................................... 42 
 Animals .......................................................................................................................... 43 2.1
 Animals models of diabetes ........................................................................................... 43 2.2
 STZ / NaCl treatment .............................................................................................. 43 2.2.1
 STZ/high fat diet treatment...................................................................................... 44 2.2.2
 STZ/ NaHS treatment .............................................................................................. 44 2.2.3
 Surgical procedure.......................................................................................................... 45 2.3
 Blood Pressure and heart rate recording under anesthesia ...................................... 45 2.3.1
 Conscious blood pressure recording via tail cuff .................................................... 46 2.3.2
 Baroreceptor reflex testing ...................................................................................... 46 2.3.3
 Implantation of brain infusion catheters and osmotic pumps .................................. 47 2.3.4
 Implantation of telemetric blood pressure monitoring devices ............................... 47 2.3.5
 Echocardiographic measurements ........................................................................... 48 2.3.6
 Ventricular hemodynamics ...................................................................................... 49 2.3.7
 Blood collection ............................................................................................................. 52 2.4
 Tissue collection ............................................................................................................. 52 2.5
 Perfusion .................................................................................................................. 52 2.5.1
 Brain collection........................................................................................................ 52 2.5.2
 Cryostat sectioning .................................................................................................. 53 2.5.3
 Table of Contents Page | XIII 
 
 
 
 Immunohistochemistry ................................................................................................... 53 2.6
 Quantification and morphological analysis .................................................................... 55 2.7
 Statistical analysis .......................................................................................................... 55 2.8
Chapter Three: Neuroinflammation in the Paraventricular Nucleus in STZ Diabetic Rats .... 57 
 Introduction .................................................................................................................... 58 3.1
 Results ............................................................................................................................ 61 3.2
 Body weight and blood glucose measurements ....................................................... 61 3.2.1
 Effect of minocycline on the mean arterial pressure and heart rate of diabetic rats 63 3.2.2
 Effect of minocycline on microglial activation in the paraventricular nucleus of 3.2.3
diabetic rats ....................................................................................................................... 65 
 Astrocyte activation in the paraventricular nucleus of diabetic rats ........................ 69 3.2.4
 Discussion ...................................................................................................................... 73 3.3
 Conclusion ...................................................................................................................... 75 3.4
Chapter Four: Drinking 1% NaCl for 2 Weeks Enhances Inflammation in the Cardiovascular 
Control Centers of the Brain in STZ Diabetic Rats ................................................................. 77 
 Introduction .................................................................................................................... 78 4.1
 Results ............................................................................................................................ 81 4.2
 Effect of 2 weeks 1% NaCl intake on general features of diabetic rats .................. 81 4.2.1
 Measurement of baroreflex-mediated bradycardia in diabetic rats ......................... 85 4.2.2
 OX-42 Immunohistochemistry in cardiovascular centres in diabetic rats ............... 89 4.2.3
 C-fos immunoreactivity in cardiovascular centres in diabetic rats .......................... 96 4.2.4
 Effect of saline and minocycline treatment on blood pressure in awake diabetic 4.2.5
rats. ................................................................................................................................... 99 
 Discussion .................................................................................................................... 101 4.3
 Conclusion .................................................................................................................... 107 4.4
Chapter Five: Drinking 1% NaCl for 6 Weeks Increases Baroreflex Sensitivity in STZ 
Diabetic Rats .......................................................................................................................... 109 
 Introduction .................................................................................................................. 110 5.1
 Results .......................................................................................................................... 113 5.2
 Table of Contents Page | XIV 
 
 
 
 Effect of 6 weeks saline intake on general features of diabetic rats ...................... 113 5.2.1
 Measurement of baroreflex-mediated bradycardia in diabetic rats ....................... 116 5.2.2
 OX-42 Immunohistochemistry in cardiovascular centres in diabetic rats ............. 119 5.2.3
 C-fos immunoreactivity in cardiovascular centres in diabetic rats ........................ 125 5.2.4
 Discussion .................................................................................................................... 130 5.3
 Conclusion .................................................................................................................... 135 5.4
Chapter Six: Inhibition of Microglial Activation Improves Cardiac Dysfunction in STZ 
Diabetic Rats .......................................................................................................................... 136 
 Introduction .................................................................................................................. 137 6.1
 Results .......................................................................................................................... 140 6.2
 Effect of minocycline on general features of diabetic rats .................................... 140 6.2.1
 Echocardiographic measurements in diabetic rats ................................................. 145 6.2.2
 Measurement of haemodynamic parameters in diabetic rats ................................. 147 6.2.3
 OX-42 and C-fos Immunohistochemistry in the paraventricular nucleus in diabetic 6.2.4
rats .................................................................................................................................. 149 
 Discussion .................................................................................................................... 155 6.3
 Conclusion .................................................................................................................... 160 6.4
Chapter Seven: Drinking 1% NaCl for 6 Weeks Improves Cardiac Dysfunction in STZ 
Diabetic Rats: The Role of Neuroinflammation .................................................................... 162 
 Introduction .................................................................................................................. 163 7.1
 Results .......................................................................................................................... 166 7.2
 Effect of saline plus or minus minocycline on general features of diabetic rats ... 166 7.2.1
 Echocardiographic measurements in diabetic rats ................................................. 171 7.2.2
 Measurement of haemodynamic parameters in diabetic rats ................................. 173 7.2.3
 OX-42 and C-fos Immunohistochemistry in the paraventricular nucleus in diabetic 7.2.4
rats .................................................................................................................................. 175 
 Discussion .................................................................................................................... 182 7.3
 Conclusion .................................................................................................................... 187 7.4
 Table of Contents Page | XV 
 
 
 
Chapter Eight: Neuronal and Microglial Activation in the Cardiovascular Centers of Diabetic 
Mice: Effect of a High-fat diet and an Antioxidant ............................................................... 188 
 Introduction .................................................................................................................. 189 8.1
 Results .......................................................................................................................... 192 8.2
 Body weights and blood glucose of STZ diabetic mice ........................................ 192 8.2.1
 Plasma osmolarity and haematocrit in STZ diabetic mice .................................... 196 8.2.2
 CD11b and C-fos Immunohistochemistry in the paraventricular nucleus in diabetic 8.2.3
mice ................................................................................................................................ 198 
 Discussion .................................................................................................................... 213 8.3
 Conclusion .................................................................................................................... 217 8.4
Chapter Nine: General Discussion ......................................................................................... 218 
 Role of neuroinflammation in deleterious cardiovascular complications in diabetes .. 220 9.1
 The effect of drinking 1% NaCl on cardiovascular parameters and CNS inflammation9.2
 ............................................................................................................................................ 223 
 Mechanism of microglial activation in diabetes .......................................................... 225 9.3
 Clinical implications .................................................................................................... 228 9.4
 Future directions ........................................................................................................... 230 9.5
 Conclusion .................................................................................................................... 232 9.6
Chapter Ten: References ........................................................................................................ 233 
  Page | XVI 
 
 
 
List of Figures 
  
Figure 1-1. Diagrams illustrating the PVN neuron pathways involved in the control of 
sympathetic activity. ................................................................................................................................ 19 
Figure 1-2. Diagram illustrating the neural pathways involved in the baroreceptor reflex.............. 21 
Figure 2-1. Echocardiogram- representative M-mode image and measurements of left ventricular 
in control animals .................................................................................................................................... 49 
Figure 2-2. Functional echocardiography: apical four-chamber view pulsed-wave Doppler 
displaing E and A wave in control animals ........................................................................................... 50 
Figure 3-1. Effect of minocycline treatment on body weight and blood glucose of diabetic rat……62 
Figure 3-2. Effect of minocycline treatment on cardiovascular parameters in diabetic rats............ 64 
Figure 3-3. Morphology of microglia in STZ diabetic rats. ................................................................. 67 
Figure 3-4. Effect of minocycline on microglial activation in the paraventricular nucleus of 
diabetic rats. ..............................................................................................................................................68 
Figure 3-5. Morphology of astrocytes in STZ diabetic rats. ................................................................ 71 
Figure 3-6. Astrocytes activation in the paraventricular nucleus in diabetic rats…..........................72 
Figure 4-1. Effect of 2 weeks saline treatment on body weight, blood glucose and fluid intake of 
diabetic rats. ............................................................................................................................................. 83 
Figure 4-2. Effect of 2 weeks saline treatment on plasma osmolarity and haemoglobin in diabetic 
rats. ........................................................................................................................................................... 84 
Figure 4-3. Effect of 2 weeks saline treatment on cardiovascular parameters in diabetic rats 
under anaesthesia. ................................................................................................................................... 86 
Figure 4-4. Measurement of baroreflex-mediated bradycardia in diabetic rats. .............................. 87 
Figure 4-5. Cardiovascular responses to phenylephrine in diabetic rats. .......................................... 88 
Figure 4-6. OX-42 Immunohistochemistry in the PVN in diabetic rats. ............................................ 91 
Figure 4-7. OX-42 Immunohistochemistry in the NTS in diabetic rats. ............................................ 92 
Figure 4-8. OX-42 Immunohistochemistry in the RVLM in diabetic rats. ........................................ 93 
Figure 4-9. Microglial activation in cardiovascular centres of the brain of 2 week saline-treated 
  Page | XVII 
 
 
 
diabetic rats. ............................................................................................................................................. 94 
Figure 4-10. Microglia exhibit shorter processes in cardiovascular centres of the brain of 2 week 
saline-treated diabetic rats....................................................................................................................... 95 
Figure 4-11. Fos activity in the PVN in diabetic rats………………………………………………98 
Figure 4-12. Fos-IR immunoreactivity indicating activated neurons in cardiovascular centres of 
the brain in diabetic rats. ........................................................................................................................ 99 
Figure 4-13. Microglial and neuronal activation in the parvocellular and magnocellular portions 
of the paraventricular nucleus of diabetic rats. .................................................................................. 100 
Figure 4-14. Effect of minocycline treatment on the development of hypertension in diabetic rats 
treated with saline for 2 weeks.............................................................................................................. 102 
Figure 5-1. Effect of 6 weeks saline treatment on body weight, blood glucose and fluid intake of 
diabetic rats. ........................................................................................................................................... 117 
Figure 5-2. Effect of 6 weeks saline treatment on cardiovascular parameters in diabetic rats 
under anaesthesia. ................................................................................................................................. 119 
Figure 5-3. Cardiovascular responses to phenylephrine in diabetic rats. ........................................ 120 
Figure 5-4. OX-42 Immunohistochemistry in the PVN in diabetic rats. .......................................... 124 
Figure 5-5. OX-42 Immunohistochemistry in the NTS in diabetic rats. .......................................... 125 
Figure 5-6. Microglial activation in cardiovascular centres of the brain of 6 weeks saline-treated 
diabetic rats. ........................................................................................................................................... 126 
Figure 5-7. Fos activity in the PVN in diabetic rats. .......................................................................... 129 
Figure 5-8. Fos-IR immunoreactivity indicating activated neurons in cardiovascular centres of 
the brain in diabetic rats. ...................................................................................................................... 130 
Figure 5-9. Microglial and neuronal activation in the parvocellular and magnocellular portions of 
the paraventricular nucleus of diabetic rats. ...................................................................................... 131 
Figure 6-1. Effect of minocycline treatment on body weight, blood glucose and fluid intake of 
diabetic rats. ...........................................................................................................................................144 
Figure 6-2. Effect of minocycline treatment on heart weight and kidney weight in diabetic rats. 
.................................................................................................................................................................. 145 
Figure 6-3. Effect of minocycline treatment on plasma osmolarity and haemoglobin in diabetic 
  Page | XVIII 
 
 
 
rats. ......................................................................................................................................................... 146 
Figure 6-4. Effect of minocycline treatment on echocardiographic measurements in diabetic rats. 
...................................................................................................................................................................148 
Figure 6-5. Effect of minocycline treatment on hemodynamic parameters in diabetic rats. ......... 150 
Figure 6-6. Morphology of microglia in STZ diabetic rats. ............................................................... 153 
Figure 6-7. Fos activity in the PVN in diabetic rats. .......................................................................... 155 
Figure 6-8. Effect of minocycline treatment on microglial and neuronal activation in the 
paraventricular nucleus of diabetic rats. ............................................................................................. 156 
Figure 7-1. Effect of saline plus or minus minocycline treatment on body weight, blood glucose 
and fluid intake of diabetic rats. ........................................................................................................... 170 
Figure 7-2. Effect of saline plus or minus minocycline treatment on heart weight and kidney 
weight in diabetic rats. .......................................................................................................................... 171 
Figure 7-3. Effect of saline plus or minus minocycline treatment on plasma osmolarity and 
haemoglobin in diabetic rats. ................................................................................................................ 172 
Figure 7-4. Effect of saline plus or minus minocycline treatment on echocardiographic 
measurements in diabetic rats. ............................................................................................................. 174 
Figure 7-5. Effect of saline plus or minus minocycline treatment on hemodynamic parameters in 
diabetic rats. ........................................................................................................................................... 176 
Figure 7-6. Morphology of microglia in STZ diabetic rats. ...............................................................180 
Figure 7-7. Fos activity in the PVN in diabetic rats. ..........................................................................182 
Figure 7-8. Effect of saline plus or minus minocycline treatment on microglial and neuronal 
activation in the paraventricular nucleus of diabetic rats.................................................................. 183 
Figure 8-1. Body weights and blood glucose of STZ diabetic mice. .................................................. 197 
Figure 8-2. Plasma osmolarity and haematocrit concentration in STZ diabetic mice. ................... 199 
Figure 8-3. Morphology of microglia in STZ mice at 7 weeks after STZ treatment. ...................... 203 
Figure 8-4. Fos activity in STZ mice at 7 weeks after STZ treatment............................................... 205 
Figure 8-5. Microglial and neuronal activation in the paraventricular nucleus of STZ mice at 7 
weeks after STZ treatment. .................................................................................................................. 206 
Figure 8-6. Morphology of microglia in STZ mice at 16 weeks after STZ treatment. .................... 207 
  Page | XIX 
 
 
 
Figure 8-7. Fos activity in STZ mice at 16 weeks after STZ treatment............................................. 208 
Figure 8-8. Microglial and neuronal activation in the paraventricular nucleus of STZ mice at 16 
weeks after STZ treatment. .................................................................................................................. 209 
Figure 8-9. Morphology of microglia in STZ mice and STZ + Fat Fed mice at 10 weeks 
following STZ treatment. ...................................................................................................................... 211 
Figure 8-10. Fos activity in STZ mice and STZ + Fat Fed mice at 10 weeks following STZ 
treatment. ............................................................................................................................................... 213 
Figure 8-11. Microglial and neuronal activation in the paraventricular nucleus of STZ mice and 
STZ + Fat Fed mice at 10 weeks following STZ treatment. ...............................................................214 
  Page | XX 
 
 
 
Abbreviations 
 
Ang II                            Angiotensin II 
 
Arc Arcuate nucleus 
 
ATP         Adenosine-5'-triphosphate 
 
BDNF Brain derived neurotrophic factor 
 
BBB    Blood–brain barrier 
 
CNS Central nervous system   
 
GABA γ-aminobutyric acid 
 
GFAP Filament / Fibrillary Acidic Protein 
 
H2O2 Hydrogen peroxide 
 
H2S Hydrogen sulfide 
 
I.C.V.                Intracerebroventricular 
 
IL-6 
 
Interleukin-6 
 
IL-10 Interleukin-10 
 
IL-1β Interleukin-1 beta               
 
IR   Immunoreactive 
 
 Abbreviations Page | XXI 
 
 
 
LPS   Lipopolysaccharides 
 
NF-kB Nuclear factor-kappaB 
 
nNOS Neuronal nitric oxide synthase 
 
NO Nitric oxide 
 
NTS Nucleus tractus solitarius 
 
PBS   Phosphate buffered saline 
 
PVN Paraventricular hypothalamic nucleus 
 
ROS Reactive oxygen species 
 
RVLM   Rostoventral medulla 
 
SD Sprague Dawley 
 
SON Supraoptic nucleus 
 
STZ Streptozotocin 
 
TNF- α  Tumor necrotic factor-alpha 
 
 
  Page | XXII 
 
 
 
Publications and Communications 
 
Journal publications 
 
Rana I, Badoer E, Alahmadi E, Leo CH, Woodman OL, Stebbing MJ (2014). Microglia are 
selectively activated in endocrine and cardiovascular control centres in streptozotocin-
induced diabetic rats. Journal of neuroendocrinology; 26(7):413-25. 
 
Alahmadi E, Badoer E, Woodman OL, Stebbing MJ. Drinking 1% saline causes 
hypertension in STZ-treated rats via increased microglial activation in CNS cardiovascular 
control centres. Hypertension, 2015. (In submission). 
 
Abstracts presented at meetings 
 
E. Alahmadi, E. Badoer, and M. J. Stebbing (2013) Dietary salt enhances inflammation in 
the cardiovascular centres of diabetic rats. Proceedings of Central Cardiovascular & 
Respiratory Control: Future Directions.  
 
E. Alahmadi, J. Ye, E. Badoer, M. Stebbing (2014)
 
Low dose STZ combined with high fat 
feeding does not cause activation of microglia astrocytes or neurons in the hypothalamus in 
mice. Proceedings of Victorian Obesity Consortium
 
 
E. Alahmadi, G. Yildiz, J. Hart, and M. Stebbing (2014)
 
Relationship between microglial 
activation, neuronal activation and dehydration in diabetes – role of antioxidant. Proceedings 
of Higher Degree Research Student Conference at RMIT.  
 
E.Alahmadi, E. Badoer, OL. Woodman, MJ. Stebbing (2015) Drinking 1% saline causes 
hypertension in STZ-treated rats via increased microglial activation in CNS cardiovascular 
control centres. Proceedings of High Blood Pressure Research Council of Australia. 
 
 
  
 
Chapter One: Literature Review 
 
Chapter One: Literature Review Page | 2 
 
 
 Overview 1.1
Diabetes mellitus is a chronic disease that affects around 382 million people worldwide both 
in developing and developed countries, according to the International Diabetes Federation 
(2013). Diabetes has been described as a lethal disease because it is estimated that 2.9 million 
deaths around the world in 2000 were attributable to diabetes, which is equivalent to 5.2% of 
all deaths (Roglic et al., 2005). In fact, the death rates among diabetic patients are two times 
higher compared to people without diabetes (Deshpande et al., 2008). Indeed, the life 
expectancy in people with diabetes is reduced by 5 to 10 years (Marshall & Flyvbjerg, 2006). 
Diabetes mellitus related cardiovascular complications are a major cause of morbidity and 
mortality. For example, in the United States, approximately 65% of deaths from diabetes are 
attributed to cardiovascular disease (Geiss LS, 1995; Engelgau et al., 2004). Because of the 
high rate of death caused by diabetic cardiovascular complications, preventing these 
complications is an important objective.  
During the last decade, improvements in insulin replacement treatment have caused the 
greatest change in diabetes therapy for type 1 and 2 diabetic patients. Insulin treatment in 
diabetic patients reduces injury to numerous internal organ systems via controlling elevated 
blood glucose concentrations. Well-designed clinical prospective studies have shown a 
reduction in the onset and progression of diabetic neuropathy, nephropathy and retinopathy in 
people with type 1 diabetes mellitus following intensive insulin treatment (Control & Group, 
1993; Albers et al., 1995; DiabetesControl & Group, 1998). Insulin therapy has also been 
shown to reduce some but not all cardiovascular diseases in people with type 1 diabetes 
(Group, 1995). Thus, treating diabetic patients with insulin does reduce and/or delay some 
diabetic complications but does not prevent the development and progression of these 
complications. Indeed, it appears that current insulin therapy is not enough to treat diabetes 
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and its complications in the long term, and a better understanding of the mechanisms of 
deleterious cardiovascular complications in diabetes is needed.  
There is increasing evidence suggesting that an abnormal activation of the sympathetic 
nervous system contributes to the development of diabetic complications, including 
hypertension as well as cardiovascular and renal dysfunction (Perin et al., 2001). For 
instance, the blocking activity of the sympathetic nervous system has been shown to reduce 
morbidity and mortality in patients with heart failure and diabetes (Shekelle et al., 2003). The 
activity of sympathetic nerves is regulated by autonomic neurons within the central nervous 
system (CNS), including the paraventricular nucleus of the hypothalamus (PVN), the rostral 
ventrolateral medulla (RVLM) and the nucleus tractus solitarius (NTS). As such, pathological 
changes in these nuclei may result in hyperactivity of the sympathetic nerves, but the detailed 
mechanisms that underlie the dysfunction of these nuclei in diabetes are poorly understood. 
Neuroinflammation in CNS cardiovascular control regions has been suggested to contribute 
to the hyperactivity of sympathetic nerves in heart failure (Kang et al., 2009a; Felder, 2010) 
and hypertension (Kang et al., 2009b; Colombari et al., 2010; Shi et al., 2010a; Waki et al., 
2010), both of which are consequences of diabetes. The resident immune cells, which 
mediate inflammation within the CNS when activated, are called microglia. Microglial 
activation in the PVN is associated with angiotensin II-induced hypertension, and the 
pharmacological inhibition of microglial activation has been shown to prevent the 
development of hypertension, decrease PVN cytokines and attenuate cardiac hypertrophy in 
response to angiotensin II infusion (Shi et al., 2010a). Diabetes is known to cause 
pathological changes in peripheral nerves, which results in subsequent inflammation within 
the CNS (Pabreja et al., 2011). Previously, we have demonstrated an increase in activated 
microglia in specific cardiovascular control regions of the brain in STZ diabetic rats (Rana et 
al., 2014). Despite this evidence, the functional consequence of microglial activation and its 
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contribution to the development of diabetic cardiovascular complications has never been 
investigated.   
In this review, the objective is to provide a general overview of diabetes and its complications 
and the role that autonomic dysfunction plays in their generation, highlighting current 
knowledge relevant to the potential contribution of central inflammation in the brain regions 
involved in autonomic control of the cardiovascular system. The rationale for the experiments 
in this thesis is also explained.  
  
Chapter One: Literature Review Page | 5 
 
 
 Diabetes mellitus 1.2
The prevalence of diabetes is growing worldwide in both developed and developing 
countries. In 1980, around 153 million people suffered from diabetes mellitus, and this 
number had increased to 347 million by 2008 (Danaei et al., 2011). By the year 2030, it is 
estimated that over 439 million people worldwide will be diagnosed with diabetes mellitus 
(Shaw et al., 2010). In Australia, 3.6 million people have diabetes or a pre-diabetic condition 
(Atlas, 2011). In 2000, around 1 million Australians aged ≥25 years suffered from diabetes, 
and its prevalence is expected to reach 2–2.9 million by 2025 (Magliano et al., 2008). 
Diabetes is one of the top ten causes of death in Australia. In 2005, an estimated 3,529 
Australians died as a consequence of diabetes and it complications. Diabetic complications 
not only increase mortality but also increase the cost of managing diabetes. For instance, type 
1 diabetes costs an individual about $4,669 each year if they are healthy; however, once 
diabetic complications develop, the cost increases up to $16,698 (Colagiuri et al., 2009). 
Thus, preventing or reducing the development of diabetic complications is an important 
objective to minimize the high prevalence of morbidity and mortality as well as the cost of 
treatments related to diabetes.  
Diabetes mellitus is a metabolic disorder characterized by elevated blood glucose levels and 
associated disturbances of the metabolism of glucose, carbohydrates, proteins and lipids 
(Mwanri et al., 2015). The elevation levels of glucose in the blood occur as a result of the 
inability of the pancreas to secrete insulin, defects in insulin action or both. Diabetes is 
classified into two main categories: type 1 diabetes and type 2 diabetes. Type 1 diabetes is 
characterised by hyperglycaemia due to the autoimmune destruction of pancreatic β cells, 
which secrete insulin to stimulate the metabolism of glucose in the body (Bluestone et al., 
2010). This type of diabetes accounts for 5% to 10% of all cases of diabetes. The risk factors 
for this type of diabetes are autoimmune, genetic and environmental factors (Deshpande et 
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al., 2008). In contrast, type 2 diabetes is characterised by the inability of the body to 
effectively respond to the insulin. Type 2 diabetes is responsible for around 90% to 95% of 
all cases of diabetes (Deshpande et al., 2008). There are many factors that can contribute to 
the incidence of this form of diabetes. These include obesity, poor diet, western diet, physical 
inactivity, increasing age, family history of diabetes and ethnicity (Alberti et al., 2007; Shaw 
et al., 2010). The normal blood level of glucose in humans during fasting is between 4 to 6 
mmol/L, and it is considered high when it reaches 12 mmol/L or above.  High blood glucose 
is a defining feature of both types of diabetes. In the long term in both of these types of 
diabetes, the direct or indirect effects of hyperglycaemia increase the risk of the development 
of diabetes complications; however, correlation studies in humans can only go so far in 
understanding the mechanisms of generating diabetic complications via hyperglycaemia in 
animals.   
 Use of streptozotocin‐induced diabetic models to study complications 1.2.1
The administration of streptozotocin (STZ) is a well-established technique to induce diabetes 
in animals through the selective destruction of the pancreatic β cells. As a consequence, 
insulin deficiency leads to hyperglycaemia and other characteristics observed in humans with 
diabetes mellitus, such as glycosuria, polyuria, polyphagia and polydipsia (Hebden et al., 
1986b); however, STZ induced diabetic animals do not show strong autoimmune features 
(Baxter & Duckworth, 2004). Because type 1 diabetes in humans results from the 
autoimmune destruction of pancreatic β cells, this model is not useful to study the mechanism 
that causes type 1 diabetes, but since an injection of STZ produces hyperglycaemia, it is a 
good model to study the mechanism that causes complications due to increased blood glucose 
levels. An injection of STZ also provides a robust and consistent hyperglycaemic in animals. 
In addition, since the hallmark symptom for humans with type 1 and 2 diabetes is 
hyperglycaemia, animal models injected with STZ may resemble both types of diabetes. STZ 
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induced hyperglycaemia rats display abnormalities in the cardiovascular system, which is a 
characteristic of humans with type 1 and 2 diabetes.  Thus, STZ-induced diabetes in animals 
is an adequate model for investigating the mechanisms of the cardiovascular complications of 
diabetes. Indeed, an STZ rat model was the primary model used for this thesis. 
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 Cardiovascular complications in diabetes 1.3
Diabetes mellitus is described as a primary risk factor for the development of cardiovascular 
disease (Grundy et al., 1999; Fowler, 2008). Cardiovascular complications are the likely 
cause of morbidity and mortality in approximately 80% of diabetes mellitus patients 
(Carlson, Shelton et al., 2000). Based on the differences in the size of the vessels injured, 
pathological mechanisms and risk factors, diabetic complications have been classified as 
either microvascular or macrovascular complications.   
 Microvascular complications  1.3.1
In diabetic patients, microvascular changes involve damage to small arteries, arterioles and 
capillaries, and these vascular abnormalities are suggested to lead to the following 
complications:   
A-  Diabetic retinopathy: destruction of the retina, leading to vision impairment and 
eventually blindness (Porta et al., 2011). 
B- Diabetic nephropathy: damage to the kidney, which progresses to renal failure. 
Diabetic nephropathy is associated with a decrease in the glomerular filtration rate 
and albuminuria (Van Buren & Toto, 2011).   
C- Diabetic neuropathy: damage to the peripheral nerves, which results in weakness, 
tingling, numbness and chronic pain (Callaghan et al., 2012). For instance, diabetic 
neuropathy can cause foot ulcers in diabetic patients. Neuropathy not only affects 
sensory neurons but also autonomic neurons, which may lead to a secondary 
dysfunction of the cardiovascular and renal systems (Tesfaye et al., 2010).   
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These microvascular complications are closely related to the severity and duration of 
diabetes. During the last decade, the most studied mechanisms of these complications 
included but were not limited to 1) increased metabolism of glucose through alternative 
polyol and hexosamine pathways to produce damage in diabetes; 2) increased activation of 
protein kinase isoforms; and 3) increased formation of advanced glycation end-products 
(Brownlee, 2001; Giacco & Brownlee, 2010; Rambhade et al., 2011). An alteration in any of 
these molecular pathways induced by hyperglycemia will cause increased oxidative stress, 
increased activity of the renin-angiotensin system and increased free radicals production in 
mitochondria, which in turn will result in an up-regulation of inflammatory cytokines and 
growth factors. Combined, these changes are suggested to lead to multiple vascular and 
neurological dysfunctions, including ischemia in the retina, glomerulosclerosis and 
proteinuria in the kidney and degeneration in peripheral nerves (Brownlee, 2001, 2005; 
Gologorsky et al., 2012; Nguyen et al., 2012). All of these abnormalities could play a role in 
the development of cardiovascular disease in people with diabetes (Kim et al., 2011). 
 Macrovascular complications 1.3.2
Macrovascular complications in people with diabetes are caused by damage to medium or 
large arteries. These complications include coronary artery disease, myocardial infarction and 
stroke, which can impair the central nervous system and the heart (Krentz et al., 2007; 
Fowler, 2008). Such complications are known to be the most common risk factors that 
increase the mortality rate in people with diabetes. The common pathological mechanism of 
these complications is thought to be the development of atherosclerosis. While the 
pathogenesis of atherosclerosis remains insufficiently understood, endothelia dysfunction and 
chronic inflammation are thought to be important contributors (Williams & Nadler, 2007; 
Forbes & Cooper, 2013). 
Chapter One: Literature Review Page | 10 
 
 
There are others factors that may be involved in the pathogenesis of cardiovascular 
complications in diabetes, such as macrophage dysfunction, dyslipidaemia and impaired 
platelet function (Cade, 2008). All of the diabetic complications mentioned above are 
dependent on the damaging effects of hyperglycemia on the blood vessels. In contrast, 
cardiomyopathy is a common complication of diabetes that is suggested to occur independent 
of vascular damage.  
 Diabetic cardiomyopathy  1.3.3
Diabetic cardiomyopathy is characterized by structural and functional changes in the 
myocardium of diabetic patients in the absence of other confounding factors, including 
coronary artery disease, valvular heart disease or hypertension (Aneja et al., 2008; Pappachan 
et al., 2013). Diabetic cardiomyopathy is associated with a left ventricular hypertrophy and 
myocardial remodelling, leading to abnormal left ventricle filling and diastolic dysfunction at 
early stages (Schilling & Mann, 2012). The progression of diastolic dysfunction accelerates 
systolic dysfunction, which in turn contributes to reducing the ejection fraction and the later 
development of heart failure (Fonseca, 2003). In both type 1 and type 2 diabetic patients, 
cardiomyopathy is common (Danielsen et al., 1987; Schannwell et al., 2002; Diamant et al., 
2003; Korosoglou et al., 2012). 
There is also evidence that cardiac functions are compromised in several types of diabetic 
animals. For example, ex-vivo studies on isolated hearts from diabetic mice and rats 
demonstrated a reduction in the maximal rate of pressure increase (+dP/dt) and decrease (‒
dP/dt) in the left ventricle and a reduction in the left ventricular developed pressure and left 
ventricular systolic pressure (Choi et al., 2002; El‐Omar et al., 2003; Belke et al., 2004; 
Ligeti et al., 2006; Cao et al., 2012). Similarly, in vivo studies have reported cardiac 
abnormalities, such as a decreased +dP/dt and decreased ‒dP/dt in the left ventricle; a 
decreased left ventricular developed pressure and left ventricular systolic pressure; an 
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increased left ventricular end-diastolic pressure; and a decreased fractional shortening and 
ejection fraction in STZ diabetic rats (Cheng et al., 2004; Borges et al., 2006; Bidasee et al., 
2008; Arozal et al., 2009; Wang et al., 2011; Bhatt & Veeranjaneyulu, 2012; Tappia et al., 
2013; Guo et al., 2014), in rats treated with STZ combined with high fat feeding and in obese 
mice, both of which are animal models of type 2 diabetes (Zhou et al., 2011; Sen et al., 
2012). Thus, in terms of cardiac changes, it appears that diabetic animals mimic cardiac 
features observed in human diabetes. The pathology of diabetic cardiomyopathy has been 
linked to several mechanisms, which include lipid accumulation in the cardiomyocytes 
(Yokoyama et al., 2004), defects in myocardial subcellular organelles (Dhalla et al., 2012), 
impairment of Ca
2+
 handling (Lagadic-Gossmann et al., 1996; Dhalla et al., 2014), 
endothelial dysfunction and myocardial fibrosis (Tschöpe et al., 2005; Asbun & Villarreal, 
2006); however, the exact mechanism behind diabetic cardiomyopathy is still unclear. There 
is evidence that suggests that increased sympathetic activity can cause cardiac dysfunction in 
other diseases (Aronson & Burger, 2002; Guggilam et al., 2008), but its role in diabetic 
cardiomyopathy has not been investigated.  
 Blood pressure  1.3.4
Hypertension is considered to be an important risk factor in the development of 
cardiovascular disease, which is the likely cause of morbidity and mortality in approximately 
80% of diabetes mellitus patients (O'Keefe et al., 1999). The risk of developing 
cardiovascular disease in persons with diabetes is increased when it occurs with hypertension 
(Epstein & Sowers, 1992). In addition, it has been suggested that up to 75% of cardiovascular 
diabetic complications can be attributed to hypertension (Bild & Teutsch, 1987). Well-
designed clinical trials have shown a reduction in complications in both types of diabetes 
following aggressive treatment for hypertension through the use of renin-angiotensin system 
inhibitors, such as diuretics, angiotensin receptor blockers and angiotensin-converting 
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enzyme inhibitors (Group, 1998; Tuomilehto et al., 1999; Association, 2003). Therefore, the 
presence of hypertension in diabetic patients is thought to contribute to the overall diabetes 
mortality, although the possibility exists that increased angiotensin II levels cause 
complications via another mechanism.  
While several clinical studies have shown that patients with type 1 and type 2 diabetes are 
likely to show hypertension (Parving et al., 1988; Turner et al., 1993), blood pressure 
changes in diabetic animals are controversial. Studies showing hypertension in STZ-diabetic 
rats have mainly used the non-invasive tail cuff measurement method (Bunag et al., 1982; 
Katayama & Lee, 1985; Hartmann et al., 1988; Ramos, 1988). It has been suggested that the 
increased blood pressure observed in STZ rats with tail cuff measurements is spurious and is 
due to structural changes in the tail. Others studies have shown a decrease or no change in the 
blood pressure in conscious STZ diabetic animal studies using direct invasive measurements 
(Hebden et al., 1987; Maeda et al., 1995; Fazan et al., 1997; Schaan et al., 1997; Van Buren 
et al., 1998; Fazan et al., 1999; Dall'Ago et al., 2002; Schaan et al., 2004; Borges et al., 
2006; Farah et al., 2007). The reasons for the difference between humans and rats in this 
aspect are not completely understood; however, several mechanisms have been postulated to 
be responsible for hypotension in STZ-diabetic rats, such as 1) a decreased cardiac output due 
to a dysfunction in the myocardium (Ren & Bode, 2000); 2) a differential sympathetic 
outflow to various organs; 3) hypovolemia due to osmotic diuresis (Teshima et al., 2000); 
and 4) the impairment of sympathetic innervation of the heart and blood vessels (Borges et 
al., 2006). For this thesis, the aim was to gain a better understanding of this difference, which 
will aid in the interpretation of the relevance of the STZ rat model to humans.   
 Salt-sensitivity of arterial blood pressure in diabetes 1.3.5
As discussed, the changes in blood pressure in STZ diabetic animals are different from the 
human condition, and the reason for the lack of an increase in blood pressure in rats treated 
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with STZ is a matter of speculation; however, it is possible that dietary factors relevant to 
hypertension in human diabetes are also required for the development of hypertension in STZ 
diabetic rats.  
There is consensus that dietary salt is a contributing factor in the development of 
hypertension in both humans and animals, particularly in salt-sensitive individuals (Campese, 
1994; Sacks et al., 2001; Jones, 2004; Brooks et al., 2005). A large number of clinical and 
animal experimental studies have shown that a reduction in dietary salt lowers blood 
pressure, while a high salt intake has been found to increase blood pressure in animal models 
(Campese et al., 1982; Koolen & van Brummelen, 1984; Howe et al., 1990; Law et al., 1991; 
Wyss et al., 1995). In addition, excessive dietary salt reduces the effectiveness of most 
antihypertensive drugs (Chobanian & Hill, 2000). 
Although the role of dietary salt in the development of hypertension in humans with type 1 
and 2 diabetes is well-documented, the relationship between salt intake and hypertension in 
STZ diabetic rats has not been fully studied. Nevertheless, two studies on STZ-induced 
diabetes using the direct recording of blood pressure have reported that 1% NaCl intake 
causes an increase in blood pressure (Santos et al., 1995; Maeda et al., 2007). Dietary salt has 
also been shown to further elevate the blood pressure levels in obese Zucker rats compared 
with non-diabetic, lean Zucker rats (Carlson et al., 2000). Collectively, this data suggests that 
dietary salt may have an important role in the development of hypertension in both diabetic 
humans and animals. Because the administration of STZ to rats induces a diabetic state that is 
not accompanied by hypertension, using STZ diabetic rats with increased salt intake may 
produce an animal model more closely related to human diabetes and thereby lead to a better 
understanding of the effects of hyperglycaemia on cardiovascular functions. This model will 
also provide a better understanding of the link between diabetes and hypertension.   
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 Diabetic cardiovascular complications: the role of sympathetic nerve 1.3.6
activity 
The mechanisms responsible for the development diabetic cardiovascular complications are 
complex and multifactorial. For example, many studies on the mechanisms of the 
development of type 1 diabetes complications have suggested an important role for 
endothelial dysfunction (Woodman et al., 2008; Woodman & Malakul, 2009); however, a 
large body of evidence shows that the autonomic nervous system is impaired in diabetic 
patients. The peripheral autonomic nervous system functions to regulate the organ systems, 
such as the cardiovascular, digestive and renal systems. It is, in turn, regulated by the 
brainstem and the hypothalamus, which contain central autonomic control areas. Both the 
sympathetic and parasympathetic nervous systems are regulated by reflex arcs between 
sensory and motor neurons in the viscera and autonomic brainstem nuclei. The sympathetic 
and parasympathetic nervous systems work together in a complex interplay to regulate the 
cardiovascular system. For example, in response to environmental stress, the activity of the 
sympathetic nervous system elevates blood pressure and accelerates the heart rate (Floras, 
2009; Triposkiadis et al., 2009); however, the parasympathetic nervous system has restorative 
functions through exerting inhibitory input to the heart to decrease blood pressure and heart 
rate (Andresen & Kunze, 1994).  
Diabetes mellitus imposes negative effects on both the function and structure of the 
autonomic nervous system, which may compromise its role in the maintenance of the body’s 
internal environment (Baydas et al., 2003; Lebed et al., 2008). Autonomic neuropathy has 
been suggested to be the most serious complication of diabetes in terms of morbidity and 
mortality (Ewing et al., 1980; Kempler et al., 2002), and it may affect sensory and motor 
autonomic nerves. Still, the roles of the autonomic neuropathy and the dysregulation of the 
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autonomic nervous system in causing long-term diabetic complications, such as 
cardiovascular diseases, have not been fully explored. 
As mentioned, diabetes affects not only the somatic sensory nerves but also autonomic 
sensory nerves, which modulate the control of the internal organs by sending signals 
regarding the state of the internal environment to the CNS, particularly into autonomic 
centres in the brainstem and hypothalamus (Perin et al., 2001; Verrotti et al., 2009). Thus, 
pathological changes in the peripheral nerves may result in the dysfunction of these 
autonomic centres, thereby causing adverse effects in the functionality of the cardiovascular, 
renal, endocrine and digestive systems. Any disturbance to the function of the autonomic 
nervous system may have substantial consequences for the health of the individual and 
mortality (Ewing et al., 1980; Kempler et al., 2002).  
There is strong evidence that abnormal elevation of the sympathetic tone is a key mechanism 
underlying the development of cardiovascular diseases, including hypertension (Dampney et 
al., 2005; Esler, 2011; Takahashi, 2012) and heart failure (Watson et al., 2006; Kishi, 2012), 
which are major consequences of diabetes in the long term. Increased activity of the 
sympathetic nervous system has been reported in both humans and animals with heart failure 
(Packer, 1988; Zheng et al., 2009; Patel et al., 2011). Blocking the effect of increased activity 
with beta-blockers has been shown to decrease the mortality rate and improve outcomes for 
patients following a heart attack (Butler et al., 2006); however, whether this approach is 
useful in diabetes has not been investigated.    
Sympathetic nerve overactivity is known to occur in diabetic patients (Langer et al., 1995; 
Stevens et al., 1997; Perin et al., 2001). Such overactivity has been shown to be involved in 
the development of diabetic complications, including hypertension (Frontoni et al., 2005) and 
an increased risk of abnormal cardiac function and adverse cardiovascular events (Perin et 
al., 2001; Manzella & Paolisso, 2005; Mori et al., 2008) as well as chronic renal failure 
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(Schlaich et al., 2009). Thus, based on the data, an impaired autonomic nervous system 
function in diabetes promotes adverse effects on various body organs, leading to substantial 
and serious consequences for the health and survival of the individual.  
Interestingly, a study on STZ-induced diabetic rats demonstrated significantly elevated basal 
renal sympathetic nerve activity (Patel et al., 2011). Despite this evidence, the brain regions 
and cellular mechanisms responsible for the increase in sympathetic nerve activity in diabetes 
remain unidentified; however, it is likely that the increase in sympathetic nerve activity 
originates in the CNS cardiovascular centres (Dampney, 1994; Sato et al., 2000; Chen & 
Toney, 2009).   
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 Cardiovascular centers in the CNS  1.4
As discussed, cardiovascular functions are regulated via several nuclei in the brainstem and 
hypothalamus (Guyenet, 2006). These nuclei control and influence the neurons in the 
intermediolateral cell column of the spinal cord, which are sympathetic preganglionic motor 
neurons. These motor neurons activate the sympathetic postganglionic neurons in the 
peripheral ganglion to regulate cardiovascular function (Guyenet, 2006). The paraventricular 
nucleus of the hypothalamus (PVN), the rostral ventrolateral medulla (RVLM) and the 
nucleus tractus solitarius (NTS) are the main areas of the brain that are involved in 
cardiovascular regulation. 
 The paraventricular nucleus (PVN) 1.4.1
The PVN is located on both sides of the third ventricle in the hypothalamus, and it consists of 
parvocellular and magnocellular neurons. The PVN regulates the autonomic nervous system, 
including its cardiovascular functions, as well as the endocrine system (Kannan et al., 1989; 
Badoer, 2001). Magnocellular neurons project to the posterior pituitary and are involved in 
secreting oxytocin and vasopressin in response to osmotic and other stimuli (Kannan et al., 
1989). Thus, the PVN plays a critical role in the control of blood volume via the secretion of 
oxytocin and vasopressin. In contrast, parvocellular neurons project to the anterior pituitary 
as well as other regions in the CNS in which they play a role in the regulation of sympathetic 
nerve activity (Cechetto & Saper, 1988; Stern et al., 2003). 
These parvocellular neurons can influence sympathetic nerve activity directly and indirectly 
(Figure1-1). They project directly into the intermediolateral cell column of the spinal cord, 
and the stimulation of this connection increases blood pressure and renal sympathetic nerve 
activity through the secretion of neurotransmitters, including vasopressin (Kawabe et al., 
2009). Parvocellular neurons also project to other brain regions, such as the RVLM, which in 
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turn projects to the sympathetic preganglionic neurons, thereby indirectly influencing 
sympathetic nerve activity (Kannan et al., 1989; Kantzides & Badoer, 2003). In addition, 
functional evidence indicates that the inhibition of the PVN by the microinjection of a GABA 
receptor agonist produces a reduction in renal sympathetic nerve activity and mean arterial 
pressure in the normotensive rat (Haselton & Vari, 1998; Zhang & Patel, 1998; Deering & 
Coote, 2000). These findings indicate that activation of the PVN can cause changes in 
cardiovascular functions through the modulation of sympathetic nerve activity. Therefore, it 
is important to determine whether the cellular and molecular changes in the PVN may 
contribute to the activation of the sympathetic nerve system in diabetes.  
The activation state of PVN is stimulated by a variety of factors, including haemorrhage 
(Badoer & Merolli, 1998), increased plasma leptin (Huang et al., 1998), increased plasma 
volume (Badoer et al., 1997), increased plasma osmolarity  (Charlton et al., 1988; Brooks et 
al., 1989), dehydration (Zheng et al., 2002), stress (Imaki et al., 1995), prostaglandins 
(Konsman et al., 2002), nuclear factor-kappa B (Kang et al., 2009b) and proinflammatory 
cytokines (Shi et al., 2010a). 
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 Figure 1-1. Diagrams illustrating the PVN neuron pathways involved in the 
control of sympathetic activity. The PVN sends projections to the IML of the spinal 
cord to influence sympathetic activity directly (blue) or sends projections to the RVLM 
neurons, which send projections to the IML to ultimately influence sympathetic activity 
(red). PVN, paraventricular nucleus; RVLM, rostral ventrolateral medulla; IML, 
intermediolateral column. Modified from (Pyner, 2009). 
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 Nucleus tractus solitarius (NTS) 1.4.2
The nucleus tractus solitarius (NTS) is located in the dorsomedial medulla oblongata and 
consists of the caudal and rostral regions. The caudal region of NTS is the region most 
involved in cardiovascular regulation. This nucleus receives projections from other brain 
regions that are known to be involved in cardiovascular regulation, such as the PVN and 
RVLM (Andresen et al., 2004). The NTS neurons play a pivotal role in regulating the 
cardiovascular system via modulating autonomic efferent activity (Paton, 1998; Silva-
Carvalho et al., 1998). The NTS is the main area of the brain that relays sensory input for 
baroreflex control. It receives sensory terminals from the carotid chemoreceptors, arterial 
baroreceptors and cardiopulmonary receptors in the heart and vessels, which is used for the 
appropriate adjustment of blood pressure (Miura & Reis, 1969; Van Giersbergen et al., 1992; 
Machado et al., 1997) (Figure1-2). Upon baroreflex activation, the sympathetic nerve activity 
to the heart and vessels increases, and the parasympathetic nerve activity to the heart 
decreases to maintain a normal blood pressure. Lesions of NTS neurons have been shown to 
abolish the baroreflex responses in anesthetized animals (Miura & Reis, 1972), and the 
electrical stimulation of these neurons also produced a significant increase in blood pressure 
in another study in rats (Doba & Reis, 1973). The microinjection of a GABA receptor agonist 
into the NTS caused a decrease in sympathetic nerve activity and mean arterial pressure in 
spontaneously hypertensive rats (Sato et al., 2000). These data indicate that the NTS is 
crucial in the regulation of the cardiovascular system and that increased NTS neuronal 
activity may contribute to the elevation of arterial pressure.  
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Figure 1-2. Diagram illustrating the neural pathways involved in the 
baroreceptor reflex. The NTS receives input from high and low-pressure 
baroreceptors and projects to the RVLM either directly or via the CVLM, which 
in turn projects to the RVLM before terminating at the IML of the spinal cord, 
which contains sympathetic post-ganglionic neurons, to ultimately influence 
sympathetic control of  effector organs, including the heart, kidney and blood 
vessels. The NTS also projects to the NA and DMV, which mediate 
parasympathetic effects on the heart. NTS, nucleus tractus solitarius; RVLM, 
rostral ventrolateral medulla; IML, intermediolateral column; NA, nucleus 
ambiguous; DMV, dorsal motor nucleus of vagus. 
 
Chapter One: Literature Review Page | 22 
 
 
 Rostral Ventrolateral Medulla (RVLM) 1.4.3
The rostral ventrolateral medulla (RVLM) is the area of the brain stem situated ventral to the 
nucleus ambiguous and caudal to the facial nucleus. This nucleus also projects into the 
intermediolateral cell column of the spinal cord (Guertzenstein & Silver, 1974; Dampney, 
1994; Card et al., 2006) and receives a variety of inputs from the NTS, PVN (Nosjean et al., 
1998) and caudal ventrolateral medulla (CVLM), which in turn are involved in the regulation 
of sympathetic activity via the inhibitory effects on the RVLM (Badoer & Merolli, 1998; 
Pyner, 2009).  
The RVLM neurons are thought to play a pivotal role in controlling the tonic excitation of 
sympathetic preganglionic neurons, and the functional integrity of these neurons is important 
for maintaining blood pressure and sympathetic vasomotor activity. Chemical or electrical 
stimulation of the RVLM neurons has been shown to increase arterial pressure and heart rates 
in animals (Guertzenstein & Silver, 1974; Ross et al., 1984). On the other hand, the bilateral 
inhibition of the RVLM neurons causes a decrease in sympathetic nerve activity and blood 
pressure (Dampney, 1994; Guyenet, 2006). The RVLM neurons are also influenced indirectly 
by the NTS through peripheral inputs that adjust sympathetic nerve activity (Figure1-2). For 
example, the arterial baroreflex is mediated via the RVLM neurons. An increase in arterial 
pressure causes the activation of arterial baroreceptors, which in turn inhibits output from the 
NTS to inhibit activation of RVLM neurons, thereby reducing sympathetic nerve activity to 
normalize blood pressure (Pilowsky & Goodchild, 2002). RVLM neurons also modulate the 
somatic pressor reflex and chemoreflex, which are involved in the regulation of blood 
pressure (Kiely & Gordon, 1994; Koshiya & Guyenet, 1996). The activity of RVLM neurons 
can also be influenced via inputs from the PVN (Badoer, 2000). Thus, multiple brain regions 
contribute to blood pressure control, and almost all are reported to show inflammation in 
disorders with increased sympathetic nerve activity.  
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 The role of microglia in inflammation of the CNS  1.5
There is increasing evidence suggesting that inflammation within the central nervous system 
(CNS) may be crucial in the pathogenesis of peripheral diseases such as diabetes (Tsuda et 
al., 2008; Patel et al., 2011). Various studies on diabetic rats have demonstrated inflammation 
in specific cardiovascular centres of the brain (Luo et al., 2002; Zheng et al., 2006; Rana et 
al., 2014). Despite this, the functional consequence of inflammation has never been 
investigated. The major cell types involved in CNS inflammation are microglia and 
astrocytes. As microglia play a significant role in the pathology of several diseases, it is 
important to understand their origins. 
 The origin of microglia  1.5.1
The functionality of the CNS is dependent on glia cells, which mainly consist of 
oligodendrocytes, astrocytes and microglia. Microglia are the primary immune cells in the 
CNS and were first described in 1899 by Nissl (1899). In 1919, Pio del Rio-Hortega began to 
characterize their function and origin. He documented that in response to brain injury, 
microglia migrate to the damaged tissue, undergo morphological changes and engulf tissue 
debris, suggesting that microglia act as an immunocompetent cell. He also suggested that 
microglia originate from mesoderm, which is similar to macrophages (del Rio-Hortega & 
Penfield, 1932).  
For some time, the precise origin of the microglia in the CNS was controversial, but the 
neuroectoderm was proposed as the microglial origin, as well as for other cells in the CNS 
(Hutchins et al., 1990; Hao et al., 1991). This view was also supported by experimental data 
from cell cultures that suggested astrocytes and microglia cells derived from a similar 
progenitor cell (Eglitis & Mezey, 1997; Fedoroff et al., 1997); however, it is now widely 
accepted that microglial cells in the CNS are derived from the mesoderm. Several studies 
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suggested that postnatally, progenitor microglia originate from circulating monocytes, 
traverse through blood vessels and eventually invade the CNS and differentiate to be ramified 
microglia (Perry et al., 1985; Rezaie & Male, 2002); however, microglial cells have been 
shown to develop in the brain before vascularization (Ashwell, 1991; Cuadros et al., 1993) 
and the formation of monocytes in hemopoietic tissues (Sorokin et al., 1992; Naito et al., 
1996), indicating that during development at least, microglia cells are not generated from 
monocytes.  
  Morphology and function of microglia 1.5.2
The CNS previously was considered an ‘immune privileged organ’, meaning it was not 
susceptible to inflammation or activation of the immune system, as the CNS was not thought 
to have lymphatic drainage and because of the presence of the blood–brain barrier (BBB); 
however, this notion has changed, as activated T-cells cross the BBB (Cross et al., 1990). In 
fact, the CNS has its own resident immune cells (microglia and astrocytes), which are 
involved in inflammation mechanisms and protect the CNS from pathogens (Gehrmann et al., 
1995; Dong & Benveniste, 2001).  
Microglia represent the predominant resident immune cells in the CNS, and similar to 
macrophages, microglia perform immune functions and communicate with other cells of the 
immune system. In the CNS, three general morphological states of microglia have been 
described, which are ramified, activated and amoeboid, but others have suggested that there 
are more than three. It is believed that these morphological states indicate different functional 
states of microglia. In a healthy brain, microglia exist in the ramified state, consisting of a 
small cell body with long and highly branched processes that extend outwards (Davalos et al., 
2005). These long microglial processes monitor the surrounding local environment, allowing 
microglia to function as sentinels that sense insults within the CNS and engulf tissue debris 
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via phagocytosis (Sierra et al., 2010). Ramified microglia also play a homeostatic role in 
supporting neurons (van Rossum & Hanisch, 2004). 
Once activated in response to infection, injury, or inflammation of the CNS, ramified 
microglia undergo morphological changes consisting of shortened processes and enlarged cell 
bodies. In this state, microglia have the potential to display a diverse set of functional 
changes. They express other molecules, such as cell adhesion molecules, which enable them 
to further detect and eliminate foreign organisms (Kreutzberg, 1996; Lee & Benveniste, 
1999). They also act as antigen-presenting cells by expressing major histocompatibility 
complexes, such as class I and II antigens, which are essential for T-cell activation and for 
allowing the entry of T-cells across the BBB (Babcock et al., 2003; Bailey et al., 2006). 
Upon activation, microglia secrete a wide variety of cytokines and express cytokine 
receptors, which facilitate communication with other cells of the immune system (Ferrari et 
al., 1996; Hide et al., 2000; Hanisch, 2002; Inoue, 2006). These immune mediators also may 
be involved in the regulation of inflammation by recruiting further microglia and other 
immune cells and causing the activation of these cells. Cytokines are subdivided into either 
pro-inflammatory or anti-inflammatory groups. When microglia become activated, they 
release both pro-inflammatory and anti-inflammatory cytokines and change their expression 
of cytokine receptors, depending on the severity and type of stimulus. Furthermore, as 
modulators of immune function, microglia express various toll-like receptors, which are 
involved in the generation of innate immune responses and stimulate the secretion of pro-
inflammatory cytokines (Carty & Bowie, 2011). Upon activation, microglia also secrete 
reactive oxygen species, which can induce the proliferation and migration of microglia to the 
site of neuronal injury to further induce inflammatory processes (Parvathenani et al., 2003; 
Block et al., 2007; Lenertz et al., 2009).  
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Prolonged activation of microglia can result in their assuming amoeboid shapes with sparse 
processes, a cell type which is often called phagocytic microglia. They are also, however, 
capable of phagocytosis in their ramified state and this process plays an important role in 
maintaining the homeostasis of the CNS environment (Koizumi et al., 2007; Fang et al., 
2009; Neumann et al., 2009). Therefore, microglia cells are the principal immune cells in the 
CNS, play a significant role in normal brain function, host defence and serve as the link 
between the CNS and the peripheral immune system.  
Several studies have reported activated microglia in pathologies of the CNS that are 
associated with brain inflammation, such as Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, neuropathic pain and diabetes. While microglia play a complex and 
multifaceted role in response to CNS pathological challenges, the situations in which 
activated microglia can be either neuroprotective or neurotoxic are still controversial.  
 Microglial activation: the dual ability of neuroprotection and neurotoxicity 1.5.3
As discussed, in response to CNS pathological challenges, such as stressful stimuli, brain 
injury, infection, inflammation or neurodegenerative diseases, microglial cells initiate and 
regulate the immune response in the CNS. This includes releasing pro-inflammatory 
cytokines and the generation of reactive oxygen species. These secretions of microglia are 
beneficial to the host through the protection from infection in the CNS, but they also can be 
detrimental when inflammatory processes are induced chronically. It has been suggested that 
similar to systemic macrophages, activated microglia can be divided into two phenotypes. M1 
microglia are the classic activated phenotype, which may be involved in the production of 
reactive oxygen species and pro-inflammatory cytokines; however, M2 or ''alternatively 
activated" microglia are an anti-inflammatory phenotype, which release anti-inflammatory 
cytokines and neurotrophic factors (Fernandes et al., 2014). In terms of morphology, no 
difference between these phenotypes has been observed and it is not yet clear whether so 
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called M2 microglia can participate in pathological processes. Therefore, additional research 
is needed to better define microglial activation phenotypes.  
Activated microglia are commonly seen in the pathologies of the CNS, and their involvement 
in neuroprotection in various models of CNS injury has been reported. For example, studies 
on models of transient cerebral ischemia have shown that inhibition of microglial activation 
via minocycline reduces neurogenesis following brain ischemia (Yanagisawa et al., 2008; 
Kim et al., 2009). The secretion of the cytokine tumour necrosis factor (TNF) from activated 
microglia has been shown to protect neurons from ischemia-induced death (Lambertsen et al., 
2009). It has also been demonstrated that activated microglia are neuroprotective and 
stimulate remyelination in mice through the synthesis of the IL-1β (Mason et al., 2001). Also, 
many studies on other diseases have reported that activated microglia can, in some 
circumstances, protect CNS cells through the removal of potentially excitotoxic glutamate 
without producing excessing amount of inflammatory mediators (Shaked et al., 2005), the 
engulfment of harmful invading neutrophils (Neumann et al., 2008) or the degradation of 
amyloid-beta peptides deposits (Lee & Landreth, 2010).  
On the other hand, a large body of evidence indicates that in a manner parallel to 
inflammation, exaggerated immune responses of activated microglia under specific 
circumstances have the potential to exert detrimental effects. Studies have reported the 
contribution of activated microglia to the pathologies of CNS diseases through the production 
of a range of neurotoxins, which include reactive oxygen species (Colton & Gilbert, 1987; 
Mao & Liu, 2008), nitric oxide (Moss & Bates, 2001; Liu et al., 2002) and pro-inflammatory 
cytokines (Bi et al., 2005; Balasubramaniam et al., 2009). Activated microglia are found in 
the CNS in various neurodegenerative disorders, and they are thought to play a critical role in 
the pathology of these diseases. Several experimental studies have indicated that the 
inhibition of microglial activation via the drug minocycline leads to reduced levels of 
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neurotoxins and improved neuronal survival in neurodegenerative diseases (Jackson-Lewis et 
al., 2002; Biscaro et al., 2012). In Alzheimer’s and Parkinson’s diseases, microglial 
activation is observed in various regions in the CNS, and their secretions, such as neurotoxic 
cytokines and reactive oxygen species, have been shown to promote neuronal damage 
(Teismann & Schulz, 2004; Mandrekar & Landreth, 2010). Further, chronically activated 
microglia have been observed in multiple sclerosis, and they have been implicated in 
contributing to the progression of the disease through the generation of nitric oxide (Hill et 
al., 2004). These data suggest that activated microglia can exacerbate inflammation by 
producing toxic molecules and thereby contributing to CNS pathologies by exacerbating 
damage to neuronal tissue.   
Even if activated microglia are not neurotoxic, they can still induce CNS dysfunction through 
increased neuronal excitability. For instance, activated microglia release brain-derived 
neurotrophic factor (BDNF) to induce neuronal survival, but increased levels of BDNF can 
induce neuronal excitability (Biggs et al., 2010). Collectively, these studies have indicated 
the complexity of the role of activated microglia in regulating the CNS immune response and 
the difficulty in determining whether activated microglia exert pathological or protective 
effects. Therefore the role of activated microglia in diabetes, whether pathological or 
protective needs to be determined.   
 Consequences of microglial activation in the CNS in diabetes 1.5.4
Previous studies on STZ diabetic rats have reported increased neuronal activity in 
cardiovascular centres of the brain (Luo et al., 2002; Zheng et al., 2006; Rana et al., 2014). 
Recently, our laboratory has shown that microglia become activated in these centres, 
including the PVN and NTS, but the functional consequence of this activation is not known 
(Rana et al., 2014). In contrast, the consequences of microglial activation are better studied in 
other parts of the brain in diabetes.  
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Diabetes is known to cause pathological changes in the peripheral nerves and to result in 
subsequent inflammation within the CNS (Tsuda et al., 2005). Chronic inflammation is also a 
major characteristic of neuropathic pain, which is a common complication of diabetes. 
Various animal models of neuropathic pain are characterised by activated microglia in the 
dorsal horn of the spinal cord and an increased expression of pro-inflammatory cytokines, 
such as TNF-α and IL-1β, which have been implicated in increased neuronal excitability 
(Coyle, 1998; Schwei et al., 1999; Tanga et al., 2004; Obata et al., 2006; Vega-Avelaira et 
al., 2007). It has been documented that microglia-released pro-inflammatory cytokines can 
exacerbate chronic and neuropathological pain via the alteration of neuronal excitability in 
the spinal cord in STZ diabetic rats (Tsuda et al., 2005). Enhanced expression of TNF-α and 
IL-1β has been observed in the spinal cords of STZ diabetic rats. The inhibition of microglia 
has been shown to reduce TNF-α and IL-1β levels and neuropathic pain-like behaviours in 
these animals (Talbot et al., 2010; Pabreja et al., 2011).  
Another possible mechanism by which activated microglia can cause detrimental 
consequences in diabetes is the production of neurotoxic agents. Hyperglycaemia is believed 
to induce the generation of reactive oxygen species (Nishikawa et al., 2000; Brownlee, 2005).  
These chemicals have been documented to be involved in the pathogenesis of diabetic 
neuropathic pain because antioxidant treatment prevents mechanical hypersensitivity in STZ 
diabetic rats (Cameron et al., 2001; Li et al., 2005a). An increase in oxidative stress in the 
spinal cord of STZ diabetic rats was reported and was attributed to microglial activation 
because the drug minocycline, which inhibits microglial activation, prevented the 
development of neuropathic pain associated with a decrease in oxidative stress (Pabreja et al., 
2011). These findings suggest that activated microglia could be a potential source of 
molecules that induce neurotoxicity and/or hyperexcitability in the context of diabetes; 
however, it appears that the functional consequence of microglial activation in the 
cardiovascular centres of the brain has not received adequate attention, and the possibility 
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that activated microglia may actually contribute to pathological cardiovascular changes in 
diabetes has not been investigated. 
 Astrocytes another cell types involved in neuroinflammation 1.6
Another important type of glial cells in the CNS is the astrocyte. As the name implies, 
astrocytes are star- or satellite-shaped cells with a central cell body and long, branched 
processes that extend outwards. The processes of adjacent astrocytes are connected to each 
other by gap junction channels that allow them to create a cellular network (Liu et al., 2011).. 
Although high in number, the functions of astrocytes in the CNS have been somewhat 
mysterious in the field of neuroscience. For decades, they have been viewed as supporting 
structural cells that hold neuronal tissue together, but in recent years, astrocytes have been 
shown to be the most multifunctional cells in the CNS. In their resting state, they play a vital 
role in the maintenance of the neuronal microenvironment, which is required for the proper 
functioning of the CNS. In fact, astrocytes have the ability to affect neuronal function by 
regulating extracellular potassium and pH levels, regulating blood flow, providing energy 
metabolites for neurons, participating in synaptic functions, contributing to the metabolism of 
neurotransmitters and facilitating cellular communication (Koehler et al., 2006; Hamby & 
Sofroniew, 2010). Thus, neuronal functioning is strongly linked to astrocytes via all of these 
processes, and astrocyte dysfunction may have a negative impact on neuronal activity. 
Astrocytes also express a diversity of receptors that enable them to respond to virtually all 
known neuroactive compounds, neuropeptides, growth factors, cytokines, small molecules 
and toxins. These receptors enable astrocytes not only to participate in signal processing but 
also to function as sentinels that sense insults within the CNS (Dong & Benveniste, 2001; 
Liberto et al., 2004), a role that has previously been attributed solely to microglia. In 
pathological conditions, astrocytes are activated and have the potential to display a diverse set 
of functional changes, including morphological changes, chemotaxis and proliferation (Ridet 
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et al., 1997). Astrocytes also perform immune functions and much like macrophage and 
microglia, are capable of phagocytosis (Magnus et al., 2002). It now seems certain that 
astrocytes have an important function in the initiation and regulation of the immune response 
of the CNS (Hauwel et al., 2005; Farina et al., 2007). Therefore, while microglia cells are the 
principal immune cells in the CNS and play a significant role in host defence, astrocytes are 
also considered to be one of the immune effecter cells in the CNS. 
 Astrocytes are key players in CNS immunity 1.6.1
In their basal state, astrocytes have a small cell body and long, highly branched processes; 
however, in response to CNS pathological challenges, such as stressful stimuli, brain injury, 
infection, inflammation or neurodegenerative diseases, they undergo a process in which they 
are recognised as activated astrocytes. This process is associated with morphological changes 
that vary according to the stimulus but include the enlargement of the soma (Pekny & 
Nilsson, 2005). Furthermore, cell-surface molecules and cellular components, such as glial 
fibrillary acidic protein (GFAP), are upregulated when astrocytes are activated (Lee & 
Brosnan, 1997). In the CNS, GFAP is specifically produced by astroglial cells, and it is 
widely used as a marker of astrocytes. Astrocyte activation causes a marked upregulation of 
GFAP that can be visualised with antibodies (Pekny & Pekna, 2004). Upon stimulation, 
astrocytes act as immune competent cells within the CNS, presenting antigens by expressing 
major histocompatibility complexes to activate T-cell activation (Benveniste, 1992; Kraus et 
al., 1992; Montgomery, 1994). Furthermore, as modulators of immune function, astrocytes 
display expressions of toll-like receptors, such as TLR3, which are involved in the generation 
of innate immune responses (Farina et al., 2007; Jacobs et al., 2011), and they secrete a wide 
variety of chemokines and cytokines that act as immune mediators, such as IL -1, -2, and -6, 
alpha and beta interferons, TNF and prostaglandins (Montgomery, 1994; John et al., 2003). 
Astrocytes also undergo other complex processes following activation, including an increase 
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in number; an upregulation of intermediate filament components (nestin and vimentin) (Lee 
& Brosnan, 1997); a release of neurotrophic factors; a release of various growth factors, 
including a basic fibroblast growth factor, glial-derived growth factor, platelet-derived 
growth factor and an insulin-like growth factor-I  (Travis, 1994; Merrill & Jonakait, 1995); a 
release of antioxidants (Wilson, 1997; Dringen et al., 2000); the generation of reactive 
oxygen species (Simmons & Murphy, 1992; Kugler & Drenckhahn, 1996; Marchetti & 
Abbracchio, 2005); and glial scar formation (Silver & Miller, 2004). Thus, activated 
astrocytes help orchestrate the immune responses of the CNS.  
 The role of activated astrocytes in pathological conditions 1.6.2
There is compelling evidence that activated astrocytes have the potential to protect neural 
functions and promote tissue repair. Their protective effects can be mediated through the 
removal of potentially excitotoxic glutamate (Bush et al., 1999; Swanson et al., 2004); the 
production of glutathione to protect the CNS from oxidative stress (Shih et al., 2003; Vargas 
& Johnson, 2009); neuroprotection via adenosine release (Lin et al., 2008); the protection of 
neurons from ammonia toxicity, which is implicated in CNS dysfunction (Rao et al., 2005); 
the protection of CNS cells by the degradation of amyloid-beta peptides (Koistinaho et al., 
2004); the repair of the BBB following injury (Bush et al., 1999); and the reduction of 
oedema following injury (Bush et al., 1999).   
Moreover, astrocytes’ involvement in the regulation of CNS inflammation in response to 
pathological insults is of particular interest regarding the neuroprotective effects of activated 
astrocytes. A large body of experimental studies have indicated that the inhibition of 
activated astrocytes is associated with a rapid infiltration of inflammatory cells into neural 
tissue following spinal cord injury (Okada et al., 2006; Herrmann et al., 2008). Similarly, 
Bush et al. showed that an ablation of activated astrocytes leads to a prolonged infiltration of 
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leucocytes associated with the degeneration of neurons in the injured CNS due to the absence 
of the glia scar (1999).  
Under pathological conditions, activated astrocytes may also result in neuronal death and/or 
hyperactivity due to their involvement in CNS inflammation. Activated astrocytes can 
interact with microglia cells, the key players in the immunological response of the CNS, and 
modulate microglial inflammatory responses by releasing pro-inflammatory or anti-
inflammatory cytokines (Min et al., 2006; Farina et al., 2007). Both in vivo and in vitro 
studies have reported TNF-α and IL-1β secretion from astrocytes (as reviewed in Dong and 
Benveniste 2001). An enhanced expression of TNF-α and IL-1β has been observed in 
activated spinal astrocytes following peripheral nerve injury (Wei et al., 2008). The inhibition 
of these pro-inflammatory cytokines has been shown to reduce neuropathic pain-like 
behaviours, suggesting that TNF-α and IL-1β contribute to increased neuronal excitability 
(Milligan et al., 2001). Moreover, studies on transgenic models that selectively delete or 
inhibit inflammatory molecules in astrocytes, such as transcription factor NF-kB, showed a 
reduction in the expression of pro-inflammatory cytokines and an improvement in functional 
recovery following spinal cord injury (Brambilla et al., 2005) or experimental autoimmune 
encephalomyelitis (Brambilla et al., 2009). These findings suggest that activated astrocytes 
could induce or facilitate neurotoxicity in various diseases.  
Interestingly, in animal models of neuropathic pain, the rapid activation of microglia has been 
observed in the spinal cord followed by a delayed activation of astrocytes (Sweitzer et al., 
1999; Winkelstein et al., 2001). Astrocyte activation persisted for a longer period compared 
with microglial activation (Coyle, 1998; Milligan & Watkins, 2009; Benarroch, 2010). At 
early time periods, microglial inhibition following peripheral nerve injury is effective on pain 
behaviours. In contrast, this inhibition at later stages has been shown to be less effective on 
pain behaviours (Raghavendra et al., 2003; Nakagawa et al., 2007; Padi & Kulkarni, 2008) 
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when compared with the inhibition of astrocytes in these animals (Meller et al., 1994; Okada-
Ogawa et al., 2009). It has been suggested that microglial activation may induce astrocyte 
activation. As such, we propose that astrocyte activation may also have a greater effect in 
causing long-term complications of diabetes than microglia; however, whether activated 
astrocytes in the PVN contribute to neuronal activation and thereby promote diabetic 
cardiovascular complications requires investigation. Activated astrocytes have been observed 
in the PVN of diabetic rats (Luo et al., 2002), but the time course, mechanism and 
consequences of astrocyte activation in the PVN have not been investigated.  
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 Inflammation in cardiovascular centres and its role in regulating 1.7
sympathetic activity and the cardiovascular system 
Although there is a lack of studies on the consequence of inflammation in the cardiovascular 
centres of diabetic rats, the consequences of inflammation in these areas is better studied in 
other cardiovascular diseases, such as hypertension and heart failure. A common cause of 
heart failure is myocardial infarction, which is characterized by an elevation in sympathetic 
nerve activity. Brain pro-inflammatory cytokines are implicated in a pathological increase in 
the sympathetic drive. An elevation of pro-inflammatory cytokines, such as TNF-α, IL-1β 
and IL-1, in the periphery has also been reported following myocardial infarction, and 
increased levels of these cytokines have been shown to correlate with the severity of heart 
failure (Tsutamoto MD et al., 1998; Maeda et al., 2000; Rauchhaus et al., 2000). Moreover, 
there is a large body of evidence suggesting that pro-inflammatory cytokine levels in the 
hypothalamic PVN are also elevated in heart failure, thereby contributing to the abnormal 
sympathetic overactivity (Felder et al., 2003; Francis et al., 2004a; Francis et al., 2004b). 
While the mechanisms responsible for increasing pro-inflammatory cytokines in the PVN are 
not known, it has been suggested that peripherally produced pro-inflammatory cytokines may 
cross the blood brain barrier (Banks et al., 1995). Despite this, local production of cytokines 
also has been demonstrated because mRNA levels for pro-inflammatory cytokines are 
elevated in the PVN (Francis et al., 2004b). In addition, in rats with acute myocardial 
infarction, an elevated expression of TNF-α and IL-1β has also been reported in the PVN. 
These cytokines induce the production of reactive oxygen species in the PVN and contribute 
to exaggerated neuronal activity and increased sympathetic activity (Guggilam et al., 2007; 
Guggilam et al., 2008). While microinjection of TNF-α into the PVN has been shown to 
increase renal sympathetic activity, most likely through the activation of PVN neurons 
(Felder et al., 2003; Kang et al., 2008), an infusion of a TNF-α blocker into the PVN of rats 
with heart failure decreased sympathetic hyperactivity (Kang et al., 2010). We have 
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demonstrated that microglia are activated in the PVN following myocardial infarction in rats, 
suggesting that these cells may be a source of the local production of pro-inflammatory 
cytokines in the PVN  (Rana et al., 2010; Dworak et al., 2012).  Microglial activation was 
also observed in the NTS and RVLM following myocardial infarction in rats (Dworak et al., 
2014).  
Hypertension is another condition for which neuroinflammation and increased activity in the 
sympathetic nervous system may be involved in the pathogenesis. TNFα and IL-1β mRNA 
were found to be increased in the PVN of spontaneously hypertensive rats (Agarwal et al., 
2011) and angiotensin II–induced hypertension rats (Kang et al., 2009b). Other researchers 
revealed that an ICV infusion of recombinant IL-1β and TNF-a results in increased 
sympathetic nerve activity and elevated arterial blood pressure in conscious control animals 
(Kimura et al., 1993; Kannan et al., 1996; Ufnal et al., 2005). Specifically, PVN stimulation 
with these mediators of inflammation has been shown to have the same effect in anesthetized 
rats (Shi et al., 2011). These studies suggest that pro-inflammatory cytokines in the PVN play 
a key role in the regulation of the cardiovascular system through the modulation of PVN 
neuronal activity.  
Previous data from our laboratory indicates that the injection of activated microglia into the 
PVN in naïve rats produces an increase in blood pressure. Interestingly, it has been postulated 
that microglia and their pro-inflammatory cytokines in the PVN participate in the 
development of Ang-II-induced hypertension. Chronic Ang II infusion has been shown to 
increase the mean arterial pressure and to activate microglia in the PVN (Shi et al., 2010a). 
The inhibition of microglial activation via ICV minocycline treatment reduced arterial blood 
pressure, reversed cardiac hypertrophy and reduced the pro-inflammatory cytokine 
expression in the PVN in response to Ang II infusion (Shi et al., 2010a). Moreover, the 
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microinjection of anti-inflammatory cytokine IL-10 into the PVN also resulted in attenuated 
microglial activation and reduced hypertension in this model (Shi et al., 2010a).   
Similarly, the NTS and RVLM regions, which are involved in the regulation of 
cardiovascular functions, have been found to exhibit abnormal inflammatory responses in 
spontaneously hypertensive rats. In the RVLM, the expression of TNFα and IL-1β are 
increased in hypertensive rats compared with normotensive rats (Agarwal et al., 2011). There 
is also evidence of an increased reactive oxygen species production in the RVLM in 
hypertensive rats. These pro-inflammatory cytokines and reactive oxygen species are well-
documented to induce neuronal activity via the transcription factor NFκB expression (Shi et 
al., 2010b; Hirooka et al., 2011). Thus, abnormal inflammatory responses seen in the RVLM 
may contribute to sympathetic overactivity in this model. The NTS of spontaneously 
hypertensive rats also exhibited signs of inflammation, including the expression of junctional 
adhesion molecule-1 (Waki et al., 2007). In addition, Takagishi et al. reported that the 
microinjection of IL-6 into the NTS decreased baroreceptor sensitivity, a phenomenon 
associated with hypertension (2010).  
Collectively, these findings support the theory that inflammation in cardiovascular centres 
induces the over-activation of sympathetic nerves, which disrupts the normal functioning of 
the heart and blood vessels and may contribute to cardiovascular complications in other 
diseases. Whether the same mechanisms are involved in the increase in sympathetic nerve 
activity in diabetes is not known. 
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 Rationale and research questions 1.8
In summary, cardiovascular complications, such as hypertension and cardiomyopathy, are 
common in diabetes mellitus. It is well-known that an elevated sympathetic drive occurs in 
diabetes and may contribute to the development of diabetic cardiovascular complications. 
Although the cause of the abnormal activation of sympathetic nerves in diabetes is not well 
understood, there is increasing evidence that increased levels of pro-inflammatory cytokines 
at the level of cardiovascular centres play an important role in other cardiovascular disorders. 
Diabetes is known to cause pathological changes in the peripheral nerves and to result in 
subsequent inflammation within the CNS, at least in the spinal cord. Our previous data 
indicated that microglia become activated in the areas of the brain that control the 
cardiovascular system in STZ diabetic rats (Rana et al., 2014). Because activated microglia 
are involved in mediating inflammation, we hypothesize that they may influence the 
cardiovascular control centres to cause increased sympathetic nerve activity, which in turn 
contributes to cardiovascular complications. Thus, we will also investigate whether the 
inhibition of activated microglia in the PVN can reduce or prevent cardiovascular changes in 
STZ diabetic rats.  
Astrocytes also contribute to inflammation in the CNS, and published studies have 
demonstrated that activated astrocytes have the potential to increase neuronal hyperactivity 
and thereby exaggerate pathological processes and are potentially more important than 
microglia in the long-term complications of diabetes. Thus, we will investigate whether 
astrocytes are activated in the PVN of diabetic rats at different time points following STZ 
treatment and whether microglia induce astrocyte activation in the PVN in these animals.  
As mentioned previously, giving STZ-treated diabetic rats 1% NaCl to drink causes a marked 
elevation in their blood pressure (Maeda et al., 2007). The mechanisms underlying this 
hypertension are poorly understood but may be explained in part by an increased blood 
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volume. Interestingly, hypertension develops quickly at 2 weeks after STZ treatment in these 
animals; however, at this time period (2 weeks), STZ diabetic rats show no microglial 
activation in the cardiovascular centres (Rana et al., 2014). Despite the possible effects of 
drinking 1% NaCl on blood volume, whether 1% NaCl also influences inflammation in 
cardiovascular centres to cause an increase in blood pressure in STZ diabetic rats is not 
known. Thus, we will investigate the effects of 1% NaCl on blood pressure, baroreceptor 
reflex, cardiac function and cardiovascular centre inflammation in STZ diabetic rats. In 
addition, we will investigate whether inhibition microglia in the PVN can reduce or prevent 
diabetic complications in STZ diabetic rats given 1% NaCl, as observed in the animal model 
of angiotensin II-induced hypertension (Shi et al., 2010a).  
Previously, we have reported the time range of microglial activation in the PVN in STZ 
diabetic rats (Rana et al., 2014), but whether this activation also occurs in other species and 
other models of diabetes is not known. The mouse is the most suitable for genetic 
manipulations and can also be used in cellular and molecular studies. Thus, it is useful to 
examine whether microglia and neurons are activated in the PVN in STZ diabetic mice and 
the time course of any activation. This would also provide information about whether the 
results obtained in STZ diabetic rats are due to the effects of diabetes or are specific to the 
model tested. 
Antioxidant treatment has been shown to prevent cardiovascular diseases in humans 
(Sugamura & Keaney, 2011). Systemic infusion of hydrogen sulphide (H2S), which is known 
to have antioxidant properties, has been reported to reduce oxidative stress and blood 
pressure in an animal model of angiotensin II (Al-Magableh et al., 2015), but whether the 
beneficial effect of H2S is mediated via a central action is not clear.  A deficiency in the 
levels of H2S has been shown to occur in diabetic humans as well as animals (Jain et al., 
2010), and this deficiency contributes to the development of diabetic complications (Lefer, 
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2008; Szabo, 2012). In fact, H2S also has anti-inflammatory actions, and several studies 
showed that H2S reduces microglial and neuronal activation in vitro (Hu et al., 2007; 
Umemura & Kimura, 2007; Hu et al., 2009). Thus, we will investigate whether hydrogen 
sulphide influences PVN inflammation in STZ diabetic mice.   
Type 2 diabetes in humans is also associated with cardiovascular disease and an overactivity 
of the sympathetic nerves that control the cardiovascular system. A high fat diet is a major 
contributing factor in the pathogenesis of type 2 diabetes, the most common form of diabetes 
in humans. If hyperglycaemia results in subsequent brain inflammation in STZ diabetic rats, 
it may be expected to also observe brain inflammation in type 2 diabetic animals. Thus, we 
will investigate whether microglia and neurons are activated in the PVN of mice treated with 
a low dose of STZ and fed a high-fat diet.   
 Project specific aims 1.8.1
The overall aim of this project is to determine whether inflammation within in the region of 
the hypothalamus that controls cardiovascular function can contribute to the development of 
cardiovascular and autonomic complications in diabetes. To achieve this, we address the 
following specific aims: 
 To determine whether the inhibition of microglial activation or action in the PVN can 
ameliorate some of the cardiovascular complications of STZ diabetes.  
 To investigate the time course of astrocyte activation in the PVN in STZ-treated diabetic 
rats and whether inhibiting the activation of microglia can prevent the activation of 
astrocytes in these animals. 
 To investigate the effects of 1% NaCl on cardiovascular parameters and whether 1% 
NaCl influences inflammation in the CNS cardiovascular centres in STZ-diabetic rats and 
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whether the inhibition of microglial activation in the PVN can reverse any of the changes 
observed. 
 To investigate whether microglia are activated in the cardiovascular centres of the brain 
in STZ diabetic mice and the time course of this activation. 
 To investigate the effect a high-fat diet and hydrogen sulphide on PVN inflammation in 
STZ diabetic mice. 
 
  
 
Chapter Two: Materials and Methods 
 
Chapter Two: Materials and Methods Page | 43 
 
 
 
 Animals  2.1
All animal experiments were approved by the RMIT University animal ethics committee and 
were conducted in accordance with the National Health and Medical Research Council 
guidelines. Male Sprague Dawley rats and C57BL6/J mice were obtained from the Animal 
Resource Centre (Perth, Australia). 
All animals were kept in standard high-top rat cages with environmental enrichment in a 
temperature-controlled room on a 12:12 hour light/dark cycle (lights on at 7:00 A.M.) in the 
Animal Facility (RMIT University, Victoria, Australia). Two male Sprague Dawley rats were 
housed per rat cage, and 4-5 C57BL6/J mice were housed per mouse cage. The plastic cages 
were cleaned and replaced once each week. Food and water were provided for all animals at 
all times. All animals were acclimatized for 4-7 days prior to undergoing any experimental 
procedure. 
 Animals models of diabetes  2.2
 STZ / NaCl treatment 2.2.1
Male Sprague Dawley rats weighing 170-200 grams were exposed to a heat lamp for 2-3 
minutes in a small animal cage to dilate the tail vasculature and then were given an 
intravenous injection of streptozotocin (STZ, 55mg/kg, Sigma) through the tail vein using a 
27-gauge needle. The control rats were injected with a citrate buffer (0.42% in sterile saline, 
pH 4.5). Each week thereafter, blood was taken by heat lamp exposure followed by 
puncturing the tail vein with a 30-gauge needle to evaluate the blood glucose levels using a 
One Touch glucometer (Accu-Chek Perfoma). When the blood glucose exceeded 25 mM, the 
subcutaneous injection of insulin (3-4 units twice per week) was given. Two days after the 
induction of diabetes, the rats were placed in individual cages with free access to a 1% NaCl 
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solution OR tap water as a control. The amount of saline or water ingested was monitored 
daily by weighting the water bottles. 
 STZ / high fat diet treatment 2.2.2
Male C57BL/6J mice (10 weeks old) were provided standard standard lab chow diet ( 8% 
calories from fat, 21% calories from protein, and 71% calories from carbohydrate) or a high-
fat diet (45% calories from fat, 20% calories from protein, and 35% calories from 
carbohydrate) for up to 10 weeks. Mice were then injected with either vehicle (saline) or a 
low dose of streptosotocin (STZ, 40 mg/kg/day) for five consecutive days in order to induce 
diabetes. Mice were then received an intraperitoneal injection with either or a citrate buffer or 
a low dose of streptosotocin (STZ, 40 mg/kg/day) for five consecutive days in order to 
induce type 2 diabetes.  
 STZ/ NaHS treatment 2.2.3
Male C57BL/6J mice aged 8 weeks (Animal Resource Centre, Western Australia) were 
randomly divided into three groups: Vehicle (Citrate buffer) control, diabetic and diabetic 
treated with NaHS. Type 1 diabetes was induced with streptozotocin (STZ, 60mg/kg/day, ip) 
for two weeks. The control group received an equivalent volume of the vehicle (0.1M citrate 
buffer, pH 4.5) daily for two weeks. NaHS (100µmol/kg/day, ip) was given daily for the final 
four weeks.  Blood glucose measurement was performed at the beginning and the end of the 
experiment and twice a week during the experiment for diabetic mice. Insulin (0.1U, i.p, 50% 
isophane insulin (Protaphane) + 50% neutral insulin (Actrapid)) was given when the blood 
glucose level exceeded 30mM.  Control group blood glucose was also measured during week 
5. Blood samples were obtained from the tail vein and blood glucose concentration was 
measured using a one touch glucometer ACCU-CHEK Advantage (Roche, NSW, Australia) 
and glycated haemoglobin (HbA1c) using an in2it (II) analyser (281-0000EX) (Bio-Rad, 
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NSW, Australia). Induction of diabetes was considered successful when the blood glucose 
level was greater than 20mM.  
 Surgical procedure  2.3
 Blood Pressure and heart rate recording under anesthesia  2.3.1
At 2 or 6 weeks following STZ/citrate buffer treatment, the animals were anaesthetized using 
isofluorane (5% in air or oxygen using a small animal anaesthetic Vetquip machine) by 
placing the animal in a closed box. Immediately following induction, the animals were placed 
on a heat pad, and isofluorane (2-3% in air or oxygen) was continually provided via a mask. 
For cannulation, the right groin region was shaved and swabbed with 70% alcohol. A midline 
incision (4-5 mm) through the skin in the right groin region was then made to expose the 
femoral vein and artery. A blunt dissection was made to clear the subcutaneous fascia and to 
separate the femoral vein from the artery. Two sutures (silk 3/0, Dynek Pty, Australia) were 
placed under the femoral vein and artery and pulled tight to obstruct the blood flow during 
the insertion of a separate cannula. Both the femoral vein and artery were then pricked with 
very fine McPherson-Vannas 8cm scissors (World Precision Instruments Inc., FL, USA). The 
cut in the femoral vein and artery was expanded by inserting closed fine tweezers # 5 (World 
Precision Instruments Inc., FL, USA) into the cut to allow a cannula tip to be introduced into 
the vessel. The cannula, filled with heparinised saline (50U/mL), was inserted into the 
femoral vein and artery while the tweezer was withdrawn. The cannula was then threaded 
along the femoral vein and artery and secured with a sutuer. The skin incision was then 
closed using stiches (silk 0-USP, Dynek Pty, Australia). At this stage, the anaesthetic agent 
was changed to urethane (1-1.4 g/kg intravenously), which has the least effect on dampening 
the cardiovascular reflexes compared to the other anaesthetics (Barringer et al., 1990). 
Supplemental doses of urethane were given as required. Every 5 minutes, the depth of 
anaesthesia was tested using the corneal and pedal reflexes. The arterial cannula was attached 
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to a transducer for monitoring blood pressure and heart rate. Prior to elicit the baroreceptor 
reflex, mean arterial pressure and heart rate were calculated from the arterial pressure pulse 
over a period of 5 minutes using labchart (ADInstruments, Bella Vista, NSW, Australia).                                                                                                                 
 Conscious blood pressure recording via tail cuff 2.3.2
The systolic blood pressure in the restrained conscious animals was recorded via a tail cuff 
blood pressure measurement system (ML125 NIBP Controller and MLT125/R Pulse 
Transducer/Pressure Cuff for NIBP - Rat). At 2 weeks following STZ/buffer treatment and 10 
days after minocycline or saline ICV infusion, the rats initially trained 2-3 times for recording 
blood pressure to acclimatize them to preheating, the restrainer and the inflation and deflation 
of the tail cuff. Prior to actual recording, the rats were exposed to a heat lamp for 5 minutes at 
30°C and then placed in restrainers, and the tail cuff was placed around the tail of the rat for 
10-15 minutes. Then, the systolic blood pressure was recorded. 
 Baroreceptor reflex testing  2.3.3
Before the beginning of the experiment recording, blood pressure and heart rat were allowed 
to stabilize for at least five minutes. The venous cannula was then flushed with saline (0.2ml), 
and five minutes later, four different doses of phenylephrine (1, 2, 5 and 10 μg/kg) were 
given I.V. These doses were given in sequence to elicit the baroreceptor reflex. For each 
dose, 0.2 ml of phenylephrine solution was injected followed by flushing with 0.2 ml of 
saline. From 5-8 minutes were allowed between each dose of phenylephrine to allow blood 
pressure and heart rate to return to their original baseline levels before the injection of the 
next dose. The peak values of mean arterial blood pressure and heart rate in response to 
increasing doses of phenylephrine were measured and recorded using a PowerLab data 
acquisition system (ADInstruments, NSW, Australia). 
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 Implantation of brain infusion catheters and osmotic pumps 2.3.4
One week following STZ/citrate buffer treatment, the animals were anaesthetized using 
isofluorane as previously described. The head of the rat was shaved and swabbed with 70% 
alcohol before being placed in a David Koph stereotaxic frame, such that the bregma and 
lambda were positioned on the same horizontal plane to allow for the accurate placement of 
the cannula in the lateral ventricle using a coordinate system. A midline incision was then 
made through the skin to expose the skull. The bregma and lambda were identified, and a 
small hole (1-2 mm diameter approximately) was drilled, centred at 0.7 mm caudal and 1.8 
mm lateral from the bregma. Another hole was then drilled at a distance of 5mm from the 
initial hole to allow for the insertion of jeweller screws to act as anchors. A guide cannula 
was then inserted into the lateral ventricle (stereotaxic coordinates: 0.7 mm caudal to bregma, 
1.8 mm lateral to midline, and 3.7 mm ventral to the surface of the dura). It was then 
advanced approximately 4 mm down to the lateral brain ventricle using a micromanipulator 
attached to the stereotactic frame. After the insertion procedure, dental cement was applied to 
the skull, the cannula and the screw. The dental cement was then set using a UV light device. 
Next, the skin of the back was separated from the underlying tissue by blunt dissection to 
insert a small osmotic pump (Alzet, 2004, Weight 1.1g, volume 1ml) under the skin. The tube 
attached to the osmotic pump was then connected to the intraventricular cannula to allow 
direct infusion of either saline (0.9% NaCl) or minocycline (5 μg/h) over a period of 4 weeks. 
Upon completion of the implantation procedures, the incision was sutured (silk 0-USP, 
Dynek Pty, Australia), and the animal was allowed to recover. 
 Implantation of telemetric blood pressure monitoring devices  2.3.5
Three weeks after the STZ/citrate buffer treatment, the animals were anaesthetized using 
isofluorane as previously described. The abdominal wall was shaved and swabbed with 70% 
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alcohol before a midline incision was made through the skin. With the aid of retractors, the 
intestine and fat tissue were pulled aside to expose the abdominal aorta. Then, the abdominal 
aorta was dissected free from the surrounding tissue under an operating microscope. Two 
sutures (silk 3/0, Dynek Pty, Australia) were placed under the abdominal aorta to obstruct the 
blood flow during the introduction of a catheter. The aorta was then cut using McPherson-
Vannas 8cm scissors or a 27-gauge needle followed by introducing the catheter and gluing 
using tissue glue. A piece of surgical mesh was applied and glued to the outside of the aorta 
to further stabilize the catheter. The body of the telemetry was covered with sterilised 
surgical mesh and placed in the abdominal cavity. Upon completion of the implantation 
procedures, the muscle layers and skin were sutured with absorbable sutures, and the animal 
was allowed to recover.  
 Echocardiographic measurements 2.3.6
Six weeks after the STZ/citrate buffer treatment, the animals were anaesthetized with 
pentobarbitone 40 mg/kg i.p. To assess the cardiovascular function in these animals, a Vivid 
e echocardiography machine with a 10-MHz phased array probe (GE Vingmed, Horten, 
Norway) was used. The left chest, abdomen and groin were shaved and swabbed with 70% 
alcohol followed by applying a layer of acoustic coupling gel. A two-dimensional and 
Doppler echocardiography were performed with the animal in the left recumbent position. M-
mode echocardiograms were recorded from the parasternal short-axis view of the left 
ventricle at the mitral valve level to measure the left ventricular internal diameter in the 
systole (LVIDs) and the left ventricular internal diameter in the diastole (LVIDd). These 
parameters were assessed using at least five cardiac cycles from the M-mode image. Next, a 
flow velocity was assessed using pulsed-wave Doppler echocardiography from the apical 
four-chamber view. Mitral inflow velocities at early diastole (E) and late diastole (A) were 
evaluated, and their ratio (E/A ratio) was calculated. The Doppler images were obtained with 
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a heart rate at approximately 300-350 bpm and all measurements were obtained from an 
average of at least three consecutive heart beats.  
 Ventricular hemodynamics 2.3.7
Immediately after the echocardiography procedures, a midline incision was made through the 
neck skin to expose the right carotid artery. The artery was dissected free from the 
surrounding tissue under an operating microscope, and 2 fine sutures (silk 3/0, Dynek Pty, 
Australia) were placed under it and pulled tight to obstruct the blood flow. The carotid artery 
was then pricked with very fine McPherson-Vannas 8cm scissors (World Precision 
Instruments Inc., FL, USA). A telemetry transducer catheter was used to insert it into the 
carotid artery, while monotring the blood pressure trace. It was then advanced 4-5 mm 
approximately into the left ventricle to assess the left ventricular end diastolic pressure, dP/dt 
max and heart rate using a PowerLab data acquisition system (ADInstruments, NSW, 
Australia).  
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Figure 2-1. Echocardiogram- representative M-mode image and 
measurements of left ventricular internal diameter in systole (LVIDs) and 
left ventricular internal diameter in diastole (LVIDd) in control animals. 
LVIDd 
=0.63mm 
LVIDs 
=0.21mm 
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Figure 2-2. Functional echocardiography: apical four-chamber 
view pulsed-wave Doppler displaing E and A wave in control 
animals.  
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 Blood collection 2.4
For blood collection, a 1ml syringe was flushed with 6% Ethylenediaminetetraacetic acid and 
10 ul of the same solution was added to the syringe before connecting it to the venous 
cannula to collect blood while the animal was under deep anaesthesia. A minimum of 500ul 
of blood was collected in each syringe. The haematocrit and haemoglobin concentration were 
determined using ACTdiff 5 blood analyser (Beckman, USA). Blood samples were 
immediately centrifuged at 1500 rpm for 10 minutes. Plasma osmolarity was measured by 
using an osmometer (Gonotec Osmomat 030). 
 Tissue collection 2.5
 Perfusion 2.5.1
Two, 6 or 8 weeks after the STZ/buffer treatment, the animals were anaesthetied with 
pentobarbital sodium (180mg/kg of body weight). The abdominal skin was cut to expose the 
end of the sternum, which was grasped and the diaphragm was cut laterally on both sides to 
access the rib cage. The pump needle (25-gauge) was inserted into the aorta through the left 
ventricle and clamped before the atrium was cut. Phosphate buffered saline (PBS) (200ml) 
was perfused at a pressure of up to 100 mmHg and when the blood had cleared from the 
body, the perfusing solution was changed to 4% paraformaldehyde solution.  
 Brain collection 2.5.2
The occipital bone and vertebrae were exposed via a midline incision in the skin of the head. 
With the aid of rongeurs, the occipital bone was carefully removed to expose the cerebellum 
and brainstem. The bone over the posterior part of the nasal cavity was then cut with the 
rongeurs. The dura mater over the cortex of the cerebellum, and the cerebral hemispheres 
were elevated slightly and cut by sharp scissors. The brain was elevated using a long thin 
spatula and the optic nerves cut to allow it to be removed and post-fixed in a 4% 
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paraformaldehyde solution for 4 hours at 4°C. It was then placed in a cryoprotection solution 
(30% sucrose in PBS) for at least 2 days at 4°C before sectioning processing. 
 Cryostat sectioning   2.5.3
A Leica CM1900 Cryostat was used for freezing and sectioning brain tissue. A few drops of 
embedding medium (OCT, Optimal Cutting Temperature) were placed on the surface of the 
specimen disc and the brain was positioned onto it. The tissue was frozen within the cryostat 
chamber at –20 °C for approximately 20 minutes. The transverse sections of the brain 
included were the paraventricular nucleus, rostral ventrolateral medulla and nucleus of the 
solitary tract, which were sectioned at 40 µm thickness and immediately mounted onto 
gelatine coated slides and left to dry for 2 hours at room temperature. 
 Immunohistochemistry 2.6
Immunohistochemistry was used to identify various markers of glial cells (microglia and 
astrocytes) and neurons in the cardiovascular centres of diabetic animals. CD11b and Glial 
Filament/Fibrillary Acidic Protein (GFAP) markers were used to show morphological 
changes in microglia and astrocytes, respectively. In addition, nuclear c-fos protein 
immunoreactivity was used to identify activated neurons in the brain tissue (Dworak et al., 
2014).   
All sections of the brain were washed 3 times in PBS (each wash for 5 min), then the 
endogenous peroxidase activity was destroyed by incubating with 0.5% H2O2 (Sigma-
Aldrich, Australia) for 30 minutes at room temperature. The sections were blocked with 10% 
normal horse serum for 1 hour at room temperature to prevent nonspecific binding and then 
washed 3 times in PBS. The PBS was then replaced and the sections were washed 3 times in 
PBS before incubation with 0.5% Triton X (Sigma-Aldrich, Australia) in PBS for 30 minutes 
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at room temperature to enhance antibody penetration, and then washed 3 times in PBS. The 
sections were then incubated with the appropriate primary antibodies. 
A mouse monoclonal primary antibody (OX-42 produced in house diluted 1:150 in 2% 
normal horse serum and 0.3% Triton X-100 in PBS) was applied to the sections, and the 
sections were placed into a humidified environment and left for three nights at –4°C. The 
sections were then washed three times with PBS and incubated with a biotinylated antimouse 
secondary antibody (diluted 1:400 in 2% normal horse serum in PBS: catalogue number BA-
2001; Vector Laboratories,Burlingame, CA, USA) for 2 hours at room temperature. Next, the 
sections were washed three times with PBS and incubated with extravidin (diluted 1:40 in 2% 
normal horse serum in PBS) for 2 hours at room temperature. The sections were then washed 
three times with PBS and the slides were placed in 0.05% 3,3-diaminobenzidine 
hydrochloride (DAB; Sigma-Aldrich, Australia) in PBS for 10 minutes. Then 5 μl of 30% 
hydrogen peroxide was added to start the reaction for 10 to 15 minutes at room temperature. 
The reaction was then stopped by washing them with PBS. The slides were left for 1 hour at 
room temperature to dry and then cover-slipped with Depex mounting medium (BDH Lab 
Supplies, Poole, UK). 
To detect changes in astrocytes and c-fos activity, similar techniques were applied using a 
rabbit monoclonal primary antibody (GFAP Sigma-Aldrich, Australia: diluted 1:150 in 2% 
normal horse serum and 0.3% Triton X-100 in PBS) and a rabbit polyclonal primary antibody 
(Fos, diluted 1:400 in 2% normal horse serum and 0.3% Triton X-100 in PBS: c-Fos (K-25): 
sc-253, Santa Cruz Biotechnology, CA, USA), respectively and then incubated with the anti-
rabbit secondary antibody (diluted 1:400 in 2% normal horse serum in PBS: catalogue 
number B8895, Sigma-Aldrich, Australia ).  
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 Quantification and morphological analysis  2.7
OX-42 antibody staining was used to identify morphological changes in microglia cells. The 
quantification and morphological analyses of microglia were performed as previously 
discussed (Rana et al., 2014) with a light microscope using ×400 magnifications. On the basis 
of subjective classification, non-activated microglia were identified by their small soma from 
which there emanated extensive, highly branched, long, thin processes. However, activated 
microglia were defined by three main criteria; stronger immunohistochemical staining for the 
marker CD11b (clone OX-42), the presence of a clearly enlarged soma, and marked changes 
in the appearance of the processes which were now reduced in number, but considerably 
thicker and shorter giving a stubby appearance. The number of microglia was counted in 
squares measuring 0.2 × 0.2 mm in size in all examined regions. The numbers of normal and 
activated microglia in the PVN were counted in two squares to cover the region from 0-1 mm 
lateral to the edge of third ventricle. In the NTS and RVLM, a similar analysis was 
performed. The percentage of activated microglia was determined by counting the number of 
activated microglia and total microglia in all examined regions. To quantify the length of 
microglial processes, the longest process was measured in 10 randomly selected microglia in 
one square in each brain region examined. A similar analysis for accounting for the number 
of neuronal activation was performed. The quantification of microglial and neuronal 
histology was done with the experimenter blinded to the experimental conditions in two 
sections from each region in all animals.  
 Statistical analysis 2.8
The statistical analysis was performed using GRAPH PAD PRISM, version 6 (GraphPad 
Software Inc., San Diego, CA, USA). Data are expressed as the mean ± SEM. The 
significance between groups was evaluated using a one way ANOVA. If a statistical 
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difference was obtained, subsequent comparisons between all groups were made using 
Tukey’s post hoc test.  
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 Introduction 3.1
Cardiovascular complications are common in diabetes mellitus (O'Keefe et al., 1999). 
Evidence demonstrates that overactivation of the sympathetic nerve is crucial in the 
development of these complications (Perin et al., 2001; Augustyniak et al., 2002; Patel et al., 
2011). Increased activity of the sympathetic nervous system has also been reported in both 
humans and animals with type 1 diabetes (Perin et al., 2001; Patel et al., 2011), but how this 
occurs is not clear.  
The paraventricular nucleus (PVN) is a region of the brain that controls sympathetic nerve 
activity and the cardiovascular system (Kannan et al., 1989; Badoer, 2001). Our study and 
other previous studies on rats injected with STZ to induce chronic hyperglycaemia have 
indicated that pathological changes occur in the PVN, including abnormally increased 
neuronal activity (Krukoff & Patel, 1990; Zheng et al., 2002; Rana et al., 2014). The central 
mechanisms behind PVN neuronal activation are not well understood, but studies on other 
cardiovascular diseases have suggested that proinflammatory cytokines increase neuronal 
activity in the PVN (Rivest et al., 1992; Shi et al., 2010a) and contribute to increased 
sympathetic activity (Guggilam et al., 2007; Guggilam et al., 2008); however, the source of 
proinflammatory cytokines in diabetes is not known.  
The resident immune cells within the CNS that mediate inflammation are microglia. These 
cells have been implicated in the development of various neurological diseases. It has been 
suggested that the inhibition of microglia is therapeutically useful in preventing the 
consequences of inflammation (Sweitzer et al., 1999; Moalem & Tracey, 2006; Milligan & 
Watkins, 2009). Previously, we found that microglia were activated in the PVN in STZ 
diabetic rats (Rana et al., 2014). Activated microglia can release proinflammatory molecules 
and cytotoxic factors, such as nitric oxide and TNF-α, which induce the activation of neurons. 
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Despite this evidence, whether the inhibition of microglial activation in the PVN can prevent 
the cardiovascular complications in STZ-induced diabetic rats has not been investigated. 
Astrocytes also contribute to immune responses and inflammation in the CNS. Published 
studies have demonstrated that activated astrocytes in the CNS have the potential to 
exaggerate pathological processes (Meller et al., 1994; Okada-Ogawa et al., 2009). 
Furthermore, in vivo and in vitro studies have reported that activated astrocytes produce a 
variety of proinflammatory cytokines, including   IL-1, IL-6 and TNFα, which may cause 
abnormal neuronal activity (Aloisi et al., 1992; Lee et al., 1993; Johnstone et al., 1999). 
Following spinal nerve injury in rats, the rapid activation of microglia in the spinal cord is 
observed followed by a delayed activation of astrocytes, and this activation persists for a long 
period compared with microglial activation (Coyle, 1998; Milligan & Watkins, 2009; 
Benarroch, 2010). Hence, we hypothesised that activated astrocytes may have a greater effect 
in causing long-term complications of diabetes than microglia. 
Regarding diabetic complications, in long-term STZ diabetic rats, hypertension has been 
demonstrated with the tail cuff measurement method (Bunag et al., 1982; Katayama & Lee, 
1985; Hartmann et al., 1988; Ramos, 1988). In contrast, data from other studies that used the 
indirect blood pressure recordings are inconsistent (Fazan et al., 1997; Van Buren et al., 
1998; Fazan et al., 1999; Schaan et al., 2004). The tail cuff measurement has been suggested 
to be inaccurate in long-term STZ diabetic rats due to morphological changes in the tail that 
lead to a change in the relationship between the pressure at the cuff and the pressure actually 
transmitted to the caudal artery. Therefore, in this study, a telemetry system was used to 
measure cardiovascular changes more precisely in conscious animals on a continuous basis, 
thereby also reducing the effect of handling induced stress.  
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Therefore, we aimed to investigate: (i) the effect of the inhibition of microglia in the PVN on 
blood pressure and heart rate in STZ diabetic rats, (ii) whether astrocytes are activated in the 
PVN in STZ diabetic rats (iii) and the mechanisms of astrocyte activation in these animals.  
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 Results 3.2
 Body weight and blood glucose measurements 3.2.1
Eight weeks after injection of Male Sprague Dawley rats with either STZ or citrate buffer, all 
groups exhibited a continuous growth in body weights, but as expected, the body weights of 
the control group were significantly higher (P<0.001) compared with diabetic animals with 
an ICV infusion of saline (STZ+saline) and the diabetic animals with an ICV infusion of 
minocycline (STZ+minocycline) (Figure 3-1A). Minocycline treatment did not significantly 
affect body weight in diabetic animals. The blood glucose levels were lower than 10 mmol/L 
in the control group and higher than 25 mmol/L in diabetic animals, indicating extreme 
hyperglycaemia (Figure 3-1B). The STZ+saline group exhibited significantly higher (P < 
0.0001) blood glucose levels compared with the control group, as expected. This was also the 
case for blood glucose levels in the STZ+minocycline group when compared to the control 
group (P < 0.0001). Minocycline treatment had no effect on blood glucose in diabetic 
animals. 
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Figure 3-1. Effect of minocycline treatment on body weight and blood glucose of 
diabetic rats. A: Body weights; and B: blood glucose levels measured at weekly intervals 
after the injection of rats with either citrate buffer in control animals with an ICV infusion of 
saline (control) or STZ in diabetic animals with an ICV infusion of saline (STZ+saline) or 
minocycline (STZ+minocycline). Number of rats = 8, 4, 8 respectively. Data are expressed as 
the mean ± SEM. Significance was evaluated using one way ANOVA followed by Tukey’s 
post hoc test for all comparisons (Control vs STZ+saline, control vs STZ+minocycline and 
STZ+saline vs STZ+minocycline) in this and all subsequent figures; * indicates P<0.05; ** 
indicates P<0.01; *** indicates P<0.001; **** indicates P < 0.0001 for comparisons between 
diabetic groups and controls; ♯ indicates P<0.05; ♯♯ indicates P<0.0; ♯♯♯ indicates P<0.001; 
♯♯♯♯ indicates P < 0.0001 for comparisons between diabetic groups. 
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 Effect of minocycline on the mean arterial pressure and heart rate of 3.2.2
diabetic rats 
In this study, there were technical issues with the telemetric recording apparatus that resulted 
in a limitation in our ability to record the mean arterial pressure and heart rate in an adequate 
number of diabetic animals as well as to perform a statistical analysis. In addition, animals 
did not recover well following surgical implantation of the telemetry; however, our 
preliminary data indicated that the STZ+saline group (N=1) showed reduced blood pressure 
compared to the control group (N=6) (Figure 3-2A). Moreover, our results from the 
STZ+minocycline group (N=2) showed decreases in blood pressure similar to those seen in 
the STZ+saline group. The STZ+saline and STZ+minocycline groups showed a decrease in 
heart rate compared to the control group (N=6) (Figure 3-2B). Because the number of rats 
examined was small, we were unable to determine the effect of minocycline treatment on the 
blood pressure and heart rate of STZ diabetic animals. 
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Figure 3-2. Effect of minocycline treatment on cardiovascular parameters in diabetic 
rats. A: The mean arterial blood pressure (MAP); and B: The heart rate of conscious control 
animals with an ICV infusion of saline (control+saline) and diabetic animals with an ICV 
infusion of saline (STZ+saline) or minocycline (STZ+minocycline). Number of rats = 6, 1, 2 
respectively. Data are expressed as the mean ± SEM.  
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 Effect of minocycline on microglial activation in the paraventricular 3.2.3
nucleus of diabetic rats  
The OX-42 antibody was used to identify morphological changes in microglia cells in the 
PVN in STZ diabetic rats. At eight weeks following vehicle injection, the microglia displayed 
normal morphology with small cell bodies and long, fine-branched processes throughout the 
PVN region in the control (Figure 3-3). In contrast, darkly stained microglia with shorter, 
thicker processes were clearly observed in the PVN in the STZ+saline group, which is 
consistent with our previous study (Rana et al., 2014). As expected, minocycline treatment 
reversed the morphological changes of microglia that was seen in STZ+saline groups. The 
quantification of the percentage of activated microglia in the PVN in the STZ+saline group 
showed a significantly greater activation compared to the control group (P<0.0001) (Figure 
3-4). Minocycline treatment in diabetic animals significantly (P<0.0001) reduced the 
percentage of activated microglia to a normal level seen in the control animals.  
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Figure 3-3. Morphology of microglia in STZ diabetic rats. Photomicrographs showing the 
morphology of CD11b (OX-42 clone) immunoreactive microglia in the paraventricular 
nucleus (PVN) in control animals with an ICV infusion of saline (A) and diabetic animals 
with an ICV infusion of saline (B) or minocycline (C). OX-42 antibody staining shows 
microglia with normal morphology with small cell bodies and long, fine-branched processes 
throughout the PVN region in the control and STZ+minocycline groups, while activated 
microglia showing larger cell bodies and shorter, thicker processes are seen in the STZ+saline 
group. Bar = 40 μm. 
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Figure 3-4. Effect of minocycline on microglial activation in the paraventricular nucleus 
of diabetic rats. The percentage of microglia showing activated morphology in the 
paraventricular nucleus (PVN) of control animals with an ICV infusion of saline 
(control+saline) and diabetic animals with an ICV infusion of saline (STZ+saline) or 
minocycline (STZ+minocycline). Number of rats = 4 in each group. Data are expressed as the 
mean ± SEM. 
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 Astrocyte activation in the paraventricular nucleus of diabetic rats 3.2.4
Within the PVN, astrocytes were stained with a GFAP antibody in all groups (Figure 3-5). In 
control rats, astrocytes showed a normal morphology with a small cell body and very fine 
processes; however, in the STZ+saline group, astrocytes had swollen cell bodies with thicker 
processes as well as a marked upregulation of GFAP immunolabeling compared to the 
control. The same pattern was also observed in the STZ+minocycline group. the percentage 
of activated astrocytes in the PVN in the STZ+saline and STZ+minocycline groups was 
significantly greater (P<0.0001) compared to the control group (Figure 3-6). Minocycline 
treatment in STZ diabetic rats had no significant effect on the percentage of activated 
astrocytes in diabetic animals. 
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Figure 3-5. Morphology of astrocytes in STZ diabetic rats. Photomicrographs showing 
GFAP immunoreactive astrocytes in the paraventricular nucleus (PVN) in control animals 
with an ICV infusion of saline (A) and diabetic animals with an ICV infusion of saline (B) or 
minocycline (C). GFAP antibody staining shows astrocytes with normal morphology with 
small cell bodies and fine processes throughout the PVN region in the control animals, while 
activated astrocytes showing intense expression of GFAP, larger cell bodies and thicker 
processes are seen in the STZ+saline and STZ+minocycline groups. Bar = 40 μm. 
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Figure 3-6. Astrocytes activation in the paraventricular nucleus in diabetic rats. A: The 
percentage of astrocytes showing activated morphology in the paraventricular nucleus (PVN) 
of control animals with an ICV infusion of saline (control+saline) and diabetic animals with 
an ICV infusion of saline (STZ+saline) or minocycline (STZ+minocycline). Number of rats = 
4 in each group. Data are expressed as the mean ± SEM. 
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 Discussion 3.3
We have previously found that microglia become activated in the PVN in STZ-diabetic rats at 
eight weeks following STZ injection (Rana et al., 2014), but the consequence of this 
activation on diabetic complications has not been investigated. Thus, in this study, we aimed 
to investigate the effect of the inhibition of microglial activation in the PVN on the blood 
pressure and heart rate of long-term STZ diabetic rats and whether astrocytes are activated in 
these animals. The main findings of the present study were that (i) microglia and astrocytes 
are activated in the PVN in STZ diabetic rats at 8 weeks after STZ injection and (ii) 
minocycline treatment inhibited PVN microglial activation but not astrocyte activation.  
In this study, we observed marked activation of microglia in the PVN in STZ diabetic rats 
when compared to the control animals, which is consistent with our previous study (Rana et 
al., 2014). Microglial activation was specifically in the PVN and not seen in surrounding 
areas. The PVN region is well-known to play an important role in the regulation of the 
autonomic nervous system, including cardiovascular functions. Several lines of evidence 
suggest that an abnormal increase in sympathetic nerve activity is linked to the pathogenesis 
of the development of cardiovascular-related diseases, including hypertension (Allen, 2002), 
myocardial infarction and heart failure (Aronson & Burger, 2002; Guggilam et al., 2008), 
which are major complications of diabetes. In the case of diabetes, over-activity of the 
sympathetic nervous system has been reported in humans and animals with type 1 diabetes 
hyperglycaemia (Perin et al., 2001; Patel et al., 2011), but the cause of this activation is not 
clear. Increased proinflammatory cytokines within the PVN are implicated in generating 
sympathetic hyperactivity in rats with heart failure (Guggilam et al., 2008; Kang et al., 2010). 
Once microglia undergo morphological changes, they can release proinflammatory cytokines. 
Hence, activated microglia seen in the PVN of STZ diabetic rats may be the source of 
proinflammatory cytokines. Combined with these studies, our data suggest that activated 
Chapter Three: Neuroinflammation in the paraventricular nucleus in STZ-diabetic rats  
 rats 
Page | 74 
 
 
 
microglia in the PVN may release proinflammatory cytokines, which may contribute to the 
observed changes in sympathetic nerve activity in diabetic animals.   
Although the role of activated microglia in the pathological consequences of brain 
inflammation has been investigated, less is known about the role of astrocytes. Nevertheless, 
it is reported that an association exists between activated spinal astrocytes and neuropathic 
pain following nerve damage (Sweitzer et al., 1999). Thus, we investigated whether 
astrocytes are activated in the PVN of diabetic rats. Our results showed that activated 
astrocytes exist in the PVN of diabetic rats. This finding is in agreement with a previous 
study that reported activated astrocytes in the PVN of diabetic rats (Luo et al., 2002). While 
the consequences of this activation is unknown, an increased expression of astroglial protein 
(S100β) in the spinal cord after nerve injury has been reported, and the inhibition of astroglial 
protein has been shown to result in a reduction of neuropathic pain behaviours in rats (Tanga 
et al., 2006). In this animal model, an enhanced expression of proinflammatory cytokines, 
such as TNF-α and IL-1β, are observed in activated spinal astrocytes following peripheral 
nerve injury (Wei et al., 2008), and the inhibition of these proinflammatory cytokines has 
been shown to reduce neuropathic pain-like behaviours (Milligan et al., 2001). Thus, the 
activation of the astrocytes may be important for mediating inflammation in the PVN of 
diabetic rats, which may cause neuronal hyperactivity and sympathetic over-activity.  
Minocycline is a second generation of a tetracycline antibiotic and has been shown to have 
anti-inflammatory actions (Yrjänheikki et al., 1999; Sapadin & Fleischmajer, 2006). Also, 
several studies have reported an inhibitory effect of minocycline on microglial activation 
(Krady et al., 2005; Shi et al., 2010a). In the present study, ICV minocycline treatment 
significantly reduced microglial activation in the PVN in STZ diabetic rats. In contrast, 
minocycline treatment was not able to inhibit astrocyte activation, which is in agreement with 
other previous studies (Yoon et al., 2012; Sauvant et al., 2014).  In animal models of 
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neuropathic pain, astrocyte activation in the CNS was seen at later stages compared with 
microglial activation, suggesting that microglia may be responsible for astrocyte activation 
(Coyle, 1998; Milligan & Watkins, 2009; Benarroch, 2010); however, data obtained in this 
study suggested that astrocyte activation is not related to microglial activation. The 
mechanism behind astrocyte activation in the PVN in STZ diabetic rats is not clear, and 
further research is needed.  
Regarding cardiovascular parameters, although the number of animals tested in this study 
was insufficient, we found that blood pressure tended to decrease in conscious STZ diabetic 
rats at eight weeks following STZ injection. This finding is in agreement with previous 
studies on long-term STZ-diabetic rats that used the direct technique for the measurement of 
blood pressure (Fazan et al., 1997; Van Buren et al., 1998; Fazan et al., 1999; Schaan et al., 
2004). The mechanisms involved in hypotension seen in STZ diabetic rats have not been 
completely understood; however, there are several possible reasons for hypotension in these 
animals. It well-known that STZ diabetic rats excrete large amounts of urine and thereby they 
lose both water and salt, causing hypervolemia. Interestingly, in two other studies, giving 
STZ-treated diabetic rats 1% saline caused a marked elevation in their blood pressure, which 
is not seen when control rats are given saline (Santos et al., 1995; Maeda et al., 2007). Thus, 
hypotension seen in STZ diabetic rats could be related to hypovolima. The observation of 
decreased cardiac output due to a dysfunction in the myocardium (Ren & Bode, 2000) or the 
impairment of sympathetic innervation of the heart and blood vessels (Borges et al., 2006) in 
STZ diabetic rats may also be possible explanations for this hypotension.  
 Conclusion  3.4
The present study demonstrated that microglia and astrocyte activation occur in the PVN in 
long-term STZ-induced diabetic rats. Minocycline treatment reduces microglial activation in 
the PVN but does not significantly affect the astrocyte activation seen in these animals. These 
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findings suggest that microglial activation does not precede astrocyte activation in the PVN 
in STZ diabetic animals. In this study, due to unintended morbidity and a lack of 
hypertension in STZ diabetic animals, we were unable to investigate the consequence of 
microglial activation. Thus, alternative routes of blood pressure recording with volume 
replacement therapy in STZ diabetic rats may be suitable for investigating the effect of PVN 
inflammation on diabetic complications. 
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 Introduction  4.1
Cardiovascular complications remain amongst the most serious long-term consequences of 
diabetes. Hypertension is the single most important risk factor for the development of 
cardiovascular disease, and it is associated with various pathological conditions, including 
diabetes (Epstein & Sowers, 1992). While many studies on the mechanisms of diabetic 
cardiovascular complications have suggested an important role for endothelial dysfunction 
(Woodman et al., 2008; Woodman & Malakul, 2009), a large body of evidence shows that 
the autonomic nervous system, which functions to regulate the cardiovascular and renal 
systems, is impaired in diabetes (Baydas et al., 2003; Lebed et al., 2008). It is well 
established that an abnormal activation of the sympathetic nervous system is associated with 
various pathological conditions and is an important mechanism underlying the development 
of hypertension (Esler, 2000; Esler & Kaye, 2000). Interestingly, elevated renal sympathetic 
nerve activity is reported in humans with type 1 diabetes and animals with chronic 
hyperglycaemia (Perin et al., 2001; Patel et al., 2011). These changes in sympathetic nerve 
activity have been suggested to contribute to the development of diabetic complications, such 
as hypertension, heart failure and sudden cardiac death (Perin et al., 2001), but so far, 
evidence is lacking. 
In addition to the role of sympathetic nerve overactivity in the pathogenesis of hypertension, 
emerging evidence shows that the sensitivity of the baroreflex, which controls heart rate, is 
reduced in conditions associated with hypertension. It is believed that this change may 
precede and contribute to the development of hypertension and its consequences (Grassi et 
al., 1998; Gao et al., 2002; Salgado et al., 2007; Maliszewska-Scislo et al., 2008). A study on 
spontaneously hypertensive rats, which showed decreased baroreflex sensitivity, 
demonstrated a direct link between an improvement of baroreflex function and a reduced 
incidence of stroke (Liu et al., 2007). Thus, the restoration of baroreflex sensitivity may be a 
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novel strategy for reducing blood pressure and lowering the cardiovascular disease risk in 
diabetic patients.  
Baroreflex impairment has been shown to occur in diabetic humans (Eckberg et al., 1986; 
Frattola et al., 1997) as well as in STZ-induced diabetic rats (Fazan et al., 1999; Gouty et al., 
2001; Schaan et al., 2004). In addition, an induction of diabetes by STZ treatment in 
spontaneously hypertensive rats further depressed baroreflex function (Farah et al., 2007). 
Dysfunction in the autonomic neurons system could explain both the decrease in baroreceptor 
reflex activity and the increase in sympathetic nerve activity seen in diabetic humans and 
STZ-induced diabetic rats. Thus, it is important to determine which pathological changes may 
be occurring in the central autonomic centers of diabetic animals. 
Cardiovascular centers of the brain, such as the hypothalamic paraventricular nucleus (PVN), 
rostral ventrolateral medulla (RVLM) and nucleus tractus solitarius (NTS), play a pivotal role 
in autonomic cardiovascular regulation. Several studies on STZ-induced diabetic animals 
have reported abnormally increased neuronal activity in the cardiovascular centers of the 
brain involved in sympathetic and baroreflex regulation, but the central mechanisms behind 
this neuronal activation are not well understood (Krukoff & Patel, 1990; Zheng et al., 2002; 
Rana et al., 2014). Interestingly, other studies have suggested that inflammation in these 
areas may result in neuronal activation (Shi et al., 2010a; Shi et al., 2011).  
We have recently reported activation of microglia in the PVN and NTS of STZ-induced 
diabetic animals at eight weeks following STZ injection (Rana et al., 2014). Microglia are the 
primary immune cells in the brain and act to protect and support neurons but also have the 
potential to exaggerate pathological processes by causing inflammation. Activated microglia 
release proinflammatory molecules and cytotoxic factors, such as nitric oxide and TNF-α, 
which can damage neurons. In addition, in other CNS regions, secretion of purines and 
BDNF from activated microglia have been shown to cause neuronal hyperexcitability by 
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increasing excitation and decreasing inhibition (Lu et al., 2009). While the effect of 
microglial activation in the PVN in diabetes is not known, in rats treated with angiotensin II, 
inhibition of microglial activation in the PVN has been shown to prevent the development of 
hypertension (Shi et al., 2010a). Collectively, this data suggests that microglia may have an 
important role in generating enhanced sympathetic nerve activity and baroreflex dysfunction 
through releasing proinflammatory cytokines, neurotrophic factors and/or purines. Whether 
inhibition of microglial activation or action in the PVN can ameliorate some of the 
cardiovascular complications of STZ-induced diabetes has not been investigated.  
While in human subjects, Type 1 diabetes is strongly associated with hypertension, rats 
treated with STZ to induce hyperglycaemia show unchanged or lowered blood pressure 
(Fazan et al., 1999; Dall'Ago et al., 2002), although there is evidence that their sympathetic 
nerves are more activated (Patel et al., 2011). Interestingly, two studies on animal models of 
STZ-induced diabetes that used direct recording of blood pressure have reported that saline 
intake (1% NaCl) increases blood pressure at  two and four weeks following STZ injections 
(Santos et al., 1995; Maeda et al., 2007). The mechanisms underlying this hypertension are 
not clear, but at early stages following STZ injections, diabetic rats showed unchanged 
baroreflex-mediated bradycardia (Maeda et al., 1995; Van Buren et al., 1998), and there was 
no microglial activation in the cardiovascular centers (Rana et al., 2014). It was therefore 
hypothesised that saline intake causes hypertension by increasing inflammation in the 
cardiovascular control centres and causing baroreflex dysfunction, thereby increasing blood 
pressure in STZ-diabetic rats. 
Therefore, we investigated the effects of saline intake on (i) blood pressure, (ii) baroreflex 
sensitivity and (iii) inflammation in the cardiovascular centres in STZ diabetic rats. In 
addition, we investigated whether inhibition of microglia in the PVN can reduce or prevent 
hypertension in STZ diabetic rats treated with saline.  
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 Results 4.2
 Effect of 2 weeks 1% NaCl intake on general features of diabetic rats  4.2.1
When Male Sprague Dawley rats were injected with either STZ or citrate buffer and 
maintained for 2 weeks with free access to either tap water or saline to drink, the non-diabetic 
control animals given water (C) and non-diabetic animals given saline (CS) exhibited a 
gradual increase in body weight, but diabetic animals given water (D) and diabetic animals 
given saline (DS) showed no significant change in body weight (Figure 4-1A). As expected, 
the body weights of the D group were significantly lower (P<0.01) compared with the C 
group animals, which is consistent with previous studies (chapter 3). Also, the body weights 
of the DS group were significantly lower (P<0.001) when compared with the CS group. 
Saline treatment did not significantly affect body weight in either the diabetic or control 
animals. Blood glucose levels were lower than 8 mmol/L in C and CS groups and higher than 
25 mmol/L in D and DS groups, indicating extreme hyperglycaemia (Figure 4-1B). The D 
group exhibited significantly higher (P < 0.0001) blood glucose levels compared with the C 
group, as expected. This was also the case for blood glucose levels in the DS group when 
compared to the CS group (P < 0.0001). Saline treatment had no effect on blood glucose in 
diabetic or control animals. The results of body weight and blood glucose measurements 
indicated that STZ-treated diabetic rats exhibited changes characteristic of this model 
(Schaan et al., 1997; Maeda et al., 2007).  
Regarding fluid intake, drinking both 1% saline and tap water increased progressively over 2 
weeks in the D and DS groups, but this was not the case in the C and CS groups, suggesting 
that diabetic animals were compensating for substantial fluid loss (Figure 4-1C). Daily water 
intake was significantly greater (P<0.001) in the D group when compared to the C group, and 
the DS group drank a significantly greater (P < 0.0001) volume of saline than the CS group. 
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In diabetic animals, the daily saline intake was significantly higher (P < 0.0001) compared to 
the daily water intake. This was not the case in the control animals.  
Because increased plasma osmolarity and dehydration are implicated in neuronal activation 
in STZ diabetic rats (Rana et al., 2014), we measured the plasma osmolarity and 
haemoglobin concentration in all groups at 2 weeks. No significant differences were found in 
the level of plasma osmolarity between C and CS or between the D and DS groups (Figure 4-
2A). As expected, plasma osmolarity was significantly increased (P<0.01) in the D group 
when compared with the C group; however, interestingly, saline treatment significantly 
decreased (P<0.05) the plasma osmolarity to normal levels in diabetic animals. As an 
indicator of blood volume status, the haemoglobin concentration was also similar between the 
C and CS groups but not between the D and DS groups (Figure 4-2B). In the D group, the 
Haemoglobin concentration were significantly higher (P<0.05) than in the C group; however, 
saline intake in diabetic animals significantly reduced (P<0.05) the levels of haemoglobin 
compared to the D group. The results of the plasma osmolarity and haemoglobin 
measurements suggested that STZ diabetic rats were dehydrated and that drinking saline 
restored blood parameters to normal levels.  
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Figure 4-1. Effect of 2 weeks saline treatment on body weight, blood glucose and fluid 
intake of diabetic rats. A: Body weight measured at weekly intervals in control animals (C) 
and diabetic animals (D) given tap water to drink and control animals (CS) and diabetic 
animals (DS) given 1% NaCl solution. B: Blood glucose levels measured at 2 weeks after the 
injection of rats with either STZ or citrate buffer. C: The amount of tap water or 1% NaCl 
solution ingested was monitored daily by weighting water bottles and then averaged for each 
week. Number of rats = 6 in each group. Data are expressed as the mean ± SEM. Significance 
was evaluated using a one way ANOVA followed by Tukey’s post hoc test for all 
comparisons (C vs D, CS vs DS and D vs DS) in this and all subsequent figures; * indicates 
P<0.05; *** indicates P<0.001; **** indicates P < 0.0001 for comparisons between diabetic 
groups and their respective controls; ♯♯♯♯ indicates P <0.0001 for comparisons between 
diabetic groups. 
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Figure 4-2. Effect of 2 weeks saline treatment on plasma osmolarity and haemoglobin in 
diabetic rats. A: Plasma osmolarity (Osmol/litre); and B: Haemoglobin concentration 
(g/litre) measured at the end of the experimental period in control animals (C) and diabetic 
animals (D) given tap water and control animals (CS) and diabetic animals (DS) given 1% 
NaCl solution. Number of rats = 8,4,10 and 12 respectively. Data are expressed as the mean ± 
SEM. * indicates P<0.05; ** indicates P<0.01 for comparisons between diabetic groups and 
their respective controls; ♯ indicates P<0.05 for comparisons between diabetic groups. 
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 Measurement of baroreflex-mediated bradycardia in diabetic rats 4.2.2
In experiments to investigate the baroreflex-mediated bradycardia at two weeks after STZ or 
citrate injection, the mean arterial blood pressure under anaesthesia was not significantly 
different between the C and D or between the CS and DS groups (Figure 4-3A). Also, no 
significant differences were found in the heart rate among the groups (Figure 4-3B). A 
progressive increase in the maximal mean arterial blood pressure and a decrease in the 
maximal heart rate in response to the infusion of increasing amounts of phenylephrine was 
seen in all groups. The maximal mean arterial blood pressure response to phenylephrine at all 
doses was not significantly different between the D and C groups (Figure 4-4) (Figure 4-5A). 
The same pattern was also observed in the DS group compared to the CS group. Saline intake 
had no effect on blood pressure changes in response to phenylephrine in the diabetic or 
control animals. The maximal heart rate response to phenylephrine was also similar between 
the D and C groups (Figure 4-5B). In the DS group, the heart rate response to phenylephrine 
appeared smaller compared with the CS and D groups but was not significantly different, 
although the variability was high, meaning our tests were underpowered for detecting small 
differences; however, when baroreflex sensitivity was quantified as the ratio of maximal 
change in heart rate divided by the maximal change in mean arterial blood pressure, there was 
less variability. The baroreflex-mediated bradycardia in response to increasing doses of 
phenylephrine was similar between the D and C groups (Figure 4-5C); however, there was a 
significant reduction in baroreflex sensitivity in the DS group compared to the CS (P<0.05) 
and D (P<0.01) groups. 
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Figure 4-3. Effect of 2 weeks saline treatment on cardiovascular parameters in diabetic 
rats under anaesthesia. A: The mean arterial blood pressure (MAP); and B: The heart rate 
of unconscious control animals (C) and diabetic animals (D) given tap water and control 
animals (CS) and diabetic animals (DS) given 1% NaCl solution. Number of rats = 6, 6, 6 
and 7 respectively. Data are expressed as the mean ± SEM. No significant differences were 
observed. 
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Figure 4-4. Measurement of baroreflex-mediated bradycardia in diabetic rats. 
Representative recordings showing changes in arterial blood pressure and heart rate in 
response to phenylephrine (10 µg/kg at the arrow) in control animals (C) and diabetic animals 
(D) given tap water and control animals (CS) and diabetic animals (DS) given 1% NaCl 
solution.   
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Figure 4-5. Cardiovascular responses to phenylephrine in diabetic rats. A: Changes in 
mean arterial pressure (MAP); and B: changes in heart rate (HR) in response to graded doses 
of intravenous phenylephrine (1, 2, 5 and 10 µg/kg) in control (C) and diabetic animals (D) 
given tap water and control (CS) and diabetic animals (DS) given saline. C: Baroreflex 
sensitivity (bpm/mmHg) of bradycardic responses represented as the average of the maximal 
change in heart rate divided by the maximal change in mean arterial blood pressure for each 
phenylephrine dose and then averaged for each animal. Baroreflex-mediated bradycardia was 
significantly attenuated in the salt-treated diabetic group compared with the diabetic group 
and the salt-treated control group. Number of rats = 6, 6, 6 and 7 respectively. Data are 
expressed as the mean ± SEM. * indicates P<0.05 for comparisons between diabetic groups 
and their respective controls; ♯♯ indicates P<0.01 for comparisons between diabetic groups. 
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 OX-42 Immunohistochemistry in cardiovascular centres in diabetic rats 4.2.3
The OX-42 antibody was used to identify morphological changes in microglia cells in the 
cardiovascular centres in STZ rats. At two weeks following STZ or vehicle injection, 
microglia displayed a normal morphology with small cell bodies and long, fine-branched 
processes throughout the PVN region in the D and C groups, which is consistent with our 
previous study (Rana et al., 2014) (Figure 4-6). While no microglial activation was seen in 
the PVN in the CS group, saline intake in the DS groups caused a significant increase in the 
percentage of activated microglia with large cell bodies and short, thick processes compared 
to the PVN microglia in the CS (P<0.0001) and D (P<0.0001) groups. Saline intake in 
diabetic animals, though not in the control group, resulted in approximately a 5-fold elevation 
in the percentage of microglia that were activated compared with other groups (Figure 4-9A). 
Interestingly, a significant increase in the percentage of activated microglial was restricted to 
the parvocellular PVN (Figure 4-12A).   
In the NTS region in which baroreceptive afferent nerves terminate, microglial cells showed 
normal morphology with small cell bodies and long, fine-branched processes in the D and C 
groups, which is in agreement with our previous study (Rana et al., 2014) (Figure 4-7). In 
contrast, darkly stained microglia with shorter, thicker processes were clearly observed in the 
NTS in the DS group. The quantification of the percentage of activated microglia in the NTS 
in the DS group showed a significantly greater activation compared to the CS (P<0.001) and 
D (P<0.001) groups (Figure 4-9B).  
Microglial cells in the RVLM region exhibited normal morphology in the D and C groups 
(Figure 4-8). In contrast, in the DS group, microglia showed markedly shortened, thicker 
processes and stronger staining for OX-42 compared with other groups. The quantitative 
analysis of microglial activation in the RVLM region indicated that saline intake caused a 
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significant increase in the percentage of activated microglia in the DS group compared to the 
CS (P<0.01) and D (P<0.05) groups (Figure 4-9C).  
To confirm our observation, we measured the microglial process length in the brain areas 
examined. We found that in the DS group, the microglia in the PVN, NTS and RVLM 
regions had significantly shorter processes compared to the microglia in the CS (P<0.0001) 
and D (P<0.0001) groups (Figure 4-10 A-B-C).  
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Figure 4-1. OX-42 Immunohistochemistry in the PVN in diabetic rats. Photomicrographs 
showing CD11b (OX-42 clone) immunoreactive microglia in the paraventricular nucleus (PVN) in 
control (C) and diabetic animals (D) given tap water and control animals (CS) and diabetic animals 
(DS) given 1% NaCl solution. Dotted lines in low-power images (A-D) outline the PVN. High-power 
images (E-H) show the morphology of microglia in the parvocellular PVN region in detail. OX-42 
antibody staining shows microglia with normal morphology with small cell bodies and long, fine-
branched processes throughout the PVN region in the C, CS and D groups, while activated microglia 
showing larger cell bodies and shorter, thicker processes are seen in the DS group. Bar = 100 μm in 
A–D, 50 μm in E–H. 
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Figure 4-2. OX-42 Immunohistochemistry in the NTS in diabetic rats. Photomicrographs 
showing CD11b (OX-42 clone) immunoreactive microglia in the nuclear tractus solitarius 
(NTS)in control (C) and diabetic animals (D) given tap water and control (CS) and diabetic 
animals (DS) given 1% NaCl solution. Dotted lines in low-power images (A-D) outline the NTS. 
High-power images (E-H) show the detailed morphology of microglia in NTS region. OX-42 
antibody staining showing microglia with normal morphology was seen throughout the NTS 
region in the C, C-S and D groups, while activated microglia showing intense immunolabelling, 
larger cell bodies and thicker processes were common in the NTS in the D-S group. Bar = 200 
μm.  
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Figure 4-3. OX-42 Immunohistochemistry in the RVLM in diabetic rats. Photomicrographs 
showing CD11b (OX-42 clone) immunoreactive microglia in the rostral ventrolateral medulla 
(RVLM) in control (C) and diabetic animals (D) given tap water and control (C-S) and diabetic 
animals (D-S) given saline. Low-power images (left panel) and high-power images (right panel) 
show the morphology of microglia in the RVLM region. a normal microglia morphology was seen 
throughout the RVLM region in the C, C-S and D groups, while activated microglia showing intense 
immunolabelling, larger cell bodies and shorter, thicker processes were again common in the D-S 
group. Bar = 200 μm left panel, 100 μm in right panel.  
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Figure 4-9. Microglial activation in cardiovascular centres of the brain of 2 week saline-
treated diabetic rats. A: The percentage of microglia showing activated morphology in the 
paraventricular nucleus (PVN); B: in the nucleus tractus solitarius (NTS); and C: in the 
rostral ventrolateral medulla (RVLM) of control (C) and diabetic animals (D) given tap water 
and control (CS) and diabetic animals (DS) given saline. After 2 weeks, the percentage of 
activated microglia was significantly increased in the saline-treated diabetic group when 
compared with the diabetic group and the saline-treated control group. Number of rats = 4, 4, 
4 and 7 respectively. Data are expressed as the mean ± SEM. ** indicates P<0.01; *** indicates 
P<0.001; **** indicates P < 0.0001 for comparisons between diabetic groups and their 
respective controls; # indicates P<0.05; ### indicates P<0.001; #### indicates P <0.0001 for 
comparisons between diabetic groups.  
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Figure 4-10. Microglia exhibit shorter processes in cardiovascular centres of the brain 
of 2 week saline-treated diabetic rats. A: Average length of microglial processes in the 
paraventricular nucleus (PVN); B: in the nucleus tractus solitarius (NTS); and C: in the 
rostral ventrolateral medulla (RVLM) of control (C) and diabetic animals (D) given tap water 
(D) and control (CS) and diabetic animals (DS) given saline. Number of rats = 4, 4, 4 and 7 
respectively. Data are expressed as the mean ± SEM. *** indicates P<0.001; **** indicates P < 
0.0001 for comparisons between diabetic groups and their respective controls; ### indicates 
P<0.001; #### indicates P <0.0001 for comparisons between diabetic groups.  
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 C-fos immunoreactivity in cardiovascular centres in diabetic rats 4.2.4
In this study, an antibody to c-fos was used to quantify neuronal activation in the regions 
where microglia were activated. In the PVN in the C and CS groups, the number of fos-
immunoreactive neurons was smaller compared to the D and DS groups (Figure 4-11 A). On 
quantification, we observed a significant increase in the number of fos-immunoreactive 
neurons in the D group compared to (P<0.01) the C group. The DS group also exhibited a 
greater level of fos activity than seen in (P<0.05) the CS group. In the D group, a significant 
increase in the number of fos-immunoreactive neurons was seen in both the magnocellular 
and parvocellular subdivisions of PVN (Figure 4-12 B). Interestingly, in the DS group, there 
was a significant increase in the number of fos-immunoreactive neurons only in the 
parvocellular PVN. In contrast to the PVN, the counts of fos-immunoreactive neurons in the 
NTS and RVLM regions showed no significant difference among all groups (Figure 4-11 B-
C).  
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Figure 4-11. Fos activity in the PVN in diabetic rats. Photomicrographs showing neuronal 
nuclei stained with anti-Fos antibody in the paraventricular nucleus (PVN) in control (C) and 
diabetic animals (D) given tap water and control animals (CS) and diabetic animals (DS) 
given 1% NaCl solution.Dotted lines the PVN. Parvocellular (P) and magnocellular (M 
regions of the paraventricular nucleus are delineated. Bar = 100 μm. 
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Figure 4-12. Fos-IR immunoreactivity indicating activated neurons in cardiovascular 
centres of the brain in diabetic rats. A: Quantification of Fos-IR positive cell nuclei in the 
paraventricular nucleus (PVN); B: in the nucleus tractus solitarius (NTS); and C: in the 
rostral ventrolateral medulla (RVLM) of control (C) and diabetic animals (D) given tap water 
and control (CS) and diabetic animals(DS) given saline. Number of rats = 7, 6, 4 and 5 
respectively. Data are expressed as the mean ± SEM. * indicates P<0.05; ** indicates P<0.01 
for comparisons between diabetic groups and their respective controls.  
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Figure 4-13. Microglial and neuronal activation in the parvocellular and magnocellular 
portions of the paraventricular nucleus of diabetic rats. A: The percentage of microglia 
showing activated morphology in the parvocellular and magnocellular of the paraventricular 
nucleus (PVN) of control (C) and diabetic animals (D) given tap water and control (CS) and 
diabetic animals (DS) given saline. B: Quantification of Fos-IR positive cell nuclei in the 
same regions. Number of rats = 5, 5, 4 and 7 respectively. Data are expressed as the mean ± 
SEM. * indicates P<0.05; ** indicates P<0.01; **** indicates P < 0.0001 for comparisons 
between diabetic groups and their respective controls; #### indicates P <0.0001 for 
comparisons between diabetic groups. 
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 Effect of saline and minocycline treatment on blood pressure in awake 4.2.5
diabetic rats. 
Because we observed no change in the blood pressure in anaesthetized STZ diabetic rats 
treated with saline and microglia become activated in the PVN following saline intake in STZ 
diabetic rats, we therefore investigated the effect of the inhibition of microglial activation in 
the PVN in another cohort of STZ diabetic rats by direct ICV infusion into the lateral 
ventricle of either saline OR minocycline. At two weeks after treatment with STZ or citrate, 
there was no significant difference in systolic blood pressure between the control (CWS) and 
diabetic animals (DWS) infused with saline and given tap water to drink, which is in 
agreement with previous studies (Kawashima et al., 1978; Hayashi et al., 1983) (Figure 4-
13). Minocycline infusion in diabetic animals given tap water (DWM) had no effect on 
systolic blood pressure compared to the DWS group. In contrast, diabetic animals infused 
with saline and given 1% NaCl (DSS) exhibited a greater increase in systolic blood pressure 
than those seen in the CWS and DWS (P<0.0001) groups, which is consistent with a previous 
study, suggesting saline causes hypertension in these rats (Maeda et al., 2007). The increase 
in systolic blood pressure in the DSS group was prevented by minocycline infusion 
(P<0.0001) (Figure 4-13). These results suggest that central inflammation contributes to the 
development of hypertension in STZ diabetic rats treated with saline.  
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Figure 4-14. Effect of minocycline treatment on the development of hypertension in 
diabetic rats treated with saline for 2 weeks. Systolic blood pressure of conscious control 
animals (CWS) and diabetic animals (DWS) given tap water to drink for 2 weeks and 
diabetic animals (DSS) given 1% NaCl solution with an ICV infusion of saline and diabetic 
animals given tap water (DWM) or 1% NaCl (DSM) with an ICV infusion of minocycline. 
Number of rats = 5, 7, 9, 9 and 8 respectively. Data are expressed as the mean ± SEM. 
Significance was evaluated using a one way ANOVA followed by Tukey’s post hoc test for 
all comparisons (CWS vs DWS , CWS vs DSS, DWS vs DWM , DWS vs DSS and DSS vs 
DSM).**** indicates <0.0001 for comparisons between diabetic groups and their respective 
controls; &&&& indicates P <0.0001 for comparisons between diabetic groups; #### 
indicates P<0.0001; for comparisons between diabetic groups and their respective groups of 
diabetic animals with minocycline treatment.  
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 Discussion 4.3
There is evidence that drinking saline causes hypertension in diabetic animals, but how this 
occurs and whether CNS pathological changes contribute to it has not been investigated. 
Thus, in this study, we aimed to investigate the effects of 1% NaCl on cardiovascular 
parameters and whether saline intake influences inflammation in CNS cardiovascular centres 
in STZ diabetic rats. The main findings of the present study were that 1% NaCl (i) increased 
the mean arterial blood pressure of conscious STZ-diabetic rats, (ii) accelerated the 
dysfunction of bradycardic baroreflex and (iii) accelerated the activation of microglia in the 
PVN, NTS and RVLM and that (iv) ICV minocycline prevented the development of 
hypertension in diabetic rats treated with saline.  
In the present study, there was no change in the blood pressure of awake diabetic animals 
when compared to the control, which is consistent with other studies at this early stage of 
diabetes (Kawashima et al., 1978; Hayashi et al., 1983). In contrast, when given to diabetic 
animals, 1% NaCl caused a significant increase in systolic blood pressure in awake animals, 
confirming a previous study by Maeda et al. (2007). Some authors have suggested that 
reduced blood volume in STZ rats due to osmotic diuresis is the mechanism of normotension 
or hypotension in STZ-diabetic rats (Hebden et al., 1986a; De Angelis et al., 2000). Thus, 
hypertension in diabetic animals given saline may be explained in part by increased blood 
volume. Interestingly, in the current study, saline intake also reduced the haemoglobin 
concentration and plasma osmolality to normal levels in diabetic rats, which indicates a 
normalization of blood volume. The effect of drinking 1% NaCl on the fluid balance of 
diabetic rats has not been studied previously. Our data provide strong support for the 
hypothesis that saline treatment normalises blood volume and may be responsible for the 
development of hypertension in STZ diabetic rats; however, it is possible that there are other 
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mechanisms involved in the development of hypertension in these animals besides blood 
volume. 
Reduction in baroreflex sensitivity has been implicated in the pathogenesis of hypertension 
(Grassi et al., 1998; Gao et al., 2002; Salgado et al., 2007; Maliszewska-Scislo et al., 2008). 
While baroreflex sensitivity in STZ diabetic animals have been widely investigated, few 
studies on the effects of saline intake on baroreflex sensitivity have been conducted in STZ 
diabetic rats. In the present study, we observed no changes in baroreflex sensitivity in 
diabetic animals compared to the control, which is in agreement with previous studies that 
have shown that the baroreflex-mediated bradycardia was unaltered in short-term (5 to 14 
days) STZ diabetic rats (Maeda et al., 1995; Van Buren et al., 1998). In contrast, 1% NaCl 
caused an impairment of baroreflex sensitivity in diabetic animals at 2 weeks. Interestingly, 
several studies have reported that baroreflex sensitivity is reduced in long-term (4 to 42 
weeks) STZ-diabetic rats (Van Buren et al., 1998; Dall'Ago et al., 2002; Harthmann et al., 
2007; Souza et al., 2007). Therefore, our results suggest that 1% NaCl accelerates the 
development of baroreflex dysfunction in diabetic animals at early stages, and this 
dysfunction may contribute to the development of hypertension seen in awake diabetic 
animals.   
Because we did not observe a significant difference in the blood pressure among diabetic 
groups under anaesthesia, the decreased baroreflex sensitivity is not attributable to a simple 
blood pressure change. Urethane may interrupt the mechanism that generates high blood 
pressure in salt-treated diabetic rats, but it is the anaesthetic of choice for studying 
baroreceptor reflexes. In support of this, Barringer et al. demonstrated that urethane had no 
effect on the baroreflex-mediated bradycardia in the normotensive rat (1990). The only other 
published study to have investigated baroreflex sensitivity in diabetic animals treated with 
saline was inconclusive (Maeda et al., 2007). We suspect that the difference between their 
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results and ours is likely due to their use of ketamine/xylazine anaesthesia. Considered 
collectively, these data indicate that 1% NaCl treatment for 14 days impaired the baroreflex-
mediated bradycardia response selectively in diabetic rats without affecting blood pressure or 
heart rate under anaesthesia.  
To understand the potential mechanism of these changes on cardiovascular parameters, we 
examined whether microglia are activated in CNS cardiovascular centres.  In the PVN, we 
found no activation of microglia in diabetic animals at two weeks following STZ injection, 
which is in agreement with our previous study that reported that microglia become activated 
at later stages (Rana et al., 2014). In contrast, we show here that 1% NaCl accelerated 
microglial activation in the PVN in STZ-induced diabetic rats. This activation was selectively 
in the PVN and not seen in surrounding areas. To clarify the pathological consequences of 
microglial activation in the PVN of diabetic rats treated with 1% NaCl, we measured blood 
pressure via the tail cuff and investigated the effect of the inhibition of microglial activation 
in another cohort of animals. There was a significant increase in the systolic blood pressure 
only in diabetic rats treated with saline. By administering minocycline, which acts as an anti-
inflammatory drug, into the lateral brain ventricle, we observed a marked reduction in blood 
pressure. It has been shown previously that microglial activation in the PVN contributes to 
the development of neurogenic hypertension (Shi et al., 2010a). In this context, our results 
strongly suggest that hypertension seen in diabetic rats given saline is neurogenic and that 
increased microglial activation in the PVN may cause the increased blood pressure in these 
rats. Because saline treatment had no effect on blood pressure in the control rats, it appears 
that 1% NaCl intake accelerates and increases the inflammatory response seen in the PVN in 
response to diabetes.  
The data from this study do not outline the mechanisms by which saline intake accelerates 
microglial activation in diabetic animals, thereby impairing baroreflex sensitivity and causing 
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hypertension; however, it is clear from other studies that high salt intake contributes to 
increased blood pressure. In fact, the only current information about the mechanisms by 
which saline may influence brain inflammation is based on studies using highly concentrated 
sodium diets (Koga et al., 2008; Braga, 2010). In this study, diabetic rats given saline 
consumed a larger amount of 1% NaCl compared to the control rats, but it is not clear if 
diabetic rats drank more 1% NaCl than they needed because their excretion was also high. 
Therefore, we must consider the possibility that the brain inflammation seen in our study 
could be in part due to increased NaCl intake. Thus, despite the fact that saline normalises 
haemoglobin concentration and plasma osmolality, it may also contribute to brain 
inflammation in diabetic rats. 
 A high salt intake (8% NaCl in food or 2% NaCl to drink) increases reactive oxygen species 
formation in brain regions that are involved in autonomic control (Koga et al., 2008; Braga, 
2010). The increase in the generation of reactive oxygen species can enhance the influx of 
Ca
2+
 in neurons, which in turn leads to neuronal activation (Wang et al., 2003; Zimmerman & 
Davisson, 2004). It is well-known that microglia become activated following neuronal death, 
damage or over excitation (Hathway et al., 2009; Lu et al., 2009). In addition, we previously 
reported increased neuronal activity in the PVN of diabetic rats at 6 weeks following STZ 
injection; however, increased microglial activation was not observed until 8 weeks following 
STZ injections. Rana et al. (2014) suggested that microglial activation in the PVN may be 
secondary to prolonged intense activation of PVN neurons in diabetic rats.  
In the parvocellular PVN, we observed increased neuronal activation in diabetic rats at 6 
weeks following STZ injection (Rana et al., 2014). These neurons play a role in the 
regulation of autonomic function, including sympathetic nerve activity and blood pressure, as 
well as endocrine functions. Since microglial activation was not seen in this region in diabetic 
rats given tap water at 2 weeks, our data support the hypothesis that neuronal activation 
Chapter Four: Drinking 1% NaCl enhances inflammation in diabetic rats 
 
Page | 107 
 
 
 
precedes microglial activation. The reason that parvocellular PVN neurons were activated in 
diabetic rats is not clear; however, parvocellular PVN neurons have been shown to be 
activated by haemorrhage (Badoer et al., 1993; Badoer & Merolli, 1998), suggesting that 
those neurons may be activated by a decrease in blood volume seen in diabetic animals. Also, 
infusion of hypertonic saline has been shown to increase neuronal activation in this region 
(Bealer & Metcalf, 2005). Thus, this activation may be also a result of increased plasma 
osmolarity in diabetic rats. Therefore, it appears that the parvocellular division of the PVN 
responds to disturbances in blood volume and plasma osmolarity in diabetic rats. In diabetic 
rats treated with saline, we observed neuronal and microglial activation in the parvocellular 
division of the PVN, although the haemoglobin concentration and plasma osmolarity were 
normalised, suggesting that the mechanisms by which PVN neurons become activated in 
these rats are different.  
Activated microglia have also been shown to cause neuronal over excitation via the release of 
proinflammatory molecules and reactive oxygen species (Shi et al., 2011; Wu et al., 2012). 
Interestingly, Shi et al. (2010a) reported that microinjection of IL-1β into the PVN increased 
PVN neuronal activation and blood pressure, suggesting IL-1β secretion from activated 
microglia enhances PVN neuronal activation to increase blood pressure. This suggests that 
PVN microglial activation may be a cause of over excitation of PVN neurons, which in turn 
elevated blood pressure seen in diabetic rats treated with saline. 
Interestingly, in the magnocellular division of the PVN, we also observed increased neuronal 
activation in diabetic rats but not in saline-treated diabetic rats. This result is in agreement 
with previous studies that reported increases in neuronal activity in the magnocellular of the 
PVN at 2 weeks following STZ injection (Krukoff & Patel, 1990). The magnocellular part of 
the PVN is the main site involved in secreting oxytocin and vasopressin in response to 
osmotic and other stimuli to control body fluid balance and blood volume. It has been 
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suggested that elevated levels of plasma osmolality (Charlton et al., 1988; Brooks et al., 
1989) and dehydration (Zheng et al., 2002) in diabetic animals may be responsible for 
neuronal activation in the magnocellular PVN and consequently increased vasopressin 
secretion (Zerbe et al., 1979; Brooks et al., 1989). In the present study, diabetic rats displayed 
increased plasma osmolality as well as increased haemoglobin concentration, which indicates 
depletion in blood plasma volume and may explain the activation of magnocellular neurons 
seen in diabetic rats. Interestingly, in the magnocellular PVN, there was no neuronal 
activation in diabetic rats treated with saline, potentially because blood volume was 
normalised.  
In the present study, we also show microglial activation in the NTS and RVLM in diabetic 
rats treated with saline. These autonomic brain areas are also involved in cardiovascular 
regulation. The NTS plays a pivotal role in mediating the baroreceptor reflex. In addition, the 
NTS also receives inputs from the PVN. The activation of microglia and neurons was not 
observed in the NTS in diabetic rats at 2 weeks after STZ injection, which is in agreement 
with our previous study (Rana et al., 2014). In contrast, there was an increase in the 
activation of microglia in diabetic rats treated with saline. Another study reported that 
microinjection of proinflammatory cytokine (IL-6) into the NTS cause a marked decrease in 
the baroreceptor sensitivity (Takagishi et al., 2010). It is well-known that activated microglia 
are capable of secreting proinflammatory cytokines, such as IL-6. Thus, it is possible that 
microglial activation may explain the decreased baroreceptor sensitivity in diabetic rats 
treated with saline. 
The RVLM also showed an increase in microglial activation in diabetic rats treated with 
saline. RVLM is an important autonomic region that is involved in blood pressure regulation 
through modulating sympathetic nerve activity. It also receives inputs from other 
cardiovascular centres, including PVN and NTS. An increase in reactive oxygen species in 
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the RVLM has been shown to precede the development of hypertension (Koga et al., 2008; 
Braga, 2010; Nunes & Braga, 2011). Interestingly, a recent study on LPS-hypertensive 
animals reported that microglial activation was associated with increased reactive oxygen 
species in the RVLM (Wu et al., 2012). Along with our results, these studies suggest that 
activated microglia contribute to an increased production of reactive oxygen species and may 
contribute to hypertension seen in diabetic rats treated with saline.   
Interestingly, there was no increase in neuronal fos expression in the NTS and RVLM in 
diabetic rats treated with saline, suggesting that the mechanisms by which microglia become 
activated in those areas are different from those in the PVN. Still, it could also be argued that 
c-fos expression is a very binary classification for each cell type, so it is not capable of 
showing an increase in the intensity of the activation of a group of neurons if the change does 
not lead to an increase in the number of neurons activated. On the other hand, there was no 
appreciable increased expression of c-fos in any condition; thus, c-fos may not be expressed 
in all activated neurons in the NTS and RVLM. Alternatively, microglial activation in those 
regions could be mediated by other mechanisms. For example, a study on STZ diabetic rats 
reported microglial activation in the dorsal horn of the spinal cord (Tsuda et al., 2008). This 
study suggested that damage to peripheral sensory neurones that terminate in the dorsal horn 
was responsible for microglial activation. Therefore, while we do not know the effect of 
saline intake on the terminals of autonomic sensory neurons, damage of those neurons may 
be responsible for microglial activation in the NTS and RVLM. 
 Conclusion 4.4
In conclusion, our data indicated that 1% NaCl intake increases blood pressure in STZ 
diabetic rats. Saline treatment also accelerates microglial activation in the PVN in diabetic 
rats. Microglial inhibition in the PVN prevents the development of hypertension in diabetic 
rats, suggesting that microglial activation is involved in the mechanisms of hypertension in 
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these animals. Microglial activation in the PVN may be either a cause or an effect of neuronal 
activation or both. In addition, saline intake can significantly effect baroreflex sensitivity in 
diabetic rats, and this is associated with microglial activation in the NTS and RVLM; 
however, the role of microglia in the NTS and RVLM is not clear, and further research is 
required to demonstrate the effect of microglia inhibition in those regions. Overall, the 
attenuation of inflammation in cardiovascular centres may be a novel strategy for lowering 
the risk of cardiovascular diseases in diabetes. In addition, salt intake may have profound and 
complex effects on brain inflammation and blood pressure in diabetic humans.  
  
 
 
Chapter Five: Drinking 1% NaCl for 6 
Weeks Increases Baroreflex Sensitivity in 
STZ Diabetic Rats  
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 Introduction  5.1
Salt intake has been associated with the risk of the development of hypertension and 
cardiovascular disease in both humans and animals (Campese, 1994; Sacks et al., 2001; 
Jones, 2004; Brooks et al., 2005). Dehydration is common in diabetes, and low salt intake 
may cause deleterious effects. Still, the mechanisms underlying the effect of salt intake on 
hypertension and its effects in diabetes has not been fully understood. It has been suggested 
that salt intake contributes to the development of hypertension via several potential 
mechanisms, including dysregulation of autonomic nervous system or increased blood 
volume, but which of these mechanisms are relatively important in diabetes is not known 
(Brooks et al., 2005).   
Autonomic dysfunction in relation to the cardiovascular system has been reported in humans 
with type 1 diabetes and animals with chronic hyperglycaemia. This includes an abnormal 
increase in the renal sympathetic activity (Perin et al., 2001; Patel et al., 2011). Evidence 
demonstrates that abnormal activation of the sympathetic nerve is crucial in the development 
of hypertension (Dampney et al., 2005; Esler, 2011; Takahashi, 2012). The cause of the 
abnormal activation of sympathetic nerves in diabetes is not well understood; however, there 
is increasing evidence that an impairment of baroreflex sensitivity, which is important in 
controlling both sympathetic activity and blood pressure levels, may play an important role. 
Interestingly, although impairment of baroreflex sensitivity is reported in long-term STZ-
induced diabetic rats, we have previously reported that drinking 1% NaCl accelerates the 
dysfunction of bradycardic baroreflex in STZ-induced diabetic rats at early stages (chapter 4). 
This dysfunction was also associated with an increase in the mean arterial blood pressure, 
suggesting that impairment of baroreflex sensitivity may be the potential mechanism that 
contributes to the development of hypertension in STZ-induced diabetic rats.  
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However, the central mechanism by which saline intake triggers baroreflex dysfunction in 
STZ diabetic rats is not completely understood. Interestingly, we have previously reported 
that saline intake in STZ diabetic rats not only accelerates baroreflex dysfunction but also 
increases microglial activation in the PVN, RVLM and NTS (chapter 4). Microglial 
inhibition in the PVN prevents the development of hypertension in these animals, suggesting 
that microglial activation is involved in the mechanisms of hypertension (chapter 4). Another 
study has shown that microinjection of proinflammatory cytokine (IL-6) into the NTS caused 
a marked decrease in the baroreceptor sensitivity (Takagishi et al., 2010). Activated 
microglia are known to release proinflammatory molecules, such as IL-6. Thus, this 
inflammation seen in STZ diabetic rats treated with saline at early stages may be responsible 
for baroreflex dysfunction; however, there is a lack of data on the effect saline intake has on 
CNS inflammation in the long term after STZ treatment.  
While it is clear from our study and other previous studies that saline intake can accelerate 
and intensify diabetic cardiovascular complications in short-term STZ diabetic rats, there is 
evidence that drinking saline improved cardiac function in the long term (Dai et al., 1994). 
Therefore, it appears that saline intake has paradoxical effects on the cardiovascular system, 
and this effect may be time dependent. It is not known whether STZ diabetic rats treated with 
1% NaCl for longer periods show similar baroreflex alterations to the ones seen during early 
stages or whether 1% NaCl causes further depression in the baroreflex function.  
At early stages in STZ diabetic rats, drinking saline accelerates microglial activation in the 
brain nuclei that are involved in cardiovascular regulatory functions. While this activation 
may explain the baroreflex dysfunction that is seen in these animals, it is not consistent with 
improving cardiac function in long-term STZ diabetic rats treated with saline. Whether saline 
intake reduces or increases CNS inflammation in STZ diabetic rats given saline for long 
periods is not known. 
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Therefore, we investigated the effects of saline intake on blood pressure and baroreflex 
sensitivity in long-term STZ diabetic rats. In addition, we investigated whether saline intake 
influences inflammation in the cardiovascular centres in long-term STZ diabetic rats. 
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 Results 5.2
 Effect of 6 weeks saline intake on general features of diabetic rats  5.2.1
When Male Sprague Dawley rats were injected with either STZ or citrate buffer and 
maintained for 6 weeks with free access to either tap water or saline to drink, the non-diabetic 
control animals given water (C) and non-diabetic animals given saline (CS) exhibited a 
gradual increase in body weight. The same pattern was also observed in diabetic animals 
given water (D) and diabetic animals given saline (DS), but the weight gained in these 
diabetic groups was lower when compared with the control groups (Figure 5-1A). As 
expected, the body weights of the D group were significantly lower (P<0.01) compared with 
the C group animals, which is consistent with previous studies (chapter 3). Also, the body 
weights of the DS group were significantly lower (P<0.001) when compared with the CS 
group. Saline treatment in long-term STZ diabetic rats did not significantly affect body 
weight in either diabetic or control animals, which is in agreement with our previous study, in 
the short term (chapter 4). Blood glucose levels were lower than 8 mmol/L in the C and CS 
groups and higher than 25 mmol/L in the D and DS groups, indicating extreme 
hyperglycaemia (Figure 5-1B). The D group exhibited significantly higher (P < 0.0001) 
blood glucose levels compared with the C group, as expected. This was also the case for the 
blood glucose levels in the DS group compared to the CS group (P < 0.0001). Interestingly, 
saline treatment significantly reduced (P<0. 0001) blood glucose levels in the diabetic group, 
though not to normal levels, and it had no effect on blood glucose in the control animals. The 
results of body weight and blood glucose measurements indicated that STZ-treated diabetic 
rats exhibited changes that are characteristic of this model.  
Regarding fluid intake, drinking both 1% saline and tap water increased progressively over 6 
weeks in the D and DS groups, but this was not the case in C and CS groups, suggesting that 
diabetic animals were compensating for substantial fluid loss (Figure 5-1C). Daily water 
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intake was significantly greater (P<0.0001) in the D group compared to the C group, as 
expected. Also, the daily saline intake was significantly greater (P<0.0001) in diabetic 
animals when compared with control animals. In diabetic animals, the daily saline intake was 
significantly higher (P < 0.01) compared to the daily water intake, which is consistent with 
data observed in early stages (chapter 4). This was not the case in the control animals.  
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Figure 5-1. Effect of 6 weeks saline treatment on body weight, blood glucose and fluid 
intake of diabetic rats. A: Body weight measured at weekly intervals in control animals (C) 
and diabetic animals (D) given tap water to drink and control animals (CS) and diabetic 
animals (DS) given 1% NaCl solution. B: Blood glucose levels measured at 6 weeks after 
injection of rats with either STZ or citrate buffer. C: The amount of tap water or 1% NaCl 
solution ingested was monitored daily by weighting water bottles and then averaged for each 
week. Number of rats = 4 in each group. Data are expressed as the mean ± SEM. Significance 
was evaluated using a one way ANOVA followed by Tukey’s post hoc test for all 
comparisons (C vs D, C vs CS, CS vs DS and D vs DS) in this and all subsequent figures; ** 
indicates P<0.01; **** indicates P < 0.0001 for comparisons between diabetic groups and their 
respective controls; ♯♯ indicates P<0.01; ♯♯♯♯ indicates P <0.0001 for comparisons between 
diabetic groups.  
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 Measurement of baroreflex-mediated bradycardia in diabetic rats 5.2.2
In experiments to investigate the baroreflex-mediated bradycardia in the long term (6 weeks) 
after STZ or citrate injection, the mean arterial blood pressure under anaesthesia was not 
significantly different between the C and D or between the CS and DS groups (Figure 5-2A). 
Also, no significant differences were found in heart rate among the groups (Figure 5-2B). 
These results are consistent with a previous study at early stages (chapter 4). A progressive 
increase in the maximal mean arterial blood and decrease in the maximal heart rate in 
response to the infusion of increasing amounts of phenylephrine was seen in all groups. The 
maximal mean arterial blood pressure response to phenylephrine at all doses was not 
significantly different between the D and C groups (Figure 5-3A). The same pattern was also 
observed in the DS group compared to the CS group. Saline intake had no effect on blood 
pressure changes in response to phenylephrine in the diabetic or control animals. The 
maximal heart rate response to phenylephrine was also similar between the DS and CS group 
(Figure 5-3B); however, in the D group, the heart rate response to phenylephrine was 
significantly lower at 1, 2 and 5 µg doses but not 10 µg compared with the C groups. When 
baroreflex sensitivity was quantified as the ratio of maximal change in heart rate divided by 
the maximal change in mean arterial blood pressure, the baroreflex-mediated bradycardia in 
response to increasing doses of phenylephrine was similar between the DS and CS groups 
(Figure 5-3C); however, there was a significant reduction in baroreflex sensitivity in the D 
group when compared to the CW group (P<0.05), which is in agreement with the findings of 
others in long-term STZ diabetic rats. Interestingly, in late stages, saline treatment 
significantly increased (P<0.05) baroreflex sensitivity to normal levels in diabetic animals, 
which is opposed to our data at early stages of diabetes. These data suggested that saline has 
paradoxical effects on baroreflex sensitivity in STZ diabetic rats and that this effect is time 
dependent.   
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Figure 5-2. Effect of 6 weeks saline treatment on cardiovascular parameters in diabetic 
rats under anaesthesia. A: The mean arterial blood pressure (MAP); and B: The heart rate 
of unconscious control animals (C) and diabetic animals (D) given tap water and control 
animals (CS) and diabetic animals (DS) given 1% NaCl solution. Number of rats = 4 in each 
group. Data are expressed as the mean ± SEM. No significant differences were observed.    
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Figure 5-3. Cardiovascular responses to phenylephrine in diabetic rats. A: Changes in 
mean arterial pressure (MAP); and B: changes in heart rate (HR) in response to graded doses 
of intravenous phenylephrine (1, 2, 5 and 10 µg/kg) in control (C) and diabetic animals (D) 
given tap water and control (CS) and diabetic animals (DS) given saline. C: Baroreflex 
sensitivity (bpm/mmHg) of bradycardic responses represented as the average of the maximal 
change in heart rate divided by the maximal change in mean arterial blood pressure for each 
phenylephrine dose and then averaged for each animal. Baroreflex-mediated bradycardia was 
significantly attenuated in the diabetic group compared with the diabetic group treated with 
saline and the control group. Number of rats = 4, 4, 5 and 3 respectively. Data are expressed 
as the mean ± SEM. * indicates P<0.05 for comparisons between diabetic groups and their 
respective controls; ♯ indicates P<0.05 for comparisons between diabetic groups. 
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 OX-42 Immunohistochemistry in cardiovascular centres in diabetic rats 5.2.3
The OX-42 antibody was used to identify morphological changes in microglia cells in the 
cardiovascular centres in STZ rats. At 6 weeks following STZ or vehicle injection, microglia 
displayed normal morphology with small cell bodies and long, fine-branched processes 
throughout the PVN region in the C and CS groups, which is consistent with our previous 
study at early stages (chapter 4) (Figure 5-4). In contrast to our data at 2 weeks, there was a 
significant increase in the percentage of activated microglia with large cell bodies and short, 
thick processes in the PVN in the D group (P<0.01) compared to PVN microglia in the C 
group. Also, the percentage of activated microglia was significantly increased in the PVN in 
the DS group compared to PVN microglia in the CS group (Figure 5-6A). Saline treatment 
had no effect on the percentage of activated microglial in the diabetic group or control group. 
A significant increase in the percentage of activated microglial in diabetic groups was seen in 
both the parvocellular and magnocellular PVN (Figure 5-9A).  
In the NTS region in which baroreceptive afferent nerves terminate, microglial cells showed 
normal morphology with small cell bodies and long, fine-branched processes in the C, CS 
and DS groups (Figure 5-5). In contrast, darkly stained microglia with shorter, thicker 
processes were clearly observed in the NTS in the D group. The quantification of the 
percentage of activated microglia in the NTS in the D group showed a significantly greater 
activation compared to the C (P<0.01) and DS (P<0.001) groups (Figure 5-6B). Saline 
treatment in long-term STZ diabetic rats reduced the increase in the percentage of activated 
microglia in the NTS seen at 2 weeks following STZ treatment. This reduction in microglial 
activation was associated with improving baroreflex sensitivity, suggesting that NTS 
inflammation contributes to baroreflex dysfunction in short-term STZ diabetic rats treated 
with saline.  
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Microglial cells in the RVLM region exhibited normal morphology in the D and C groups. 
The same pattern was also observed in the DS and CS groups. The quantitative analysis of 
microglial activation in the RVLM region indicated that no significant differences were found 
among any of the groups (Figure 5-6C). 
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Figure 5-4. OX-42 Immunohistochemistry in the PVN in diabetic rats. Photomicrographs 
showing CD11b (OX-42 clone) immunoreactive microglia in the paraventricular nucleus (PVN) 
in control (C) and diabetic animals (D) given tap water and control animals (CS) and diabetic 
animals (DS) given 1% NaCl solution. Dotted lines in low-power images (A-D) outline the PVN. 
High-power images (E-H) show the morphology of microglia in the parvocellular PVN region in 
detail. OX-42 antibody staining shows microglia with normal morphology with small cell bodies 
and long fine-branched processes throughout the PVN region in the C and CS groups, while 
activated microglia showing larger cell bodies and shorter, thicker processes are seen in the D and 
DS group. Bar = 100 μm in A–D, 50 μm in E–H. 
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Figure 5-1. OX-42 Immunohistochemistry in the NTS in diabetic rats. Photomicrographs 
showing CD11b (OX-42 clone) immunoreactive microglia in the nuclear tractus solitarius (NTS) 
in control (C) and diabetic animals (D) given tap water and control (CS) and diabetic animals 
(DS) given 1% NaCl solution. Dotted lines in low-power images (A-D) outline the NTS. High-
power images (E-H) show the detailed morphology of microglia in NTS region. OX-42 antibody 
staining showing microglia with normal morphology was seen throughout the NTS region in the 
C, CS and DS groups, while activated microglia showing intense immunolabelling, larger cell 
bodies and thicker processes were common in the NTS in the D group. Bar = 200 μm in A–D, 100 
μm in E–H. 
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Figure 5-6. Microglial activation in cardiovascular centres of the brain of 6 weeks 
saline-treated diabetic rats. A: The percentage of microglia showing activated morphology 
in the paraventricular nucleus (PVN); B: in the nucleus tractus solitarius (NTS); and C: in the 
rostral ventrolateral medulla (RVLM) of the control (C) and diabetic animals (D) given tap 
water and control (CS) and diabetic animals (DS) given saline. After 6 weeks, the percentage 
of activated microglia was significantly increased in the PVN in the diabetic groups 
compared with the control groups. Also, the percentage of activated microglia was 
significantly increased in the NTS in the diabetic group compared with other groups. Number 
of rats = 4 in each group. Data are expressed as the mean ± SEM. ** indicates P<0.01 for 
comparisons between diabetic groups and their respective controls; ### indicates P<0.001 for 
comparisons between diabetic groups. 
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 C-fos immunoreactivity in cardiovascular centres in diabetic rats 5.2.4
In this study, an antibody to c-fos was used to quantify neuronal activation in the regions in 
which microglia were activated. In the PVN in the C and CS groups, the number of fos-
immunoreactive neurons was smaller compared to the D and DS groups (Figure 5-7). On 
quantification, we observed a significant increase in the number of fos-immunoreactive 
neurons in the D group compared to (P<0.05) the C group (Figure 5-8A). No significant 
differences were observed in the number of fos-immunoreactive neurons between the DS and 
CS groups. In the D group, a significant increase in the number of fos-immunoreactive 
neurons was restricted to parvocellular subdivisions of the PVN (5-9B). The number of fos-
immunoreactive neurons in the NTS was not significantly different between the C and D or 
between the CS and DS groups (Figure 5-8B); however, saline treatment significantly 
reduced (P<0.05) fos activity in the NTS in the diabetic animals. This was not case in the 
control animals. The counts of fos-immunoreactive neurons in the NTS and RVLM regions 
showed no significant difference among any of the groups (Figure 5-8C).  
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Figure 5-7. Fos activity in the PVN in diabetic rats. Photomicrographs showing neuronal 
nuclei stained with anti-Fos antibody in the paraventricular nucleus (PVN) in control (C) and 
diabetic animals (D) given tap water and control animals (CS) and diabetic animals (DS) given 
1% NaCl solution.Dotted lines the PVN. Bar = 100 μm. 
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Figure 5-8. Fos-IR immunoreactivity indicating activated neurons in cardiovascular 
centres of the brain in diabetic rats. A: Quantification of Fos-IR positive cell nuclei in the 
paraventricular nucleus (PVN); B: in the nucleus tractus solitarius (NTS); and C: in the 
rostral ventrolateral medulla (RVLM) of control (C) and diabetic animals (D) given tap water 
and control (CS) and diabetic animals (DS) given saline. Number of rats = 4 in each group. 
Data are expressed as the mean ± SEM. * indicates P<0.05 for comparisons between diabetic 
groups and their respective controls; # indicates P<0.05 for comparisons between diabetic 
groups. 
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Figure 5-9. Microglial and neuronal activation in the parvocellular and magnocellular 
portions of the paraventricular nucleus of diabetic rats. A: The percentage of microglia 
showing activated morphology in the parvocellular and magnocellular of the paraventricular 
nucleus (PVN) of control (C) and diabetic animals (D) given tap water and control (CS) and 
diabetic animals (DS) given saline. B: Quantification of Fos-IR positive cell nuclei in the 
same regions. Number of rats = 4 in each group. Data are expressed as the mean ± SEM. * 
indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001; **** indicates P < 0.0001 for 
comparisons between diabetic groups and their respective controls.  
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 Discussion 5.3
While drinking saline causes improvement in some cardiovascular changes in long-term 
STZ- induced diabetic rats, there is a lack of data on the effect of saline intake on baroreflex 
sensitivity and CNS inflammation. Thus, in this study, we aimed to investigate the effects of 
1% NaCl on baroreflex sensitivity and whether saline intake influences inflammation in CNS 
cardiovascular centres in long-term STZ diabetic rats. The main findings of the present study 
were that 6 weeks of treatment with 1% NaCl (i) had no effect on the mean arterial blood 
pressure under anaesthesia but (ii) restored the function of bradycardic baroreflex and (iii) 
reduced the activation of microglia and neurons in the NTS in STZ diabetic rats. 
We previously reported no changes in baroreflex sensitivity at 2 weeks in STZ diabetic 
animals compared to the control. In contrast, in the current study, there was dysfunction in 
the baroreflex-mediated bradycardia in the longer term, which is in agreement with previous 
studies (Van Buren et al., 1998; Dall'Ago et al., 2002; Harthmann et al., 2007; Souza et al., 
2007). This suggests that a reduction in baroreflex sensitivity is dependent on the time course 
of diabetes. The detailed mechanism of bradycardic baroreflex dysfunction in STZ diabetic 
rats is not known. There is evidence that suggests CNS inflammation can alter baroreflex 
function. For example, in a previous study, we have shown that the NTS exhibited microglial 
activation that was associated with baroreflex dysfunction in short-term STZ diabetic rats 
treated with saline. In addition, Takagishi et al. reported that microinjection of IL-6 into the 
NTS decreased baroreceptor sensitivity (Takagishi et al., 2010). It is well documented that 
activated microglia can contribute to inflammation by producing proinflammatory cytokines, 
such as IL-6. Therefore, we investigated whether microglia are activated in autonomic brain 
areas that are involved in cardiovascular regulation, including the baroreceptor reflex. In the 
NTS but not in the RVLM, we found activation of microglia in diabetic animals at 6 weeks 
following STZ injection, which is in agreement with our previous study that reported that 
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microglia become activated at later stages (Rana et al., 2014). Consistent with this result, it is 
well-known that over time after STZ treatment, autonomic dysfunction occurs. This includes 
abnormal increases in the renal sympathetic activity and impairment of baroreflex sensitivity. 
It is believed that these pathological changes in the autonomic nervous system may contribute 
to the development of cardiovascular complications (Grassi et al., 1998; Gao et al., 2002; 
Salgado et al., 2007; Maliszewska-Scislo et al., 2008). In the present study, microglial 
activation in the NTS in diabetic rats was observed around the time that autonomic system 
dysfunction occurred. These data suggest that microglial activation in the NTS may be 
responsible for baroreflex dysfunction seen at 6 weeks in STZ diabetic animals. 
Interestingly, prolonged saline intake in STZ diabetic rats caused improvement of baroreflex 
sensitivity, which is not consistent with the effect of saline seen at 2 weeks. The detailed 
mechanism by which saline intake restores the baroreflex dysfunction is not known. A likely 
mechanism would be involvement of neuroinflammation in autonomic centres in the brain. In 
contrast to early stages of diabetes, saline intake reduced microglial activation in the NTS in 
STZ diabetic rats compared to STZ diabetic rats given tap water to drink. Also, there was no 
increase in microglial activation in the RVLM at 6 weeks in STZ diabetic rats treated with 
saline, suggesting that drinking saline reduces microglial activation over time. This reduction 
in microglial activation was accompanied with an enhancement of baroreceptor sensitivity. 
These findings also provide support for the effect of NTS microglial activation on baroreflex 
function. 
The mechanisms by which microglia become activated in diabetic animals and saline intake 
reduces this activation are not completely understood. As discussed previously, neuronal over 
excitation can enhance microglial activation (Hathway et al., 2009; Lu et al., 2009). 
Therefore, we examined whether neurons were activated in CNS cardiovascular centres. In 
the NTS, we observed no significant increase in neuronal activation in diabetic rats compared 
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to non-diabetic control rats. Thus, the present finding is consistent with our earlier 
observations, supporting our interpretation that microglial activation was not mediated by 
neurons activation in the NTS and that damage to sensory neurons could be the potential 
mechanism; however, interestingly, prolonged saline treatment was able to reduce NTS 
neuron activation in diabetic rats. Studies on naïve animals have shown that salt intake 
potentiates the depressor responses to excitation of the NTS with a microinjection of 
glutamate (Ito et al., 1999; Isogai et al., 2005), but the exact mechanism is not clearly 
understood. 
A change in sodium balance is a possible mechanism that may be involved in altering the 
NTS neuron activity and baroreflex function. A sodium imbalance is characteristic of STZ 
diabetic rats because their excretion of sodium is high (Wald & Popovtzer, 1984; Schaan et 
al., 2005). Animal studies have shown that sodium depletion can cause impairment of the 
baroreceptor sensitivity (Kunze & Brown, 1978; Echtenkamp & Anderson, 1988; Huang & 
Leenen, 1994). Moreover, sodium depletion has been shown to activate the NTS neurons 
(Geerling & Loewy, 2007). We speculate that the dysfunction of baroreflex may be related to 
sodium depletion in STZ diabetic rats; therefore, drinking saline may restore sodium balance, 
thereby improving baroreflex sensitivity. 
Another possibility is that hormonal factors, such as renin angiotensin aldosterone, may 
influence the NTS neurons and baroreflex sensitivity. There have been studies that have 
demonstrated that an increase in angiotensin II is associated with diminished baroreflex 
sensitivity in dahl salt-sensitive rats (Ferrari et al., 1984) and that the inhibition of renin 
angiotensin aldosterone can improve baroreflex sensitivity in hypertensive animals (Gordon 
et al., 1981). In addition, microinjection of angiotensin II into the NTS decreased 
baroreceptor sensitivity (Casto & Phillips, 1986). An increase in the level of circulating 
angiotensin II can also activate neurons in brain regions that are involved in autonomic 
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control (Li et al., 1997). In early stages of diabetes, Kalinyak et al. found no change in the 
levels of angiotensin II in STZ diabetic rats (Kalinyak et al., 1993). In contrast, increased 
internal angiotensin II has been found at 6-8 weeks following STZ injection (Anderson et al., 
1993). Interestingly, salt intake has been shown to reduce angiotensin II in Zucker diabetic 
fatty rats (Takenaka et al., 2011). Thus, the decreased neuronal activity in diabetic rats treated 
with saline may be a result of decreased angiotensin II. Consequently, we presume that 
elevated angiotensin II may be responsible, at least in part, for the dysfunction of baroreflex 
seen in diabetic animals and that saline intake reduces angiotensin II, which in turn enhances 
baroreflex sensitivity. 
In addition to the role of angiotensin II in baroreflex dysfunction, it has also been shown that 
systemic infusion of angiotensin II increases blood pressure and activates microglia in the 
PVN (Shi et al., 2010a). In the present study, there was no change or reduction in the blood 
pressure of diabetic animals under anaesthesia compared to the control, which is in agreement 
with other studies at this later stage (Fazan et al., 1997; Van Buren et al., 1998; Fazan et al., 
1999; Schaan et al., 2004). In addition, we observed no changes in the blood pressure of 
anaesthetized diabetic animals when given 1% NaCl to drink, which is consistent with our 
previous study at early stages of diabetes (chapter 4), although we and others have provided 
evidence that drinking 1% NaCl caused a significant increase in blood pressure in awake 
diabetic animals in the short and longer terms (Santos et al., 1995; Maeda et al., 2007). 
Because of the potential effects of anaesthesia on the mechanism that generates hypertension, 
recording actual blood pressure under anaesthesia is not a valid method. Therefore, it is 
difficult to compare the effect of saline on blood pressure seen in our study and other 
previous studies in awake animals (chapter 4). Although saline was able to restore baroreflex 
dysfunction in diabetic rats in this study, another study reported that saline intake increases 
blood pressure at 8 weeks after STZ injection in awake animals. This suggests that prolonged 
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saline intake contributes to the development of hypertension in diabetic rats independently of 
baroreflex sensitivity, but how this occurs is not known. 
We previously provided evidence that saline intake promotes the development of 
hypertension and induces microglial activation in the PVN at 2 weeks in STZ diabetic rats 
and that the inhibition of microglial activation via a minocycline drug prevents hypertension. 
This suggests that microglial activation in the PVN contributes to this neurogenic 
hypertension. In the present study, we observed increased microglial activation in the PVN in 
diabetic rats compared with control rats, which is in agreement with our previous study that 
reported that microglia become activated at later stages. Also, we found microglial activation 
in the PVN of diabetic rats treated with saline, similar to our observations at earlier stages of 
diabetes. Microglial activation was seen in the parvocellular and magnocellular PVN; 
however, the functional consequences of microglial activation in the PVN are not known, and 
further studies are needed. 
The mechanisms by which microglia become activated in the PVN in diabetic groups remain 
to be determined. We previously provided evidence that microglial activation in the PVN 
may be secondary to prolonged intense activation of PVN neurons in diabetic rats. 
Interestingly, neuronal activation was observed in the parvocellular PVN but not in the 
magnocellular. The parvocellular PVN is involved in the regulation of autonomic function. 
We previously reported increased neuronal activity in this region at 2 weeks following STZ 
injection, but the microglia were not activated. In the present study at 6 weeks, both neuronal 
and microglial activation were seen in this region. Thus, it appears that microglial activation 
is related to neuronal activation. In diabetic rats treated with saline, no increase in neuronal 
activation was observed in the parvocellular or magnocellular division of the PVN, although 
microglia were activated. These findings indicate that microglial activation can occur without 
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neuronal activation, suggesting that saline may trigger microglial activation directly or via 
another mechanism. 
 Conclusion 5.4
In conclusion, our data indicated that 1% NaCl intake enhances baroreflex sensitivity in long-
term STZ diabetic rats. This enhancement was accompanied by a reduction in microglial 
activation in the NTS in diabetic rats treated with saline. Microglial activation in the NTS 
may contribute to the attenuated arterial baroreflex function observed in diabetic rats through 
the production of proinflammatory cytokines; however, further research is required to 
determine the full effect of microglia inhibition in the NTS. Saline intake had no effect on 
blood pressure in long-term STZ diabetic rats under anaesthesia. We conclude that prolonged 
saline intake may have beneficial effects on the cardiovascular system through a reduction of 
brain inflammation in diabetes.   
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 Introduction  6.1
Type I diabetes mellitus is an independent risk factor for the development of cardiovascular 
complications, which are the leading cause for 80% of deaths in diabetic patients (Kannel & 
McGee, 1979; Bell, 2003; Hayat et al., 2004). Diabetic cardiomyopathy is a common cause 
of heart failure that may occur independently of arterial hypertension and coronary artery 
disease (Rubler et al., 1972; Francis, 2001; Boudina & Abel, 2007). Diabetic cardiomyopathy 
is characterised by an impaired ventricular function of the heart. This includes left ventricular 
diastolic dysfunction (Joffe et al., 1999; Schannwell et al., 2001), and the progression of this 
dysfunction accelerates systolic dysfunction, which in turn contributes to the development of 
heart failure (Fonseca, 2003). While several mechanisms have been implicated in the 
pathogenesis of diabetic cardiomyopathy, including endothelial dysfunction and myocardial 
fibrosis (Tschöpe et al., 2005; Asbun & Villarreal, 2006), the exact mechanism is still 
unclear.  
Activity in the sympathetic nervous system that controls the heart and blood vessels has been 
shown to increase in heart failure diseases (Packer, 1988). Such activation may exacerbate 
and cause some of the aforementioned cardiovascular problems since interventions such as 
‘beta-blocker’ drugs can improve patient prognosis following myocardial infarction, which is 
another common complication of diabetes (Butler et al., 2006); however, whether this 
approach is useful in diabetes has not been investigated. There is growing evidence that 
abnormal cardiac function is associated with over-activity of sympathetic nerves measured by 
norepinephrine in both humans (Langer et al., 1995; Stevens et al., 1997; Perin et al., 2001) 
and animals with type 1 diabetes (Paulson & Light, 1981; Schmid et al., 1999). In addition, 
an abnormal activation of the sympathetic nervous system has also been reported in animals 
with type 1 diabetes via a direct measurement (Patel et al., 2011). This abnormal activation of 
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the sympathetic nervous system has been suggested to contribute to the development of heart 
failure in diabetes, but the cause is not known. 
Sympathetic nerve activity in the cardiovascular system is controlled via several regions in 
the brain called cardiovascular centres. The PVN is a key site within the brain that regulates 
sympathetic nerve activation. Our study and other previous studies on STZ-induced diabetic 
animals have reported abnormally increased neuronal activity in the PVN (Krukoff & Patel, 
1990; Zheng et al., 2002; Rana et al., 2014), but the central mechanisms behind this neuronal 
activation are not well understood. Interestingly, inflammation in the PVN has been shown to 
activate PVN neurons in other diseases (Shi et al., 2010a; Shi et al., 2011).  
Previously, we have shown that the resident immune cells within CNS, called microglia, 
become activated in the PVN in diabetic rats (Rana et al., 2014). Microglia have been 
implicated in the pathogenesis of several neurodegenerative diseases, including neuropathic 
pain. Once they become activated, they release proinflammatory molecules, which have been 
shown to cause neuronal hyperexcitability by increasing excitation and decreasing inhibition 
in the spinal cord (Sweitzer et al., 1999; Tsuda et al., 2008; Milligan & Watkins, 2009).  
Therefore, we hypothesize that activated microglia may be the cause for PVN neurons 
activation, which in turn activates sympathetic drive and contributes to cardiac dysfunction. 
The use of drugs that inhibit microglial activation in diabetic rats will help to understand 
whether microglial activation contributes to the development of diabetic complications. It has 
been suggested that dehydration may be responsible for the PVN neuron activation seen in 
diabetic rats.  
Accordingly, we investigated whether the inhibition of microglia in the PVN via minocycline 
can reduce or prevent PVN neuron activation and thereby result in an improved cardiac 
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function in STZ-induced diabetic rats. In addition, we investigated whether plasma 
osmolarity and/or dehydration contributes to PVN neuron activation.  
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 Results 6.2
 Effect of minocycline on general features of diabetic rats  6.2.1
At 6 weeks following injection with either STZ or citrate buffer, the body weights of diabetic 
animals with an ICV infusion of saline (DS) were significantly lower (P<0.05) compared 
with control animals with an ICV infusion of saline (CS), as expected (Figure 6-1A). The 
body weights of diabetic animals with an ICV infusion of minocycline (DM) were also 
significantly lower (P<0.001) compared with the CS group. Minocycline did not significantly 
affect the body weight of diabetic animals. Blood glucose levels were around the normal 
levels (6-7 mmol/L) in the CS group, but the diabetic groups showed high blood glucose 
(higher than 25 mmol/L) (Figure 6-1B). As expected, the diabetic groups exhibited 
significantly higher (P < 0.0001) blood glucose levels compared with the CS group, and 
minocycline treatment had no effect on blood glucose.  Daily water intake was significantly 
greater (P<0.0001) in the DS group compared to the CS group (Figure 6-1C), which is 
consistent with previous studies (chapter 5). The DM group drank a significantly greater (P < 
0.0001) volume of water than the CS group. Interestingly, minocycline treatment in diabetic 
animals significantly reduced the daily water intake. Heart weight (heart weight/body weight) 
was not significantly different between the CS and DS or between the DS and DM groups 
(Figure 6-2A); however, kidney weight (kidney weight/body weight) was significantly 
greater (P<0.0001) in the DS group compared to the CS group (Figure 6-2B). This was also 
the case for kidney weight in the DM group compared to the CS group (P < 0.05). Despite 
this, minocycline treatment significantly decreased the kidney weight of diabetic animals. 
To assess whether STZ diabetic rats were dehydrated, we measured plasma osmolarity, 
haemoglobin and haematocrit  at the end of the experimental period. As expected, the plasma 
osmolarity was significantly elevated (P<0.001) in the DS group compared with the CS 
group, which is consistent with our previous study (Rana et al., 2014) (Figure 6-3A); 
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however, no significant differences were found in plasma osmolarity between the DM group 
and CS group. When compared to the DS group, minocycline treatment significantly reduced 
(P<0.05) plasma osmolarity, suggesting it had restored plasma osmolarity to normal levels in 
diabetic animals. As indicators of blood volume status, the haematocrit and Haemoglobin 
concentration were significantly elevated (P<0.01) in the DS group compared to the CS 
group (Figure 6-3B-C). The haematocrit (P= 0.13) and Haemoglobin concentration (P= 0.30) 
were similar between the DM and CS groups, suggesting that minocycline-treated diabetic 
rats were not dehydrated; however, there was no significant difference in the haematocrit (P= 
0.18) and Haemoglobin concentration (P= 0.21) between the diabetic animals.   
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Figure 6-1. Effect of minocycline treatment on body weight, blood glucose and fluid 
intake of diabetic rats. A: Body weight measured at 6 weeks after injection of rats with 
either STZ or citrate buffer in control animals and diabetic animals with an ICV infusion of 
saline (CS, DS, respectively) and diabetic animals with an ICV infusion of minocycline 
(DM). B: Blood glucose levels measured at 6 weeks. C: The amount of tap water ingested 
was monitored daily at week 6 by weighting water bottles. Number of rats = 6, 8, and 8 
respectively. Data are expressed as the mean ± SEM. Significance was evaluated using a one 
way ANOVA followed by Tukey’s post hoc test for all comparisons (CS vs DS, CS vs DM, 
and DS vs DM) in this and all subsequent figures; * indicates P<0.05; ** indicates P<0.01; *** 
indicates P<0.001; **** indicates P < 0.0001 for comparisons between diabetic groups and 
controls; ♯ indicates P<0.05; ♯♯ indicates P<0.0; ♯♯♯ indicates P<0.001; ♯♯♯♯ indicates P < 
0.0001 for comparisons between diabetic groups. 
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Figure 6-2. Effect of minocycline treatment on heart weight and kidney weight in 
diabetic rats. A: Heart weight (heart weight / body weight); and B: kidney weight (kidney 
weight / body weight) as a proportion of the body weight of control animals and diabetic 
animals with an ICV infusion of saline (CS, DS respectively) and diabetic animals with an 
ICV infusion of minocycline (DM). Number of rats = 6, 8, and 8 respectively. Data are 
expressed as the mean ± SEM.  
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Figure 6-3. Effect of minocycline treatment on plasma osmolarity and haemoglobin in 
diabetic rats. A: Plasma osmolarity (Osmol/litre); B: Haemoglobin concentration (g/L); and 
C: Haematocrit (%) measured at the end of the experimental period in control animals and 
diabetic animals with an ICV infusion of saline (CS, DS respectively) and diabetic animals 
with an ICV infusion of minocycline (DM). Number of rats = 6, 8, and 8 respectively. Data 
are expressed as the mean ± SEM.  
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 Echocardiographic measurements in diabetic rats  6.2.2
The left ventricle of diabetic animals displayed a significant increase in the internal diameter 
in systole and diastole compared to the CS group, (P<0.01) and (P<0.0001), respectively 
(Figure 6-4A-B). The treatment of diabetic animals with ICV minocycline significantly 
reduced the left ventricle internal diameter in systole and diastole compared with the DS 
group, (P<0.05) and (P<0.01), respectively. No significant difference was seen in the internal 
diameter in the systole between the DM and CS groups, but there was a significant difference 
in the diastole. Diabetic animals demonstrated a significant reduction (P<0.0001) in the E/A 
ratio compared with the CS group (Figure 6-4C). No differences were observed in the E/A 
ratio between the DM group and CS group. Interestingly, minocycline treatment significantly 
improved (P<0.0001) the E/A ratio in diabetic animals. Heart rate did not differ among any of 
the groups (Figure 6-4D).   
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Figure 6-4. Effect of minocycline treatment on echocardiographic measurements in 
diabetic rats. A: Left ventricular internal diameter in systole — LVIDs (mm); B: left 
ventricular internal diameter in diastole — LVIDd (mm); C: E/A ratio (the ratio of the early 
(E) to late (A) ventricular filling velocities); and D: the heart rate of control animals and 
diabetic animals with an ICV infusion of saline (CS, DS respectively); and diabetic animals 
with an ICV infusion of minocycline (DM). Number of rats = 6, 8, and 8 respectively. Data 
are expressed as the mean ± SEM. 
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 Measurement of haemodynamic parameters in diabetic rats 6.2.3
Immediately after the echocardiography procedure, cardiac catheterization was performed to 
assess the left ventricular end diastolic pressure, dP/dt max and heart rate. Compared to 
control rats, the DS group exhibited significantly higher (P<0.0001) left ventricular end 
diastolic pressure at 6 weeks following STZ injection, indicating clear left ventricular 
dysfunction (Figure 6-5A). No difference was observed in the left ventricular end diastolic 
pressure between the DM group and CS group. The treatment of diabetic animals with 
minocycline significantly restored (P<0.0001) the elevated end diastolic pressure to levels 
comparable to the CS group. The maximal rate of pressure change (dP/dt max) was 
significantly lower (P<0.05) in the DS group compared to the level observed in the CS group 
(Figure 6-5B); however, there was no significant difference in the maximal rate of pressure 
change between the DM group and CS group. Minocycline did not significantly affect the 
maximal rate of pressure change in diabetic animals (P= 0.07). The heart rate under deep 
anaesthesia was similar among all groups (Figure 6-5C).  
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Figure 6-5. Effect of minocycline treatment on hemodynamic parameters in diabetic 
rats. A: End-diastolic pressure; (EDP); B: the maximal rate of pressure change (dP/dt max); 
and C: the heart rate of control animals and diabetic animals with an ICV infusion of saline 
(CS, DS, respectively); and diabetic animals with an ICV infusion of minocycline (DM). 
Number of rats = 6, 8, and 6 respectively. Data are expressed as the mean ± SEM.  
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 OX-42 and C-fos Immunohistochemistry in the paraventricular nucleus in 6.2.4
diabetic rats 
At 6 weeks following STZ or vehicle injection, the microglia displayed normal morphology 
with small cell bodies and long, fine-branched processes throughout the PVN region in the 
CS group, which is consistent with our previous study (Rana et al., 2014); however, 
microglial cells in the PVN in the DS group appeared to be present in an activated form with 
larger cell bodies and shorter, thicker processes (Figure 6-6). The quantification of the 
percentage of activated microglia in the PVN showed that it was lower than 7% in the CS 
group and higher than 60% in the DS group (Figure 6-8 A). Thus, the DS group exhibited a 
significant increase (P<0.0001) in the percentage of activated microglia compared with the 
CS group. There was no significant difference in the percentage of activated microglia in the  
PVN between the DM group and CS group. Minocycline treatment in diabetic animals caused 
a significant reduction (P<0.0001) in the percentage of activated microglia in the PVN. 
The number of fos-immunoreactive neurons in the PVN in the CS group appeared smaller 
when compared to the DS group (Figure 6-7). On quantification, we observed a significant 
increase (P<0.01) in the number of fos-immunoreactive neurons in the DS group compared to 
the CS group (Figure 6-8 B). Fos-immunoreactive neurons in the PVN showed no significant 
difference between the DM group and CS group. When the diabetic groups were compared, 
the increased number of fos-immunoreactive neurons seen in the PVN in the DS was 
significantly reduced (P<0.05) by the minocycline treatment.  
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Figure 6-6. Morphology of microglia in STZ diabetic rats. Photomicrographs showing CD11b 
(OX-42 clone) immunoreactive microglia in the paraventricular nucleus (PVN) of control animals 
and diabetic animals with an ICV infusion of saline (CS, DS respectively) and diabetic animals with 
an ICV infusion of minocycline (DM). Dotted lines in low-power images (A-C) outline the PVN. 
High-power images (D-F) show the morphology of microglia in the PVN region in detail. OX-42 
antibody staining shows microglia with normal morphology with small cell bodies and long, fine-
branched processes throughout the PVN region in the CS and DM groups, while activated microglia 
showing larger cell bodies and shorter, thicker processes are seen in the DS group. Bar = 100 μm in 
A–D, 50 μm in E–H. 
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Figure 6-7. Fos activity in the PVN in diabetic rats. Photomicrographs showing neuronal nuclei 
stained with anti-Fos antibody in the paraventricular nucleus (PVN) of control animals and 
diabetic animals with ICV infusion of saline (CS, DS respectively); and diabetic animals with ICV 
infusion of minocycline (DM). Dotted lines outline the PVN. Scale bar = 100 μm. 
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Figure 6-8. Effect of minocycline treatment on microglial and neuronal activation in the 
paraventricular nucleus of diabetic rats. A: The percentage of microglia showing activated 
morphology in the paraventricular nucleus (PVN) of control animals and diabetic animals 
with an ICV infusion of saline (CS, DS respectively) and diabetic animals with an ICV 
infusion of minocycline (DM). B: Quantification of Fos-IR positive cell nuclei in the same 
region. Number of rats = 6 in each group. Data are expressed as the mean ± SEM. 
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 Discussion 6.3
There is evidence that an over-activity of the sympathetic nervous system is a potential 
contributing factor to the development of diabetic cardiomyopathy, which is characterized by 
left ventricular dysfunction; however, whether PVN inflammation contributes to this 
sympathetic over-activity has not been investigated. Therefore, in this study, we aimed to 
investigate cardiovascular function in diabetic rats at 6 weeks following STZ injection and 
whether the inhibition of microglial activation in the PVN can reverse any of the changes 
seen. The main findings of the present study were that diabetic rats exhibited (i) left 
ventricular dysfunction, including elevated end diastolic pressure, an increased internal 
diameter in systole and diastole and a decreased E/A ratio; (ii) renal hypertrophy and elevated 
plasma osmolarity; (iii) microglial and neuronal activation in the PVN and that (iv) ICV 
minocycline inhibited microglial and neuronal activation and that (v) this inhibition was 
accompanied by improved left ventricular and renal changes without affecting 
hyperglycaemia or the body weight in STZ diabetic rats. 
In the present study, we observed increased microglial activation in the PVN in diabetic rats 
compared with control rats, which is similar to our observations in an earlier study (chapter 
5). This activation of microglia was accompanied by left ventricle impairment and renal 
hypertrophy. Increased microglial activation in the PVN and left ventricle and renal changes 
were significantly attenuated via administering ICV minocycline. Minocycline treatment not 
only attenuated microglial activation but also neuronal activation in the PVN in diabetic rats; 
however, minocycline did not alter the glycaemia level in diabetic rats, indicating that it 
improved cardiovascular and renal function via another mechanism.  
There is evidence that suggests that an abnormal activation of sympathetic nerves can result 
in ventricular dysfunction in human and animals with heart failure (Aronson & Burger, 2002; 
Guggilam et al., 2008). In the current study, echocardiographic measurements of the left 
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ventricle function and structure demonstrated diastolic dysfunction in STZ diabetic rats when 
compared with control rats, which is consistent with other previous studies at the same or 
earlier stages (Hoit et al., 1999; Wichi et al., 2007; Arozal et al., 2009). Similarly, a direct 
evaluation of left ventricle function demonstrated increased end diastolic pressure and 
decreased dP/dt max in diabetic rats, confirming diastolic dysfunction, which is in agreement 
with previous studies  (Riad et al., 2007; Wichi et al., 2007; Arozal et al., 2009); however, 
treating diabetic animals with ICV minocycline caused a significant reduction in left 
ventricular end diastolic pressure. The increase in internal diameter in the systole and diastole 
in diabetic rats was also significantly decreased by minocycline, and the decrease in the E/A 
ratio was also significantly reversed by minocycline. In almost all cases, there was no longer 
any difference from the control. These data indicate that ICV minocycline improved left 
ventricle diastolic function in STZ diabetic rats. Although we did not measure sympathetic 
activity directly in the present study, other studies have reported that over-activity of the 
sympathetic nervous system occurs in both humans and animals with type 1 diabetes (Perin et 
al., 2001; Patel et al., 2011; Salman et al., 2011). Thus, the cardiovascular dysfunction seen 
in diabetic animals may be related to autonomic dysfunction. 
PVN neuronal activation has been implicated in driving sympathetic overactivity in several 
diseases, including hypertension (Allen, 2002), heart failure (Li et al., 2003), water 
deprivation (Stocker et al., 2005) and chronic hypoxia (Sharpe et al., 2013). In the present 
study, we observed increased neuronal and microglial activation in the PVN in diabetic rats at 
6 weeks after STZ injection, which is consistent with our previous observation (chapter 5). 
Minocycline treatment significantly reduced both microglial and neuronal activation in the 
PVN. This drug has multiple anti-inflammatory actions (Yrjänheikki et al., 1999; Du et al., 
2001; Sapadin & Fleischmajer, 2006). Proinflammatory cytokines in the PVN have been 
shown to contribute to the activation of  PVN neurons in cardiovascular disease models (Shi 
et al., 2010a; Shi et al., 2011). In addition, a study on rats with chronic heart failure, which is 
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associated with increased sympathetic activity, reported evaluated levels of proinflammatory 
cytokines, such as TNF-α and IL-1β, in the PVN (Felder et al., 2003; Francis et al., 2004a; 
Francis et al., 2004b). Inhibition of these cytokines in the PVN has been shown to reduce 
sympathetic over-activity, resulting in improvement in left ventricle function, including left 
ventricle end diastolic pressure in these animals (Guggilam et al., 2008). In addition, Yu et al. 
reported that the microinjection of anti-inflammatory cytokines (IL-10) into the PVN in rats 
with heart failure decreased left ventricle end diastolic pressure (Yu et al., 2007). One 
possible source of these cytokines is microglia. Once microglia become activated in response 
to infection, injury or inflammation of the CNS, they release proinflammatory molecules and 
cytotoxic factors, such as nitric oxide (NO) and tumor necrosis factor (TNF-α), that induce 
neuronal over excitation. We have previously provided evidence that activated microglia in 
the PVN contribute to hypertension in STZ diabetic rats (chapter 4). Along with these studies, 
our data suggest that activated microglia in the PVN may release proinflammatory cytokines 
that lead to the observed over-activation of PVN neurons, which activates the sympathetic 
nerves and thereby contributes to cardiac dysfunction in diabetic rats. 
As discussed previously, abnormal sympathetic over-activation is reported in diabetic 
humans and animals. This abnormality has also been shown to be involved in the 
pathogenesis of renal dysfunction in diabetes, including glomerular hyper-filtration and 
increased renal plasma flow. For instance, an elevated glomerular filtration rate has been 
shown to occur in STZ diabetic animals, and renal denervation reversed glomerular hyper 
filtration (Luippold et al., 2004; Salman et al., 2011). Although we did not measure the renal 
haemodynamic properties directly in the present study, diabetic rats exhibited an increased 
kidney weight/body weight ratio, indicating that STZ diabetic rats display renal hypertrophy. 
Several studies have reported that increased kidney size is associated with elevated 
glomerular filtration rate as seen in diabetic humans (Christiansen et al., 1981; Gundersen & 
Mogensen, 1981) and animals (Luippold et al., 2004; Malatiali et al., 2008). It was believed 
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that an increase in kidney size precedes glomerular hyperfiltration, which would lead to 
subsequent albuminuria and diabetic nephropathy (Christiansen, 1984; Bak et al., 2000; 
Zerbini et al., 2006). Thus, the enlarged kidney size observed in STZ diabetic rats may be 
indicative of renal dysfunction. Interestingly, this hypertrophy was significantly reversed by 
ICV minocycline treatment. The precise mechanism is not clear, but inhibition of abnormal 
PVN activation via minocycline would be expected to reduce sympathetic activity and may 
therefore attenuate renal hypertrophy in diabetic rats via this mechanism.  
In addition to sympathetic nerve over-activity, other mechanisms may be involved in the 
development of renal hypertrophy in diabetic rats. In the present study, we found a significant 
increase in plasma osmolality in diabetic rats compared with the control. The haematocrit and 
Haemoglobin concentration were also increased in diabetic rats, indicating depletion in blood 
plasma volume. These results suggest that our diabetic animals were dehydrated, which is in 
agreement with our previous observation at an earlier stage (chapter 4). The PVN neurons 
would cause secretion of vasopressin in response to osmotic stimuli to regulate body fluid 
balance and blood volume in diabetic animals (Zerbe et al., 1979; Charlton et al., 1988; 
Brooks et al., 1989; Zheng et al., 2002). Elevated vasopressin secretion is well documented 
in diabetic humans and animals (Zerbe et al., 1985). This elevation has been implicated in the 
development of diabetic renal complications, including renal hypertrophy, glomerular 
hyperfiltration and albuminuria (Bouby et al., 1999; Lamarche et al., 1999; Donnelly et al., 
2000). Normalization vasopressin secretion in vasopressin-deficient rats injected with STZ to 
induce diabetes reversed these structural and physiological changes (Bardoux et al., 1999; 
Bouby et al., 1999). Therefore, we speculate that renal hypertrophy may be related to an 
increased vasopressin concentration in STZ diabetic rats, and minocycline treatment 
attenuated PVN neuronal activation and consequently normalised vasopressin secretion, 
preventing renal hypertrophy. 
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Our previous study on STZ diabetic rats showed that neuronal activation in the PVN occurs 
at an earlier stage (2 weeks) than the onset of microglial activation in the PVN (6-8weeks), 
suggesting that neuronal activation precedes microglial activation in this nucleus; however, 
the result obtained here that minocycline treatment attenuated both microglial and neuronal 
activation suggests that the opposite may be true. It has been reported that minocycline 
inhibits microglial activation without affecting neurons in the spinal cord of neuropathic rats 
(Raghavendra et al., 2003; Ledeboer et al., 2005). Thus, a possible scenario is that firstly, 
neuronal activation at early stages induces microglial activation. Consequently, via a positive 
feedback mechanism, microglial activation induces the secondary and sustained neuronal 
activity that appears to cause the diabetic cardiovascular and renal complication observed in 
this study. 
Although several studies have reported activated neurons in the PVN in STZ diabetic animals 
(Krukoff & Patel, 1990; Zheng et al., 2002; Morgado et al., 2011; Rana et al., 2014), the 
mechanism by which diabetes induces this activation in the hypothalamic PVN or other 
cardiovascular regions is unclear. A large body of evidence shows that hyperglycaemia 
induces the production of reactive oxygen species in the PVN (Patel et al., 2011) and other 
brain areas in STZ diabetic rats (Acar et al., 2012; Ola et al., 2014). It has been reported that 
the increase in the generation of reactive oxygen species can enhance the influx of Ca
2+
 in 
neurons, which in turn leads to neuronal activation (Wang et al., 2003; Zimmerman & 
Davisson, 2004). We have preliminary evidence that an antioxidant can significantly 
attenuate the increase in neuronal activation in the PVN in STZ diabetic mice at 5 weeks 
following the induction of diabetes. Reactive oxygen species in dorsal horn neurons have 
been shown to contribute to neuronal hyperexcitability and the development of neuropathic 
pain, since the administration of antioxidants prevents neuropathic pain-like behaviours 
(Stevens et al., 2000; Ho et al., 2006). These findings suggest that PVN neuron activity may 
be mediated by increased reactive oxygen species in diabetic animals, but it is also clear that 
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microglia are a major source of reactive oxygen species in the brain and that reactive oxygen 
species are required for microglial activation and cytokine release.  
Elevated levels of plasma osmolality in diabetic animals has also been implicated in PVN 
neuronal activation (Charlton et al., 1988; Brooks et al., 1989); however, it seems unlikely 
that elevated plasma osmolality seen in diabetic rats is responsible for the neuronal activation 
because the inhibition of PVN via minocycline reduced the plasma osmolality to normal 
levels. Despite this, if a positive feedback mechanism is involved, then breaking the cycle at 
any point may prevent multiple detrimental outcomes. 
Interestingly, ICV minocycline was able to restore cardiac and renal dysfunction seen in our 
diabetic rats without affecting high blood glucose. Whatever the mechanisms by which high 
blood glucose can cause central inflammation may be, it is clear from our animals at 6 weeks 
following STZ injection that the changes in the brain are a major cause of the development of 
the cardiovascular and renal complications seen. Indeed, at this stage, our study provides little 
evidence of a direct effect of high blood glucose in cardiac function. Our data suggest that 
these pathological changes are mediated by CNS inflammation as a second mechanism or 
pathway to contribute to these diabetic complications.  
 Conclusion 6.4
This study suggests that microglial activation in the PVN in STZ-induced diabetic rats leads 
to PVN neuronal excitation. We speculate that this increase in the neuronal activity could 
explain increased sympathetic activity seen in humans and animals with type 1 diabetes. 
Consequently, this abnormal activity may be responsible for altered cardiac and renal 
function in diabetes. We provide evidence here that the inhibition of central inflammation 
may lead to preventing cardiac and renal diseases associated with diabetes. Thus, targeting 
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microglial activation in the PVN may be an effective therapeutic approach through 
preventing neuronal activity and multiple diabetic complications.  
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 Introduction  7.1
Cardiovascular complications are the likely cause of morbidity and mortality in 
approximately 80% of diabetes mellitus patients (O'Keefe et al., 1999). As previously 
discussed, diabetic cardiomyopathy occurs frequently in humans and animals with type 1 
diabetes, and this includes left ventricular diastolic dysfunction (Joffe et al., 1999; 
Schannwell et al., 2001). Over-activity in the sympathetic nervous system that controls the 
cardiovascular system is associated with diabetes. Such activity may contribute to left 
ventricular dysfunction and consequently to the development of heart failure in diabetes 
(refer to chapter 6).  
The paraventricular nucleus (PVN) in the hypothalamus is a major focus for studies on 
cardiovascular complications because it regulates the autonomic nervous system and the 
endocrine system, including their cardiovascular functions (van den Pol, 1982; Badoer, 2001, 
2010). Previously, we have reported that PVN neurons are activated in STZ diabetic rats, 
potentially due to dehydration in these animals (refer to chapter 6). Therefore, increased 
sympathetic nerve activity and diabetic complications may be caused by dehydration and its 
effects on the PVN. In support of this, Stocker and Keith have reported that renal sympathetic 
nerve activity is increased in water-deprived rats, PVN neurons are activated by this stimulus 
and renal sympathetic nerve activity is decreased via inhibiting PVN neurons in these animals 
(Stocker et al., 2004). Treatment with normal saline may be expected to reverse this 
dehydration in diabetes, but the effect of long-term saline intake on dehydration and 
cardiovascular changes in STZ diabetic rats has not been investigated. 
In contrast, our previous data suggest that the activation of PVN neurons is also caused by 
local microglial activation in STZ diabetic rats and that inhibiting microglia prevents 
dehydration (refer to chapter 6). Microglia are the primary immune cells that mediate 
inflammation in the CNS. They have been implicated in the pathogenesis of several 
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neurodegenerative diseases, including neuropathic pain. When these cells become activated, 
they can further induce inflammatory processes via secreting cytokines, such as tumour 
necrosis factor alpha (TNF-α), interleukins (IL), interferon (INF), reactive oxygen species 
and superoxides. These cytokines have been found to increase neuronal excitability in the 
CNS in many neurological disorders (refer to chapter 6). We have previously provided 
evidence that the pharmacological inhibition of PVN microglia can prevent not only PVN 
neuronal activity but also the cardiac dysfunction seen in diabetic animals, suggesting that 
inflammation in the CNS may be a mechanism contributing to the development of 
cardiovascular complication in diabetes (refer to chapter 6). The interactions between 
dehydration and CNS inflammation are therefore complex and require further investigation. 
Our previous study found that drinking 1% NaCl influenced CNS inflammation in STZ 
diabetic rats (refer to chapters 4-5). Oral intake of 1% NaCl caused the activation of 
microglia in the PVN and increases in blood pressure in diabetic rats at 2 weeks following 
STZ injection. The inhibition of microglial activation prevented the hypertension seen in 
these animals (refer to chapter 4); however, drinking 1% NaCl for 6 weeks in STZ diabetic 
rats reduced the activation of microglia and neurons in the NTS, a baroreceptor reflex 
regulator region. This reduction was accompanied by a restoration of the function of the 
bradycardic baroreflex in STZ diabetic rats (refer to chapter 5). Thus, it appears that drinking 
1% NaCl for a longer period in STZ diabetic animals produces beneficial effects on the 
cardiovascular system. 
Our previous study showed that microglial activation in the PVN may cause the cardiac 
dysfunction seen in diabetic rats (refer to chapter 6).  Dai et al. (1994) reported that saline 
intake for 6 weeks improved ex vivo cardiac function in STZ diabetic rats. Despite this, in our 
study, prolonged saline intake did not reduce microglial activation in the PVN in STZ 
Chapter Seven: Drinking 1% NaCl improves cardiac dysfunction Page | 167 
 
 
 Page | 167 
 
 
diabetic rats, even though the number of rats tested was small (refer to chapter 5), suggesting 
the effect of long-term saline on the cardiac function may not occur via the PVN. 
Therefore, in this study, we investigated the effects of prolonged saline intake on (i) the in 
vivo cardiac function, (ii) dehydration and (iii) microglial activation in the PVN in STZ 
diabetic rats. In addition, we investigated whether the microglial inhibitor minocycline 
provided any additional effect to that of prolonged saline treatment in STZ diabetic rats. 
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 Results  7.2
 Effect of saline plus or minus minocycline on general features of diabetic 7.2.1
rats  
At 6 weeks following injection with either STZ or citrate buffer, the body weights of diabetic 
animals (DWS) given tap water to drink and diabetic animals (DSS) given 1% NaCl solution 
with an ICV infusion of saline and diabetic animals given 1% NaCl with an ICV infusion of 
minocycline (DSM) were significantly lower (P<0.01, <0.001 and < 0.01, respectively) 
compared with control animals with an ICV infusion of saline (CWS), as expected (Figure 7-
1A). Saline and saline plus minocycline treatments did not significantly affect the body 
weight of diabetic animals. As expected, all diabetic groups exhibited significantly higher (P 
< 0.0001) blood glucose levels compared with the CWS group, and saline ± minocycline 
treatment had no effect on blood glucose (Figure 7-1B). Daily water intake was significantly 
greater (P<0.0001) in all diabetic groups when compared to the CWS group (Figure 7-1C). 
Saline ± minocycline treatment in diabetic animals showed no significant effect on daily fluid 
intake. Heart weight (heart weight/body weight) was not significantly different between any 
of the groups (Figure 7-2A); however, kidney weight (kidney weight / body weight) was 
significantly greater (P<0.0001) in the DWS group compared to the CWS group (Figure 7-
2B). This was also the case for kidney weight in the DSS and DSM groups compared to the 
CWS group (P < 0.05), but the saline + minocycline treatment tended to decrease kidney 
weight compared to the DWS group (P = 0.07).  
To assess whether STZ diabetic rats were dehydrated and whether saline ± minocycline 
prevented dehydration, we measured plasma osmolarity, haemoglobin and haematocrit  at the 
end of the experimental period. As expected, plasma osmolarity was significantly elevated in 
the DWS group as well as in the DSS group (P<0.001 and <0.05, respectively) compared 
with the CWS group (Figure 7-3A); however, no significant differences were found in plasma 
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osmolarity between the DSM group and CWS group. When compared to the DWS group, the 
combination of saline and minocycline treatment significantly reduced (P<0.05) plasma 
osmolarity, suggesting that plasma osmolarity was restored to normal levels in these animals. 
As an indicator of blood volume status, the haematocrit and Haemoglobin concentration were 
significantly elevated (P<0.01) only in the DWS group compared to the CWS group (Figure 
7-3B-C). There was no significant difference between the DSS and CWS groups, suggesting 
that diabetic rats treated with saline did not have a significantly reduced blood volume. This 
also was the case between the DSM and CWS groups; however, there was also no significant 
effect of saline ± minocycline on haematocrit and Haemoglobin concentration when 
compared to diabetic animals. The results of plasma the osmolarity, haemoglobin and 
haematocrit  measurements indicated that STZ-treated diabetic rats were dehydrated, and 
saline ± minocycline tended to prevent this characteristic of this model.  
  
Chapter Seven: Drinking 1% NaCl improves cardiac dysfunction Page | 170 
 
 
 Page | 170 
 
 
  
A. B. 
C
W
S
D
W
S
D
SS
D
SM
0
200
400
600
B
o
d
y
 w
e
ig
h
t 
(g
)
**
****
**
 
C
W
S
D
W
S
D
SS
D
SM
0
10
20
30
40
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
L
)
****
****
****
 
C.  
C
W
S
D
W
S
D
SS
D
SM
0
100
200
300
400
D
a
il
y
 f
lu
id
 c
o
n
s
u
m
p
ti
o
n
 (
m
ls
)
****
****
****
 
 
 
Figure 7-1. Effect of saline plus or minus minocycline treatment on body weight, blood 
glucose and fluid intake of diabetic rats. A: Body weight measured at 6 weeks after 
injection of rats with either STZ or citrate buffer in the following groups: control animals 
(CWS), diabetic animals (DWS) given tap water to drink with an ICV infusion of saline and 
diabetic animals (DSS) given 1% NaCl solution with an ICV infusion of saline and diabetic 
animals (DSM) given 1% NaCl with an ICV infusion of minocycline. B: Blood glucose 
levels measured at 6 weeks in these groups. C: The amount of tap water or 1% NaCl ingested 
was monitored daily at week 6 by weighting water bottles. Number of rats = 6, 8, 8 and 8 
respectively. Data are expressed as the mean ± SEM. Significance was evaluated using a one 
way ANOVA followed by Tukey’s post hoc test for all comparisons (CWS vs DWS , CWS 
vs DSS, CWS vs DSM, DWS vs DSS, DWS vs DSM and DSS vs DSM) in this and all 
subsequent figures; * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001; **** indicates 
P < 0.0001 for comparisons between diabetic groups and controls; ♯ indicates P<0.05; ♯♯ 
indicates P<0.0; ♯♯♯ indicates P<0.001; ♯♯♯♯ indicates P < 0.0001 for comparisons between 
diabetic groups; & indicates P<0.05; && indicates P<0.01; &&& indicates P<0.001 for 
comparisons between diabetic groups and diabetic animals with minocycline treatment. 
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Figure 7-2. Effect of saline plus or minus minocycline treatment on heart weight and 
kidney weight in diabetic rats. A: Heart weight (heart weight / body weight); and B: kidney 
weight (kidney weight / body weight) as a proportion of control animals (CWS), diabetic 
animals (DWS) given tap water to drink with an ICV infusion of saline and diabetic animals 
(DSS) given 1% NaCl solution with an ICV infusion of saline and diabetic animals (DSM) 
given 1% NaCl with an ICV infusion of minocycline.  Number of rats = 6, 7, 7 and 7 
respectively in each group. Data are expressed as the mean ± SEM.  
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Figure 7-3. Effect of saline plus or minus minocycline treatment on plasma osmolarity 
and haemoglobin in diabetic rats. A: Plasma osmolarity (Osmol/litre); B: Haemoglobin 
concentration (g/L); and C: Haematocrit (%) measured at the end of the experimental period 
in control animals (CWS), diabetic animals (DWS) given tap water to drink with an ICV 
infusion of saline and diabetic animals (DSS) given 1% NaCl solution with an ICV infusion 
of saline and diabetic animals (DSM) given 1% NaCl with an ICV infusion of minocycline. 
Number of rats = 6, 8, 8 and 7 respectively in each group. Data are expressed as the mean ± 
SEM.  
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 Echocardiographic measurements in diabetic rats  7.2.2
The left ventricle of diabetic animals given water to drink displayed a significant increase in 
the internal diameter in systole and diastole compared to the CWS group (P<0.001 and 
P<0.01, respectively) (Figure 7-4A-B). In contrast, no significant difference was seen in the 
internal diameter in the systole and diastole between the DSS and CWS groups or the DMS 
and CWS groups. Treatment of diabetic animals with a combination of saline and 
minocycline significantly reduced the left ventricle internal diameter in systole and diastole 
compared with the DWS group (P<0.0001 and P<0.01, respectively), suggesting saline ± 
minocycline reversed structural changes in the heart. When compared to the DSS group, 
minocycline + saline treatment had no significant effect on the internal diameter in the 
diastole, but it significantly (P<0.001) reduced the internal diameter in the systole, suggesting 
that the effect of saline was intermediate. The E/A ratio of the DWS and DSS groups 
demonstrated a significant reduction (P<0.001 and <0.01, respectively) compared with the 
CWS group, suggesting diastolic dysfunction (Figure 7-4C); however, no differences were 
observed in the E/A ratio between the DSM group and CWS group, and the combination of 
saline and minocycline significantly improved (P<0.01) the E/A ratio in the DWS and DSS 
groups, suggesting no effect of saline on this parameter in diabetes. The heart rate under 
anaesthesia did not differ among any of the groups (Figure 7-4D).   
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Figure 7-4. Effect of saline plus or minus minocycline treatment on echocardiographic 
measurements in diabetic rats. A: Left ventricular internal diameter in systole — LVIDs 
(mm); B: left ventricular internal diameter in diastole — LVIDd (mm); C: E/A ratio (the ratio 
of the early (E) to late (A) ventricular filling velocities); and D: the heart rate of control 
animals (CWS), diabetic animals (DWS) given tap water to drink with an ICV infusion of 
saline and diabetic animals (DSS) given 1% NaCl solution with an ICV infusion of saline and 
diabetic animals (DSM) given 1% NaCl with an ICV infusion of minocycline. Number of rats 
= 6, 8, 6 and 8 respectively. Data are expressed as the mean ± SEM. 
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 Measurement of haemodynamic parameters in diabetic rats 7.2.3
Immediately after echocardiography, cardiac catheterization was performed to assess the left 
ventricular end diastolic pressure and the maximal rate of pressure change (dP/dt max). Heart 
rate was again measured during this procedure. Compared to control rats, the DWS group 
exhibited significantly higher (P<0.0001) left ventricular end diastolic pressure at 6 weeks 
following STZ injection, indicating clear left ventricular dysfunction (Figure 7-5A). 
Treatment of diabetic animals with saline significantly restored (P<0.001) the elevated end 
diastolic pressure to levels comparable to the CWS group. This also was the case in diabetic 
rats treated with minocycline compared with the DWS group (P<0.0001). No difference was 
observed in left ventricular end diastolic pressure in the DSS and DSM groups compared with 
the CWS group.  When dP/dt max was quantified, it was significantly lower (P<0.05) in the 
DWS and DSS groups compared to the level observed in the CWS group (Figure 7-5B); 
however, there was no significant difference in the maximal rate of pressure change between 
the DSM group and CWS group. Despite this, a combination of minocycline and saline did 
not significantly increase the maximal rate of pressure change in diabetic animals. The heart 
rate under deep anaesthesia was similar among all groups (Figure 7-5C). These data indicated 
that saline ± minocycline treatment was able to prevent diastolic dysfunction seen in diabetic 
animals given water to drink. 
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Figure 7-5. Effect of saline plus or minus minocycline treatment on hemodynamic 
parameters in diabetic rats. A: end-diastolic pressure; (EDP); B: the maximal rate of 
pressure change (dP/dt max); and C: the heart rate of in control animals (CWS), diabetic 
animals (DWS) given tap water to drink with an ICV infusion of saline and diabetic animals 
(DSS) given 1% NaCl solution with an ICV infusion of saline and diabetic animals (DSM) 
given 1% NaCl with an ICV infusion of minocycline. Number of rats = 6, 8, 7 and 7 
respectively. Data are expressed as the mean ± SEM.  
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 OX-42 and C-fos Immunohistochemistry in the paraventricular nucleus in 7.2.4
diabetic rats 
At 6 weeks following vehicle injection, microglia in the CWS group displayed normal 
morphology with small cell bodies and long, fine-branched processes throughout the PVN 
region, which is consistent with our previous study; however, microglial cells in the PVN in 
the DWS group appeared to be present in an activated form with larger cell bodies and 
shorter, thicker processes (Figure 7-6). The quantification of the percentage of activated 
microglia in the PVN showed that it was lower than 7% in the CWS group and higher than 
60% in the DWS group (Figure 7-8A). Thus, the DWS group exhibited a significant increase 
(P<0.0001) in the percentage of activated microglia compared with the CWS group. Saline 
treatment in long-term STZ diabetic rats significantly reduced (P<0.01) the percentage of 
activated microglia in the PVN compared to the DWS group, but it was still significantly 
higher (P<0.0001) compared with the CWS group, suggesting that saline treatment was not 
able to inhibit microglial activation completely. There was no significant difference in the 
percentage of activated microglia in the PVN between the DSM group and CWS group. 
Minocycline treatment in diabetic animals given saline caused a significant reduction 
(P<0.0001) in the percentage of activated microglia in the PVN compared to diabetic animals 
to a level comparable to that in the CWS group. 
The number of fos-immunoreactive neurons in the PVN in the DWS group appeared larger 
compared to the CWS group (Figure 7-7). On quantification, we observed a significant 
increase (P<0.001) in the number of fos-immunoreactive neurons in the DWS group 
compared to the CWS group (Figure 7-8B). Although the DSS groups also exhibited a 
significant increase (P<0.05) in the number of fos-immunoreactive neurons compared to the 
CWS group, saline treatment significantly reduced (P<0.05) fos activity in the PVN in the 
diabetic animals. The number of fos-immunoreactive neurons in the PVN showed no 
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significant difference between the DSM group and CWS group. When diabetic groups were 
compared, the increased number of fos-immunoreactive neurons seen in the PVN in the DWS 
and DSS groups was significantly reduced (P<0.0001 and <0.05) by the minocycline 
treatment. These results suggested that saline ± minocycline treatment prevented the 
activation of PVN neurons in STZ diabetic rats. 
 
 
  
Chapter Seven:                            Drinking 1% NaCl improves cardiac dysfunction  Page | 1 
 
 
 Page | 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
       CWS 
 DWS 
DSS 
   DSM 
A 
B 
C 
D 
E 
F 
G 
H 
Chapter Seven: Drinking 1% NaCl improves cardiac dysfunction Page | 180 
 
 
 Page | 180 
 
 
 
 
 
 
 
 
  
Figure 7-6. Morphology of microglia in STZ diabetic rats. Photomicrographs showing CD11b 
(OX-42 clone) immunoreactive microglia in the paraventricular nucleus (PVN) of control animals 
(CWS), diabetic animals (DWS) given tap water to drink with ICV infusion of saline and diabetic 
animals (DSS) given 1% NaCl solution with ICV infusion of saline; and diabetic animals (DSM) 
given 1% NaCl with ICV infusion of minocyclineDotted lines in low-power images (A-C) outline 
the PVN. High-power images (D-F) show the morphology of microglia in the parvocellular PVN 
region in detail. OX-42 antibody staining shows microglia with normal morphology with small 
cell bodies and long fine-branched processes throughout the PVN region in the CS and DM 
groups, while activated microglia showing larger cell bodies and shorter, thicker processes are 
seen in the DS group. Bar = 100 μm in A–D, 50 μm in E–H. 
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Figure 7-7. Fos activity in the PVN in diabetic rats. Photomicrographs showing neuronal 
nuclei stained with anti-Fos antibody in the paraventricular nucleus (PVN) of control animals 
(CWS), diabetic animals (DWS) given tap water to drink with ICV infusion of saline and 
diabetic animals (DSS) given 1% NaCl solution with ICV infusion of saline; and diabetic 
animals (DSM) given 1% NaCl with ICV infusion of minocycline.Dotted lines the PVN. Bar = 
100 μm. 
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Figure 7-8. Effect of saline plus or minus minocycline treatment on microglial and 
neuronal activation in the paraventricular nucleus of diabetic rats. A: The percentage of 
microglia showing activated morphology in the paraventricular nucleus (PVN) of control 
animals (CWS), diabetic animals (DWS) given tap water to drink with an ICV infusion of 
saline and diabetic animals (DSS) given 1% NaCl solution with an ICV infusion of saline and 
diabetic animals (DSM) given 1% NaCl with an ICV infusion of minocycline. B: 
Quantification of Fos-IR positive cell nuclei in the same region. Number of rats = 6 in each 
group. Data are expressed as the mean ± SEM. 
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 Discussion 7.3
There are increasing indications from previous studies that prolonged drinking of normal 
saline reduced cardiovascular complications in STZ diabetic animals, including cardiac 
dysfunction (Dai et al., 1994) (chapter 5), but the exact mechanism is still unclear. We 
previously provided evidence that inflammation in CNS cardiovascular centres plays a key 
role in the pathogenesis of diabetic cardiovascular complications; however, whether the effect 
of saline intake on cardiovascular complications is mediated by PVN inflammation has not 
been investigated. Therefore, in this study, we aimed to investigate the effects of 1% NaCl on 
the cardiovascular function in vivo, whether saline intake influences PVN inflammation in 
longer term (6 weeks) STZ-diabetic rats and whether the inhibition of microglial activation in 
the PVN can reverse any of the changes seen. The main findings of the present study were 
that prolonged treatment with 1% NaCl (i) restored elevated end diastolic pressure and (ii) 
reduced the activation of microglia and neurons in the PVN and that (iii) ICV minocycline 
further inhibited microglial and neuronal activation and that (iv) this inhibition was 
accompanied by a further improvement in left ventricular function in STZ diabetic rats.      
In the present study, the structure of the left ventricle in diabetic rats treated with saline 
tended to be normalised when assessed by an echocardiographic approach, although there 
was no significant difference when functional parameter was measured (E/A ratio). Similarly, 
a direct evaluation of the left ventricle function demonstrated that saline treatment 
significantly restores elevated end diastolic pressure in diabetic rats to the level seen in 
control rats but not dP/dt max. Thus, although 1% NaCl intake did not significantly improve 
all aspects of left ventricle functions and structure, these data provide evidence confirming an 
improvement in cardiac function in STZ diabetic rats treated with saline, which is in 
agreement with previous ex vivo studies (Dai et al., 1994); however, how this effect of saline 
occurs is not known. Interestingly, the improvement observed in cardiac function in diabetic 
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rats treated with saline was associated with a significant reduction in microglial activation in 
the PVN when compared to diabetic rats. We previously provided evidence that microglial 
activation in the PVN contributes to the development of left ventricle dysfunction in STZ 
diabetic rats. Inhibition of this activation via minocycline improved cardiac function. In 
addition, in a previous study, we have shown that another CNS cardiovascular centre, the 
NTS, exhibited microglial activation that was associated with baroreflex dysfunction in STZ 
diabetic rats at the same stages examined here. Prolonged saline intake reduced the NTS 
microglial activation and restored the baroreflex dysfunction seen in STZ diabetic rats. 
Therefore, this current study also supports the hypothesis that drinking saline in long-term 
STZ diabetic rats can prevent cardiovascular complications through a reduction in PVN 
inflammation.  
To understand the effect of microglial activation in the PVN in diabetic rats treated with 
saline, we inhibited this activation via ICV minocycline in these animals. We observed that 
minocycline treatment significantly reduced microglial activation in the PVN when compared 
to both of the other diabetic groups to the level comparable to control rats, which is consistent 
with our previous study (chapter 6). As a consequence of this inhibition, diabetic rats treated 
with saline plus minocycline exhibited a significant improvement in almost all aspects of 
cardiac performance compared to diabetic groups, and there was no significant difference 
from the control rats. Because the effect of the combination of saline and minocycline 
treatment on cardiac function and PVN inflammation was greater when compared to the 
effect of saline treatment alone in the present study, collectively, these data suggest that 
changes in the left ventricle function in diabetic groups were paralleled by the levels of 
microglial activation in the PVN seen in these rats. 
Several lines of evidence have suggested that inflammatory changes within the PVN mediate 
the over-activity of the sympathetic nervous system, which is linked to the pathogenesis of 
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the development of cardiovascular-related diseases, including hypertension, myocardial 
infarction and heart failure, which are major consequences of diabetes. These inflammatory 
changes include abnormally increased proinflammatory cytokines. In rats with acute 
myocardial infarction that is associated with increased sympathetic activity, elevated TNF-α 
and IL-1β in the PVN has been reported (Felder et al., 2003; Francis et al., 2004a; Francis et 
al., 2004b). Microinjection of a TNF-α blocker into the PVN of rats with heart failure has 
been shown to decrease sympathetic hyperactivity (Guggilam et al., 2008; Kang et al., 2010). 
This reduction in sympathetic activity normalised left ventricle end diastolic pressure in these 
animals (Guggilam et al., 2008). In addition, Yu et al. (2007) reported that the microinjection 
of anti-inflammatory cytokines (IL-10) into the PVN in rats with heart failure decreased left 
ventricle end diastolic pressure. Our laboratory demonstrated that microglial activation in the 
PVN also occurs in animal models of heart failure. As discussed previously, once microglia 
become activated in response to infection, injury or inflammation of the CNS, they release 
pro-inflammatory molecules and cytotoxic factors, such as nitric oxide (NO) and TNF-α. 
Therefore, one possible source of these cytokines is activated microglia. Along with these 
studies, our data suggest that activated microglia observed in the PVN in diabetic rats may 
secrete proinflammatory cytokines that activate the sympathetic nerves, and thereby 
contributes to the cardiac dysfunction seen here.   
In addition to the beneficial effect of drinking saline on the cardiac function of STZ diabetic 
rats, emerging evidence confirms a previous result that kidney function is also improved by 
saline intake (McDonald et al., 1969). Vallon et al. reported that drinking 1% NaCl for 6 
weeks following STZ injection caused a reduction in glomerular hyperfiltration (Vallon et al., 
1997). Glomerular hyper-filtration is a risk factor for the development of diabetic 
nephropathy and renal failure (Mogensen & Christensen, 1984; Mogensen, 1986). In the 
present study, we did not measure the glomerular filtration rate, but we did measure kidney 
size. Saline intake tended to reduce kidney hypertrophy in diabetic rats, although there was 
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no significant difference, which is consistent with a previous study (Vallon et al., 1997). This 
was also the case when diabetic rats were treated with saline + minocycline. In fact, several 
studies have reported that increased kidney size is associated with an elevated glomerular 
filtration rate, as seen in diabetic humans (Christiansen et al., 1981; Gundersen & Mogensen, 
1981) and animals (Luippold et al., 2004; Malatiali et al., 2008). It has been suggested that 
increased kidney size contributes to the glomerular hyperfiltration seen in diabetes 
(Christiansen, 1984; Bak et al., 2000; Zerbini et al., 2006). Therefore, these data suggest that 
saline ± minocycline treatment in long-term STZ diabetic rats may blunt renal changes. Our 
data on plasma osmolality also support this view.  
Abnormally high renal sympathetic activation has been implicated in causing glomerular 
hyper filtration because renal denervation reversed glomerular hyper filtration in STZ 
diabetic rats (Luippold et al., 2004; Salman et al., 2011). It is well documented that PVN 
neuronal activation contributes to increased sympathetic nerve discharge observed in several 
diseases, including hypertension (Allen, 2002), heart failure (Li et al., 2003), water 
deprivation (Stocker et al., 2005) and chronic hypoxia (Sharpe et al., 2013). Thus, the 
decreased PVN neuronal activity in diabetic rats treated with saline ± minocycline may 
explain improved renal changes in diabetic rats. 
Elevated vasopressin secretion is another possible mechanism that may induce renal changes 
seen in diabetic rats (Bouby et al., 1999; Lamarche et al., 1999; Donnelly et al., 2000). 
Normalization vasopressin secretion has been shown to prevent renal hypertrophy and 
glomerular hyperfiltration in vasopressin-deficient rats injected with STZ to induce diabetes 
(Bardoux et al., 1999; Bouby et al., 1999). In the present study, we found a significant 
increase in plasma osmolarity in diabetic rats compared with the control. Haematocrit and 
Haemoglobin concentration were also increased in diabetic rats, indicating depletion in blood 
plasma volume. These results suggest that our diabetic animals were dehydrated. In response 
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to osmotic stimuli to regulate body fluid balance and blood volume in diabetes, the PVN 
neurons would cause secretion of vasopressin (Zerbe et al., 1979; Charlton et al., 1988; 
Brooks et al., 1989; Zheng et al., 2002). In this study, treatment with saline prevented 
dehydration seen in diabetic animals, and the effects were found to be significant with the 
combination of saline and minocycline. Therefore, we speculate that decreased PVN neuronal 
activity by saline ± minocycline would normalise vasopressin secretion, which may in turn 
prevent renal hypertrophy. 
We previously provided evidence that minocycline treatment not only attenuated microglial 
activation but also neuronal activation in the PVN in diabetic rats, suggesting that microglial 
activation induces the secondary and sustained neuronal activity via a positive feedback 
mechanism. In this study, saline treatment reduced both PVN microglia and neuron activation 
in diabetic rats, though not completely. Also, the increase in microglial and neuronal 
activation within the PVN was significantly inhibited by minocycline, which is consistent 
with our earlier observations. Thus, the present finding supports our interpretation that 
neuronal activation may be mediated by microglial activation in the PVN.  
The mechanisms by which saline intake reduces microglial activation in the PVN are not 
clearly understood. Increased internal angiotensin II has been found at 6-8 weeks following 
STZ injection (Anderson et al., 1993). Several reports have established that an increase in the 
renin-angiotensin system is associated with diabetic cardiomyopathy in experimental and 
clinical studies (Kumar et al., 2012; Mandavia et al., 2013) and that the inhibition of the renin 
angiotensin/aldosterone system can improve cardiac dysfunction in STZ diabetic rats (Zheng 
et al., 2015). In addition, the involvement of the renin-angiotensin system in PVN 
inflammation has previously been reported. For example, systemic infusion of angiotensin II 
in naïve rats has been shown to cause hypertension and activate microglial cells in the PVN 
(Shi et al., 2010a). Interestingly, salt intake has been shown to reduce angiotensin II in 
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Zucker diabetic fatty rats (Takenaka et al., 2011). Therefore, prolonged drinking of saline 
may reduce microglial activation indirectly through a reduction in the angiotensin II levels in 
STZ diabetic rats. Consequently, we presume that elevated angiotensin II may be responsible, 
at least in part, for cardiac dysfunction seen in diabetic animals and that saline intake reduces 
angiotensin II, which in turn improves this dysfunction.  
 Conclusion 7.4
The present study demonstrated that the cardiac and renal complications seen in STZ-induced 
diabetic rats were prevented by drinking 1% NaCl. Saline treatment also reduces microglial 
activation in the PVN in diabetic rats. Microglial inhibition in the PVN via ICV minocycline 
prevents the development of diabetic complications. This strongly suggests that microglial 
activation within the PVN is involved in the mechanisms of these complications. The 
beneficial effect of saline intake in diabetic rats was mediated by a reduction in central brain 
inflammation induced by diabetes; however, the exact mechanism is not clear, and further 
studies are needed.  
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 Introduction  8.1
As discussed in previous chapters, sympathetic nerve over-activity is widely accepted as a 
risk factor for several cardiovascular complications related diseases, including hypertension, 
cardiomyopathy, atherosclerosis, myocardial infarction and stroke. Blocking the increase in 
nerve activity with beta-blockers has been shown to decrease the mortality rate and improve 
outcomes for patients following a heart attack (Butler et al., 2006). Elevated sympathetic 
nerve activity has been characterized in humans and animals with type 1 diabetes mellitus 
(Refer to chapter 1); however, the cause of this abnormal activation in diabetes is not clear. 
Sympathetic nerve activity to the cardiovascular system is controlled via several regions in 
the brain, including the paraventricular nucleus (PVN). Previously, we have reported that the 
resident immune cells within CNS, called microglia, become activated in the PVN in STZ 
diabetic rats. These cells have been implicated in the development of many neurological 
disorders, including neuropathic pain. Once they become activated, they release 
proinflammatory molecules, which have been shown to induce the death of neurons as well 
as cause neuronal hyperexcitability by increasing excitation and decreasing inhibition in the 
spinal cord (Sweitzer et al., 1999; Tsuda et al., 2008; Milligan & Watkins, 2009). Moreover, 
we provided evidence that activated microglia contribute to PVN neuronal hyperexcitability, 
hypertension and cardiomyopathy in STZ diabetic rats and that the inhibition of microglia in 
the PVN via minocycline prevents the hypertension and cardiac dysfunction seen in these 
animals (Refer to chapter 4, 6 and 7). Therefore, we hypothesize that activated microglia may 
be the cause of PVN neuronal activity, which in turn activates sympathetic drive and 
contributes to cardiovascular complications; however, whether microglial activation occurs in 
other species and other models of diabetes is not known. The mouse is the most suitable 
animal model for genetic manipulations and can also be used in cellular and molecular 
studies. Therefore, for several reasons, we determined that it was important to examine 
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whether microglia are activated in cardiovascular centres in STZ diabetic mice and the time 
course of any activation. This would also provide an opportunity to further investigate 
mechanisms and test the effects of other interventions in CNS inflammation in diabetes.  
Hydrogen sulphide (H2S) donor has been reported to play beneficial roles in cardiovascular 
diseases, such as hypertension (Zheng et al., 2011)  and atherosclerosis (Beltowski et al., 
2010), but deficiency in the levels of H2S in the blood is reported in diabetic humans and STZ 
diabetic animals (Jain et al., 2010). Several studies have documented that lower levels of H2S 
contribute to the development of diabetic complications, including diabetic cardiomyopathy 
and nephropathy (Lefer, 2008; Szabo, 2012). Interestingly, H2S has been shown to act as an 
anti-inflammatory in activated microglia in vitro experiments (Hu et al., 2007); however, the 
effect of the systemic infusion of H2S on PVN inflammation in STZ mice is not known. 
Type II diabetes is the most common form of diabetes in humans, and it has become a serious 
health problem worldwide. It is characterized by hyperglycemia due to insulin resistance and 
often associated with obesity in humans. Therefore, whether PVN inflammation contributes 
to complications of type II diabetes deserves investigation. A high fat diet is a major 
contributing factor in the pathogenesis of type II diabetes; however, a high fat diet only 
causes insulin resistance but not hyperglycemia in rodents. Thus, in this study, we combined 
a high-fat feeding with a low dose of STZ to produce an animal model that is more closely 
related to human type II diabetes (Reed et al., 2000; Sugano et al., 2006; Zhang et al., 2009). 
Abnormal sympathetic nerve activity has also been implicated in the development of 
cardiovascular complications in type II diabetic animals (Carlson et al., 2000). Whether 
similar pathophysiological changes in the PVN as seen in type I diabetic animals may cause 
this increase in sympathetic nerve activity in models of type II diabetes has not been 
investigated. 
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Therefore, in the present study, we examined (i) whether microglia and neurons are activated 
in the PVN in STZ diabetic mice, (ii) the time course of microglial and neuronal activation 
and (iii) the effects of hydrogen sulphide and high-fat feeding on the PVN in these mice.  
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 Results 8.2
 Body weights and blood glucose of STZ diabetic mice 8.2.1
At 7 weeks following injection of C57BL6/J mice with STZ (50 mg/kg/day, 5 days), the body 
weights of diabetic mice (STZ) were found to be significantly lower (P < 0.0001) than the 
control mice (Figure 8-1A). The body weights of STZ mice treated with Na H2S (STZ+H2S) 
were also significantly lower (P<0.0001) compared with the control mice. There was no 
significant difference in the body weights between the STZ and STZ+ H2S groups. Blood 
glucose levels in STZ and STZ+ H2S groups were significantly higher (P<0.0001) in 
comparison to control mice (Figure 8-1B). Hydrogen sulphide had no effect on blood glucose 
in STZ mice. 
In a second study, male FVB/N mice were injected with STZ (50mg/kg/day, 5 days) and 
maintained for 16 weeks. The body weights of the control mice were significantly greater 
than in diabetic mice (STZ) (Figure 8-1C). Blood glucose levels in STZ mice were 
significantly higher (P < 0.0001) than in the control mice (Figure 8-1D). The STZ treatment 
had less of an effect on body weight in FVB/N mice than in C57BL6/J mice, but the blood 
glucose levels were similar. 
In the final study, at 10 weeks after C57BL6/J mice were injected with STZ (40 mg/kg/day, 5 
days), the body weights were not significantly different when compared to the control mice 
(Figure 8-1E). This was also the case between the control mice and STZ mice with fat 
feeding (STZ+FF). Fat feeding did not significantly affect the body weight of STZ mice; 
however, blood glucose levels in STZ mice were significantly higher (P<0.01) compared 
with control mice, as expected (Figure 8-1F). This was also the case for blood glucose levels 
in the STZ+FF group (P < 0.0001) compared to the control mice. Fat feeding in STZ mice 
caused a significant increase in blood glucose levels (P<0.01) compared with STZ-alone 
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mice. The blood glucose in mice injected with a low dose of STZ alone was lower compared 
with mice treated with a high dose.   
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Figure 8-1. Body weights and blood glucose of STZ diabetic mice. Top panel: Body 
weights (A); and blood glucose levels (B) measured at 7 weeks after injection of mice with 
either STZ or citrate buffer in control animals, diabetic animals (STZ) or diabetic animals 
treated with hydrogen sulphide (STZ+ H2S). Number of mice = 4 in each group. Middle 
panel: Body weights (C); and blood glucose levels (D) of mice at 16 weeks following 
treatment with either citrate buffer (control) or STZ. Number of mice = 4 in each group. 
Bottom panel: Body weights (E); and blood glucose levels (F) measured at 10 weeks after 
injection of mice with either citrate buffer in control animals or STZ in diabetic animals 
(STZ) and diabetic animals treated with fat feeding (STZ+FF). Number of mice = 12 in each 
group. Data are expressed as the mean ± SEM. Significance was evaluated using a one way 
ANOVA followed by Tukey’s post hoc test for all comparisons in the top and bottom panels 
or an unpaired t test in the middle panel. In this and all subsequent figures; * indicates 
P<0.05; ** indicates P<0.01; *** indicates P<0.001; **** indicates P < 0.0001 for 
comparisons between diabetic groups and control; ♯ indicates P<0.05; ♯♯ indicates P<0.0; 
♯♯♯ indicates P<0.001; ♯♯♯♯ indicates P < 0.0001 for comparisons between diabetic groups.  
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 Plasma osmolarity and haematocrit in STZ diabetic mice 8.2.2
In this study, we measured plasma osmolarity and haematocrit at 7 and 16 weeks after STZ 
treatment because increased plasma osmolarity and dehydration are implicated in neuronal 
activation in STZ diabetic rats. We observed a significant increase in plasma osmolarity in 
STZ mice at 8 weeks (P<0.001) compared to the control mice (Figure 8-2A); however, no 
significant differences were found in plasma osmolarity between STZ mice treated with H2S 
and the control mice. When compared to STZ mice, Na H2S treatment significantly reduced 
(P<0.01) plasma osmolarity. At 16 weeks, plasma osmolarity was also significantly higher (P 
< 0.01) in STZ mice compared to the control mice (Figure 8-2B).  
Regarding haematocrit , we found no significant difference in haematocrit between STZ mice 
and control mice at 7 weeks (Figure 8-2C). Also, the haematocrit  was similar between the 
STZ mice and control mice at later stages (Figure 8-2D). H2S had no effect on haematocrit in 
STZ mice. 
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Figure 8-2. Plasma osmolarity and haematocrit  in STZ diabetic mice. Left panel: Plasma 
osmolarity (A); and Haematocrit (C) measured at 7 weeks after injection of mice with either 
citrate buffer in control animals or STZ in diabetic animals (STZ) and diabetic animals 
treated with Na H2S (STZ+ H2S). Right panel: Plasma osmolarity (B); and Haematocrit (D) 
of mice at 16 weeks following treatment with either citrate buffer or STZ. Number of mice = 
4 in each group. Data are expressed as the mean ± SEM. 
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  CD11b and C-fos Immunohistochemistry in the paraventricular nucleus in 8.2.3
diabetic mice 
A CD11b antibody was used to identify morphological changes in microglia cells in the PVN 
in STZ mice. The microglia displayed normal morphology with small cell bodies and long, 
fine-branched processes throughout the PVN region in the control mice examined at 7 weeks 
(Figure 8-3). A similar observation was seen in the PVN in STZ mice with and without H2S 
treatment at same stages, although STZ-alone mice appeared to show a more subtle change in 
microglial morphology. The quantitative analysis of the percentage of microglial activation in 
the PVN region indicated that no significant differences were found at 7 weeks when 
comparing STZ mice and control mice (Figure 8-5A). The percentage of activated microglia 
in the PVN was not significantly affected by H2S treatment in STZ mice. In the PVN in 
control mice, the number of fos-immunoreactive neurons was smaller compared to STZ mice 
at 7 weeks (Figure 8-4). On quantification, we observed a significant increase (P<0.0001) in 
the number of fos-immunoreactive neurons in STZ mice compared to control mice (Figure 8-
5B). Interestingly, H2S treatment was able to be significantly reduce (P<0.0001) fos activity 
in the PVN in STZ mice.  
At later stages (16 weeks), the microglia in the PVN in STZ mice exhibited an activation 
form with larger cell bodies and thicker processes when compared to control mice (Figure 8-
6). The percentage of activated microglia was significantly greater (P<0.0001) in the PVN in 
STZ mice compared with the control mice (Figure 8-8A). Compared with control mice, the 
counts of fos-immunoreactive neurons in the PVN showed a greater (P<0.01) level of fos 
activity in the PVN in STZ mice at this stage (Figure 8-7) (Figure 8-8B).   
In the STZ + fat feeding study, microglial cells in the PVN region exhibited normal 
morphology in control mice at 10 weeks (Figure 8-9). This was also the case in low-dose 
STZ mice. There was no significant difference in the percentage of activated microglia 
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between the low-dose STZ and control mice (Figure 8-11A). Fat feeding had no effect on the 
percentage of microglial activation in low-dose STZ mice. In diabetic mice, a significant 
increase (P<0.05) in number of fos-immunoreactive neurons was seen in the PVN compared 
with the control, despite the lower blood glucose in these animals (Figure 8-10) (Figure 8-
11B). No significant differences were observed in the number of fos-immunoreactive neurons 
between the low-dose STZ mice treated with fat feeding and control mice. Low-dose STZ 
mice treated with fat feeding displayed a significant reduction (P<0.05) in the levels of fos 
activity when compared to STZ mice on a normal diet. 
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Figure 8-3. Morphology of microglia in STZ mice at 7 weeks after STZ treatment. 
Photomicrographs showing CD11b immunoreactive microglia in the paraventricular nucleus 
(PVN) in control, diabetic (STZ) and diabetic animals treated with Na H2S (STZ+ H2S) at 7 
weeks. Dotted lines in low-power images (A, C and E) outline the PVN. High-power images 
(B, D and F) show the morphology of microglia in the PVN region in detail. Scale bar = 100 
μm.  
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Figure 8-4. Fos activity in STZ mice at 7 weeks after STZ treatment. Photomicrographs 
showing neuronal nuclei stained with anti-Fos antibody in the paraventricular nucleus (PVN) 
in control, diabetic (STZ) and diabetic animals treated with Na H2S (STZ+ H2S) at 7 weeks. 
Dotted lines outline the PVN. Scale bar = 100 μm. 
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Figure 8-5. Microglial and neuronal activation in the paraventricular nucleus of STZ 
mice at 7 weeks after STZ treatment. A: The percentage of microglia showing activated 
morphology in the paraventricular nucleus (PVN) of control, diabetic (STZ) and diabetic 
animals treated with Na H2S (STZ+ H2S). B: Quantification of Fos-IR cell nuclei in the same 
region. Number of mice = 4 in each group. Data are expressed as the mean ± SEM.  
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Figure 8-1. Morphology of microglia in STZ mice at 16 weeks after STZ treatment. 
Photomicrographs showing CD11b immunoreactive microglia in the paraventricular nucleus 
(PVN) in control and diabetic animals (STZ) at 16 weeks. Dotted lines in low-power images 
(A-B) outline the PVN. High-power images (C-D) show the morphology of microglia in the 
PVN region in detail. CD11b antibody staining shows microglia with normal morphology 
with small cell bodies and long, fine-branched processes throughout the PVN region in the 
control, while activated microglia showing larger cell bodies and thicker processes are seen in 
the STZ group. Scale bar = 100 μm in (A-B), 50 μm in (C-D). 
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Figure 8-2. Fos activity in STZ mice at 16 weeks after STZ treatment. Photomicrographs 
showing neuronal nuclei stained with anti-Fos antibody in the paraventricular nucleus (PVN) 
in control and diabetic animals (STZ) at 16 weeks. Dotted lines outline the PVN. Bar = 100 
μm. 
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Figure 8-8. Microglial and neuronal activation in the paraventricular nucleus of STZ 
mice at 16 weeks after STZ treatment. A: The percentage of microglia showing activated 
morphology in the paraventricular nucleus (PVN) of control and diabetic animals (STZ). B: 
Quantification of Fos-IR cell nuclei in the same region. Number of mice = 4 in each group. 
Data are expressed as the mean ± SEM.  
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Figure 8-9. Morphology of microglia in STZ mice and STZ + Fat Fed mice at 10 weeks 
following STZ treatment. Photomicrographs showing CD11b immunoreactive microglia in 
the paraventricular nucleus (PVN) in control, diabetic (STZ) and diabetic + fat feeding 
animals (STZ + Fat feeding) at 10 weeks. Dotted lines outline the PVN. Images (A-C) show 
the morphology of microglia in the PVN. CD11b antibody staining in all cases shows 
microglia with normal morphology with small cell bodies and long, fine-branched processes 
throughout the PVN region. Scale bar = 100 μm. 
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Figure 8-10. Fos activity in STZ mice and STZ + Fat Fed mice at 10 weeks following 
STZ treatment. Photomicrographs showing neuronal nuclei stained with an anti-Fos 
antibody in the paraventricular nucleus (PVN) in control (A), diabetic (B) and diabetic + fat 
feeding animals (C) at 10 weeks. Dotted lines outline the PVN. Scale bar = 100 μm. 
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Figure 8-11. Microglial and neuronal activation in the paraventricular nucleus of STZ 
mice and STZ + Fat Fed mice at 10 weeks following STZ treatment. A: The percentage of 
microglia showing activated morphology in the paraventricular nucleus (PVN) of control, 
diabetic (STZ) and diabetic + fat feeding animals (STZ+FF). B: Quantification of Fos-IR cell 
nuclei in the same region. Number of mice = 4 in each group. Data are expressed as the mean 
± SEM.  
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 Discussion   8.3
We previously provided evidence that PVN microglia become activated in STZ diabetic rats 
at 6 and 8 weeks following STZ treatment. Despite this, whether PVN inflammation also 
occurs in other species and other models of diabetes is not known. Therefore, in this study, 
we aimed to investigate whether microglia are activated in the PVN in diabetic mice at 7 and 
16 weeks after STZ injection and whether hydrogen sulphide and high-fat feeding influence 
PVN inflammation in STZ diabetic mice at 7 and 10 weeks, respectively. The main findings 
of the present study were that (i) microglia are activated in the PVN in STZ diabetic mice at 
16 weeks after STZ injection but not at 7 weeks or 10 weeks (low-dose STZ), (ii) PVN 
neuron activation was observed in STZ diabetic mice at all stages examined, suggesting that 
neuronal activation precedes microglial activity (iii) and both Na H2S and high-fat feeding 
treatments inhibited PVN neuron activation in STZ diabetic mice.   
It is well-known that microglia are the resident immune inflammatory cells in the central 
nervous system. Once microglia become activated in response to infection, injury or 
inflammation of the CNS, they undergo morphological changes and can release 
proinflammatory molecules and cytotoxic factors, such as nitric oxide and tumor necrosis 
factor (TNF)-α, which induces neuronal activity (Li et al., 2005b; Shi et al., 2010a). 
Activated microglia have been implicated in the pathologies of the CNS that are associated 
with brain inflammation, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis 
and neuropathic pain (chapter 1).  We previously reported microglial activation in the PVN in 
STZ diabetic rats. From our previous studies, we have provided evidence that activated 
microglia in the PVN and other cardiovascular centres in the brain of STZ diabetic rats are 
involved in the development of diabetic cardiovascular and renal complications (chapter 4, 5, 
6 and 7). This observation complements the findings of other studies on hypertensive animal 
models (Shi et al., 2011). In the present study in mice, we found that microglial activation in 
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the PVN was present at 16 weeks but not at 7 weeks after STZ injection. Some STZ diabetic 
mice (3 out of 4) at the 7 week stage exhibited an increase in the percentage of activated 
microglia, but the variability was high, suggesting our tests may be underpowered for 
detecting small differences. At 10 weeks (low-dose STZ), there was no indication of 
microglial activation. STZ diabetic mice (at 10 weeks) did not show extreme hyperglycaemia, 
as seen with higher STZ doses at other stages. These findings suggest that microglial 
activation in the PVN of STZ diabetic mice is dependent on the time course and severity of 
diabetes. 
To clarify the mechanisms of changes in the PVN in STZ diabetic mice, we examined 
whether PVN neurons were activated in these animals. We found activation of neurons in the 
nucleus in diabetic mice at all stages tested (7 and 16 weeks). Therefore, the data support our 
suggestion that microglial activation in the PVN may be secondary to the prolonged intense 
activation of PVN neurons (Wu & Ling, 1998). Despite this, how diabetes induces this 
activation in the hypothalamic PVN is not known.  
Previously, we and other researchers provided evidence that PVN neuronal activation 
contributes to the development of cardiovascular diseases, including hypertension and cardiac 
dysfunction in STZ diabetic rats (chapter 6 and 7). Interestingly, in the present study, 
systemic treatment with a Na H2S donor in STZ-diabetic mice (7 weeks) caused the inhibition 
of PVN neuron activation, which is consistent with other studies, showing that H2S has a 
neuroprotective role (Kimura & Kimura, 2004; Kimura et al., 2006; Umemura & Kimura, 
2007). No significant difference was seen in the percentage of activated microglia between 
the STZ and control mice, but we cannot rule out that H2S also has an inhibition effect on 
microglia functions. Deficiency in the levels of H2S has been shown to occur in diabetic 
humans as well as in STZ-induced diabetic rats (Jain et al., 2010), and this deficiency 
contributes to the development of diabetic complications (Lefer, 2008; Szabo, 2012). 
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Although we did not measure cardiovascular changes in the present study, another study has 
reported that exogenous H2S reduced blood pressure in diabetic hypertensive rats (Ahmad et 
al., 2012). This study also reported lower levels of H2S in these animals compared to the 
control. In fact, H2S has anti-inflammatory actions, and several studies have shown that H2S 
reduces microglial and neuronal activation in vitro (Hu et al., 2007; Umemura & Kimura, 
2007; Hu et al., 2009). Combining our results with these studies, we speculate that the effect 
of H2S on diabetic cardiovascular complications may be mediated, at least in part, by the 
inhibition of central inflammation in the PVN; however, the mechanisms through which H2S 
reverses the PVN neuronal activity require further investigation. 
As discussed previously, hyperglycaemia has been implicated in the increase of the 
generation of reactive oxygen species in the PVN (Patel et al., 2011) and other brain areas in 
STZ diabetic rats (Acar et al., 2012; Ola et al., 2014). It is well documented that such an 
increase in the generation of reactive oxygen species can lead to neuronal activation through 
an enhanced influx of Ca
2+
 in neurons (Wang et al., 2003; Zimmerman & Davisson, 2004). 
Reactive oxygen species in dorsal horn neurons have been shown to contribute to neuronal 
hyperexcitability and the development of neuropathic pain since the administration of 
antioxidants prevents neuropathic pain-like behaviours (Stevens et al., 2000; Ho et al., 2006). 
It is well documented that H2S can protect neurons via its anti-oxidant effects (Kimura & 
Kimura, 2004; Kimura et al., 2006). In the present study, Na H2S significantly attenuated the 
increase in neuronal activation in the PVN without affecting blood glucose levels, as seen in 
STZ diabetic mice. Therefore, H2S may reduce neuronal activation indirectly through a 
reduction in the reactive oxygen species levels in the PVN in STZ diabetic mice. 
Another possible mechanism of PVN neuronal activation is the elevation levels of plasma 
osmolality in diabetic animals (Charlton et al., 1988; Brooks et al., 1989). In the current 
study, elevated plasma osmolality seen in diabetic mice was reduced to normal levels 
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following treatment with Na H2S. Interestingly, a recent study on diabetic hypertensive 
animals reported that H2S improved renal function in these animals (Ahmad et al., 2012). 
Therefore, taken together, these findings suggest that H2S can prevent hyperglycaemia-
induced changes in the function of the kidneys and the PVN. Despite this, whether the H2S 
has a direct effect on neurons in the PVN or an indirect effect through preventing kidney 
damage and increasing plasma osmolarity remains to be determined.   
Like type 1 diabetes, type 2 diabetes in animals is also associated with cardiovascular disease 
and over-activity of the sympathetic nerves that control the cardiovascular system. As 
discussed previously, PVN inflammation contributes to the development of cardiovascular 
complications seen in STZ-induced hyperglycaemia in rats (type 1 diabetes), but whether 
similar changes in the PVN occur in models of type II diabetes is not clear. Therefore, we 
examined whether microglia and neurons were activated in the CNS cardiovascular centres. 
In the PVN, there was no significant difference in the percentage of microglia activated in 
mice treated with a low dose of STZ and high fat feeding, although their blood glucose levels 
were high compared to the control. Also, we observed no microglial activation in the arcuate 
nucleus in either low-dose STZ mice or mice treated with a low dose of STZ and high fat 
feeding, which is in agreement with a previous study from our lab in fat-fed rats and in STZ-
induced diabetic rats; however, these data are inconsistent with studies that reported that 
high-fat feeding caused microglial activation in the PVN in mice (de Kloet et al., 2014) and 
in the arcuate nucleus in rats (Thaler et al., 2012). In these studies, high-fat feeding was 
accompanied by obesity, but our mice did not become obese following treatment with fat 
feeding. This may be due to a lower percentage of fat in food used here compared to earlier 
studies. The differences in the percentage of fat in the diet associated with differences in body 
weight may explain our data. Therefore, microglial activation in fat-fed animals may be a 
consequence of obesity that was absent in our model.   
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Interestingly, the addition of a high-fat diet to the low-dose STZ treatment significantly 
attenuated the increase in neuronal activation seen in the PVN in low-dose STZ diabetic 
mice. We have no explanation for this phenomenon, but the systemic infusion of glucose has 
been shown to excite PVN neurons (Dunn-Meynell et al., 1997). This excitation in the PVN 
was reversed in diet-induced obese animals (Levin et al., 1998). Collectively, these data 
suggest that a high-fat diet may reduce central glucose sensitivity; however, how this occurs 
is not known, and further research is needed.   
 Conclusion   8.4
The present study demonstrated that neuronal and microglial activation occur in the PVN in 
STZ-induced diabetic mice. Hydrogen sulphide treatment reduces neuronal activation in the 
PVN and prevents dehydration in these animals, but it does not significantly affect blood 
glucose. These findings suggest that the dehydration seen in these animals was not a direct 
effect of high blood glucose. They also suggest that using hydrogen sulphide can prevent 
diabetic changes in the function of the PVN. No microglial activation was observed in the 
cardiovascular centres of the brain in mice treated with a low-dose of STZ and high-fat 
feeding. These findings suggest that the activation of microglia in the hypothalamus does not 
occur in all animal models of diabetes. High-fat feeding blocks the neuronal activation seen 
in the PVN of STZ-treated mice; however, the exact mechanism is not clear, and further 
studies are needed. 
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Prior to this thesis, it was known that diabetes contributes to defects in the autonomic nervous 
system (Tesfaye et al., 2010). Impairment of the baroreflex control of heart rate and abnormal 
increases in the renal sympathetic activity are important candidate mechanisms for the 
development of diabetic complications, and they contribute to morbidity and mortality in 
diabetic patients (Ewing et al., 1980; Kempler et al., 2002; El-Menyar, 2006). These 
abnormalities in the autonomic neurons system are also reported in diabetic animals. 
Neuroinflammation, including oxidative stress and proinflammatory cytokine release in 
central autonomic centres, emerged as potentially important contributing factors in the 
pathogenesis of autonomic dysfunction and its consequences in other diseases. Resident 
immune cells (microglia and astrocytes) were recognized to play crucial roles in the 
pathogenesis of several CNS disorders and activated microglia, and astrocytes had been 
observed in central autonomic centres in diabetic animals; however, little was known about 
the influence of 1% NaCl, antioxidants and high-fat feeding on microglial activation in 
central autonomic centres in diabetic animals of different species. More importantly, whether 
inhibition of activated microglia in the PVN could reduce or prevent cardiovascular changes 
in STZ diabetic rats was not clear. Therefore, the overall aim of this thesis was to advance 
our understanding of the mechanisms of deleterious cardiovascular complications in diabetes, 
and in particular, to address the role of brain inflammation in these complications and the 
mechanisms of microglial activation in this condition. 
The main findings of the present thesis were that (1) microglia and astrocytes are activated in 
the PVN in STZ diabetic rats at 6-8 weeks after STZ injection but not at earlier stages; (2) 
drinking 1% NaCl causes increased microglial activation in the cardiovascular centres, 
hypertension and dysfunction of bradycardic baroreflex at 2 weeks post STZ treatment in 
diabetic rats; (3) prolonged drinking of 1% NaCl reduces the activation of microglia in the 
cardiovascular centres, restores the function of the bradycardic baroreflex and normalises 
elevated end diastolic pressure at 6 weeks post STZ treatment in diabetic rats; (4) inhibition 
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of microglial activation in the PVN via ICV minocycline infusion prevented the development 
of diabetic complications in STZ diabetic rats with or without 1% NaCl treatment; (5) 
microglial activation does not appear to mediate astrocyte activation in the PVN  and  
astrocyte activation may not be associated with the development of diabetic complications in 
STZ diabetic rats; (6) microglial activation also occurs in the PVN in STZ diabetic mice at 
later stages than neuronal activation, and at early stages, hydrogen sulphide as well as high-
fat feeding treatment attenuates PVN neuronal activity.   
 Role of neuroinflammation in deleterious cardiovascular complications 9.1
in diabetes 
In chapters 5 and 6, we have shown that both baroreflex sensitively and cardiac function are 
impaired in STZ diabetic rats compared to control rats. This finding confirms previously 
published studies on rats (Fazan et al., 1999; Gouty et al., 2001; Schaan et al., 2004; Wichi et 
al., 2007; Arozal et al., 2009). Baroreflex dysfunction along with sympathetic over-activity 
are important cardiovascular risk factors in diabetes (Ewing et al., 1980; Kempler et al., 
2002; El-Menyar, 2006). In addition, a positive correlation has been shown between diabetic 
autonomic dysfunction and diabetic cardiac dysfunction (Fang et al., 2004). Thus, an 
improvement of autonomic function may be a novel strategy for lowering cardiovascular 
disease risk in diabetic patients. The mechanisms behind the dysregulation of the autonomic 
nervous system in diabetic rats are not well understood but may include inflammation and 
changes in central autonomic centres.   
We have confirmed the previously published data that microglia are activated in the PVN and 
NTS in STZ diabetic rats (Rana et al., 2014). Moreover, we have observed that microglia 
become activated in the PVN in STZ diabetic mice, indicating that a similar mechanism may 
be responsible for the activation of PVN microglia in both species in diabetes. To understand 
the role of microglia in the development of diabetic complications, we have inhibited 
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activated microglia via ICV infusion of minocycline. Our data from chapters 4, 6 and 7 
revealed that minocycline ameliorates diabetic complications of STZ diabetic rats; it reduces 
the PVN neuronal activity, prevents hypertension, improves cardiac function and protects 
kidney tissue. The results strongly suggest that cardiovascular and renal pathological 
processes in diabetes are largely mediated, at least in this time frame, by inflammation in 
cardiovascular centres of the brain. This finding is consistent with published data about the 
role of activated microglia in increased neuronal excitability in the CNS (Tsuda et al., 2005) 
as well as in the development of cardiovascular complications in other diseases (Shi et al., 
2010a). Thus, attenuation of microglial activation in the PVN may be a novel strategy for 
lowering cardiovascular and renal disease risks in diabetes.  
Astrocytes are another important cell for mediating inflammation in the CNS. Activated 
astrocytes release proinflammatory cytokines and have been implicated in spinal neuronal 
hyperexcitability and consequently the development of diabetic neuropathic pain (Sweitzer et 
al., 1999; Milligan et al., 2001; Wei et al., 2008). In chapter 3, we have confirmed the 
previous data that astrocytes are activated in the PVN in STZ diabetic rats (Luo et al., 2002); 
however, our results indicate that astrocyte activation does not play a crucial role in the 
development of diabetic complications since the inhibition of microglial activation via ICV 
minocycline was able to prevent diabetic complications but was not able to inhibit astrocyte 
activation. Hence, it appears that the functional consequences of astrocyte activation in the 
PVN may be different from those in the spinal cord (Okada-Ogawa et al., 2009).   
Our observations that ICV infused minocycline inhibits PVN inflammation and that this 
inhibition improves left ventricular and renal changes in STZ diabetic rats beg the question: is 
the effect of minocycline a result of crossing the blood-brain barrier and acting peripherally 
rather than exerting its influence in the CNS?  The latter view is an unlikely possibility 
because Bhatt et al. reported that the oral administration of minocycline did not significantly 
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improve cardiac function in STZ diabetic rats as it did in our study, even though the dose of 
minocycline used was much greater (50mg/kg) and for the same period compared with our 
study (Bhatt & Veeranjaneyulu, 2012). Despite this, since minocycline was given orally, it 
was potentially metabolised in the gut or liver before reaching the rest of the body. 
Consequently, the concentration of minocycline may not have been sufficient to act on the 
brain to reverse cardiac function when compared with our study; however, when minocycline 
was combined with aspirin, which also has anti-inflammatory actions and can enter the CNS, 
the cardiac function in STZ diabetic rats was improved (Bhatt & Veeranjaneyulu, 2012). This 
suggests that the beneficial effects of anti-inflammatory drugs in both studies are centrally 
mediated.  
Along with neuroinflammation, there is also evidence that increased oxidative stress mediates 
neuronal activity in cardiovascular autonomic centres and contributes to the pathogenesis of 
autonomic dysfunction. Reactive oxygen species have been shown to contribute to neuronal 
hyperexcitability in the CNS (Stevens et al., 2000; Ho et al., 2006) and to abnormal cardiac 
reflex function in STZ diabetic rats (Ustinova et al., 2000). In chapter 8, we have shown that 
the systemic infusion of H2S reduces neuronal activation in the PVN in STZ diabetic mice. 
We also provided evidence that PVN neuronal activation contributes to the development of 
cardiovascular diseases in STZ diabetic rats (chapters 6 and 7). Deficiency in the levels of 
H2S is reported in diabetic humans (Jain et al., 2010), and this deficiency contributes to the 
development of diabetic complications (Lefer, 2008; Szabo, 2012). Spontaneously, when 
hypertensive rats were injected with STZ, they showed low levels of H2S, and when these 
animals were treated with exogenous H2S, blood pressure was reduced (Ahmad et al., 2012). 
It is well documented that H2S can protect neurons via its anti-oxidant effects (Kimura & 
Kimura, 2004; Kimura et al., 2006). Therefore, we proposed that H2S may mediate its 
beneficial effect on cardiovascular complications through attenuating oxidative stress as well 
as PVN neuronal activation.   
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A high-fat diet is a major contributing factor in the pathogenesis of type 2 diabetic 
complications, but whether PVN inflammation contributes to these complications is not clear. 
In chapter 8, we have shown that no microglial activation was observed in the PVN in mice 
treated with a low dose of STZ and high-fat feeding. These findings suggest that the 
activation of microglia in the hypothalamus does not occur in all animal models of diabetes. 
Interestingly, high-fat feeding blocks neuronal activation seen in the PVN of STZ treated 
mice; however, the exact mechanism is not clear, and further studies are needed.   
 The effect of drinking 1% NaCl on cardiovascular parameters and CNS 9.2
inflammation  
Previous data have shown different effects of 1 % NaCl intake on diabetic complications in 
short and long-term STZ diabetic rats (Dai et al., 1994; Santos et al., 1995; Maeda et al., 
2007); however, no previous studies have investigated the effect of drinking 1% NaCl on 
CNS inflammation and fluid balance in diabetic rats and the contribution of these 
mechanisms to diabetic complications.  Our results from chapters 4, 5 and 7 confirm 
previous studies, indicating that diabetic complications were differentially affected by short 
(2 weeks) and longer term (6 weeks) treatment of drinking 1% NaCl in STZ diabetic rats (Dai 
et al., 1994; Santos et al., 1995; Maeda et al., 2007).  
Diabetes in patients is commonly associated with hypertension, which is considered the likely 
cause of developing cardiovascular disease in around 75% of persons with diabetes (Bild & 
Teutsch, 1987). One major known contributor to the development of hypertension and its 
consequences in diabetic humans is salt intake (He & MacGregor, 2003; Franz, 2008). Our 
observation that 2 weeks of treatment with 1% NaCl causes increased blood pressure in STZ 
diabetic rats (chapter 4) is consistent with another study (Maeda et al., 2007). Two weeks of 
1% NaCl intake was able to normalise blood volume in these animals. Some evidence 
suggests that a lack of hypertension in STZ diabetic rats is due to decreased blood volume, 
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which may explain our findings (Hebden et al., 1986a; De Angelis et al., 2000). Dysfunction 
in baroreflex sensitivity is also believed to precede hypertension (Grassi et al., 1998; Gao et 
al., 2002; Salgado et al., 2007; Maliszewska-Scislo et al., 2008). We have shown that 2 
weeks of 1% NaCl intake causes dysfunction of the bradycardic baroreflex in STZ diabetic 
rats compared STZ diabetic rats given tap water. Based on this data, we cannot rule out 
baroreflex dysfunction as the mechanism for blood pressure changes seen in diabetic rats 
given 1% NaCl; however, these changes are accompanied by increased microglial activation 
within the cardiovascular autonomic centres of the brain. The inhibition of activated 
microglia in the PVN via ICV infusion of the drug minocycline prevents the hypertension 
seen when 1% NaCl is given. While 1% NaCl seems to act on blood volume increases and/or 
baroreflex dysfunction to develop hypertension, our data provide strong support for the 
hypothesis that activation of microglia in the PVN is required for the development of 
neurogenic hypertension in these diabetic rats, as concluded by Shi in another model of 
hypertension (Shi et al., 2010a).   
In contrast, 6 weeks of treatment with 1% NaCl restored baroreflex sensitivity and improved 
cardiac function compared to STZ diabetic rats given tap water, confirming the results of a 
previous study on cardiac function (Dai et al., 1994). While our findings appear to be 
contradictory to the established dogma, some researchers have demonstrated that very low 
salt diets have the potential for adverse effects on human patients with diabetes (Ekinci et al., 
2011; Thomas et al., 2011) and heart failure (Paterna et al., 2008; Paterna et al., 2009). In 
fact, the effect of low-salt intake in reducing blood pressure is well documented in humans, 
but this intervention also increased renin–angiotensin–aldosterone system activity and 
increased sympathetic nerve over-activity (Graudal et al., 1998; Grassi et al., 2002), both of 
which can contribute to the development of cardiovascular complications. At 6-8 weeks after 
STZ treatment, diabetic rats exhibited elevated levels of circulating angiotensin II (Anderson 
et al., 1993) as well as abnormal sympathetic over-activity (Patel et al., 2011). In our study, 
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STZ diabetic rats showed dehydration, which is characterised by both water and salt loss, and 
in the longer term, 1% NaCl intake prevents this dehydration, as seen in shorter term 
experiments. Therefore, we speculate that cardiovascular changes seen in STZ diabetic rats in 
this study may be related to salt deficiency and that longer term treatment with 1% NaCl 
normalises salt levels and consequently prevents diabetic complications in these animals. 
Interestingly, improved cardiovascular outcomes were associated with reduction in the 
activation of microglia and neurons in cardiovascular autonomic centres. Therefore, it 
appears that in both the short and longer term, neuroinflammation is the mechanism that links 
salt and cardiovascular complications in STZ diabetic rats. 
This conclusion is controversial because hypertension is considered a major cause of 
cardiovascular disease in humans. We have shown that STZ diabetic rats given 1% NaCl 
develop hypertension in the short term, but the same pattern was also observed in the longer 
term in another study (Santos et al., 1995). Despite this, in the longer term, drinking 1% NaCl 
prevents cardiovascular complications of STZ diabetic rats in ours and other studies 
(McDonald et al., 1969; Dai et al., 1994). These data suggest that 1% NaCl intake provides 
beneficial effects on the cardiovascular system, even though blood pressure is high in STZ 
diabetic animals. They also suggest there is no causal link relation between changes in blood 
pressure and cardiovascular disease in these diabetic animals, as concluded in some studies 
on diabetic humans (Bild & Teutsch, 1987; Epstein & Sowers, 1992).  
 Mechanism of microglial activation in diabetes  9.3
This thesis has also shed light on the potential mechanisms by which microglia become 
activated in the PVN in STZ diabetic animals. It is well-known that microglia become 
activated following neuronal over excitation (Hathway et al., 2009; Lu et al., 2009). Our 
results from chapters 4, 5, 6 and 8 indicated that neuronal activity occurs before microglial 
activation in the PVN in STZ diabetic animals, suggesting that neuronal activation causes 
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microglial activation (Rana et al., 2014). Our studies also provided further insight into the 
mechanisms that initiate the PVN neuronal activity in diabetic animals. Both STZ diabetic 
rats and mice showed signs of dehydration (chapters 4, 5, 6 and 8). This stimulus has been 
shown to activate PVN neurons in another animal model (Stocker et al., 2004). We have 
shown that longer term 1% NaCl intake prevents dehydration and also reduces the activation 
of neurons and microglia in the PVN (Chapter 7). Thus, one possible mechanism underling 
microglial activation is the intense neuronal activity elicited in the PVN by dehydration in 
STZ diabetic rats.  
Another potential mechanism behind PVN neuronal activation may be the increased 
production of reactive oxygen species in diabetes. Hyperglycaemia has been shown to induce 
the production of reactive oxygen species in STZ diabetic rats (Nishikawa et al., 2000; 
Brownlee, 2005). These chemicals are known to increase cytokine production and neuronal 
hyperactivity in the brain (Stevens et al., 2000; Ho et al., 2006). Our results (chapter 8) show 
that an antioxidant can significantly attenuate the increase in neuronal activation in the PVN 
in STZ diabetic mice, suggesting that reactive oxygen species play an important role in the 
PVN neuronal activation seen in STZ diabetic animals; however, the detailed mechanism by 
which reactive oxygen species elicit PVN neuronal activation in diabetes requires further 
investigation.   
Despite these possible mechanisms, activated microglia have also been shown to cause 
neuronal over excitation via the release of proinflammatory molecules and reactive oxygen 
species (Shi et al., 2011; Wu et al., 2012). Our results obtained from chapters 6 and 7 reveal 
that ICV minocycline treatment significantly reduces both microglial and neuronal activation 
in the PVN in STZ diabetic rats. This suggests that neuronal activation may be responsible 
for initiating microglial activation, but activated microglia may also increase the secondary 
and sustained neuronal activity via a positive feedback mechanism.   
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One potential large range positive feedback may involve angiotensin II, which is a hormonal 
factor that regulates blood pressure and fluid balance during the dehydrated state through 
stimulating sympathetic nervous activity. This hormone acts on different tissues, including 
the brain, and has also been shown to be an important mediator of inflammation and 
oxidative stress in the PVN (Sriramula et al., 2013). In early stages of diabetes, Kalinyak et 
al. found no change in the levels of angiotensin II in STZ diabetic rats (Kalinyak et al., 1993). 
In contrast, increased plasma angiotensin II has been found at 6-8 weeks following STZ 
injection (Anderson et al., 1993). It was reported that the systemic infusion of angiotensin II 
in naïve rats activates microglial cells in the PVN (Shi et al., 2010a). Our results from 
chapters 3, 4, 5, 6 and 7 show no significant increase in microglial activation in diabetic rats 
until 6-8 weeks after STZ injection. Therefore, increased angiotensin II levels in STZ diabetic 
rats may be responsible for microglial activation. Interestingly, drinking 1% NaCl reduced 
the activation of microglia in the NTS and PVN in STZ diabetic rats (chapters 5 and 7). In 
fact, salt intake has been shown to reduce angiotensin II in Zucker diabetic fatty rats 
(Takenaka et al., 2011). Thus, it is likely that 6 weeks of 1% NaCl intake may reduce 
microglial activation indirectly through a reduction in the angiotensin II levels in STZ 
diabetic rats.  
Another possibility is that peripheral proinflammatory cytokines induce microglial activation 
in the brain. Previous studies have provided evidence that peripheral proinflammatory 
cytokines, such as IL-β and TNF-α, lead to microglial activation in the CNS (Wu et al., 
2012). Elevated levels of these cytokines in the blood stream are reported in STZ diabetic rats 
(Ugochukwu & Figgers, 2007). Thus, increased peripheral cytokines, which are also believed 
to initiate the inflammatory process in the PVN in other models, may also play a role here 
(Felder et al., 2009; Felder, 2010); however, how this occurs in diabetic animals is not clear, 
and further studies are needed.   
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Therefore, based on all of these potential mechanisms, we propose the following hypothesis 
as a mechanism for the development of diabetic complications. Dehydration stimulates PVN 
neuronal excitation, resulting in the activation of microglia. Alternatively, increased 
peripheral cytokines and/or peripheral angiotensin II in diabetes lead to an increase in the 
production of reactive oxygen species. This can directly activate PVN microglial activation, 
which in turn increases the production of proinflammatory cytokines and reactive oxygen 
species. These chemicals would further stimulate neuronal activity in the PVN via a positive 
feedback mechanism. This increase in the PVN neuronal activity would result in abnormal 
activation of the sympathetic nerve system, and thereby contributes to the development of 
diabetic complications.  
 Clinical implications  9.4
Our observations in this thesis illustrate that STZ-induced hyperglycaemia in a rat model 
produces several symptoms that mimic those in humans with diabetes, especially the 
cardiovascular changes. STZ rats exhibit changes in the baroreflex sensitivity and cardiac 
dysfunction, and these changes are well documented in diabetic humans (chapters 5 and 6); 
however, STZ rats do not show hypertension as seen in humans with diabetes (chapter 3). 
Thus, an STZ rat is an adequate model to investigate the mechanisms of hyperglycaemia 
induced cardiovascular complications of diabetes, which are independent of hypertension, 
and to identify possible therapeutic targets.  
Because of its consequences for many organ systems, diabetic autonomic neuropathy could 
be regarded as the most serious complication of diabetes associated with an increased risk of 
the development of cardiovascular complications. Although several trials have reported that 
controlling blood glucose levels reduces diabetes related complications, this approach does 
not completely prevent the development and progression of these complications. Indeed, our 
finding that inhibiting or reducing microglial activation in cardiovascular autonomic centres 
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prevents the development of cardiovascular complications in STZ diabetic rats are potentially 
of substantial clinical importance. While in type 1 diabetic patients, neuronal abnormalities 
have been found at brain autopsy (Reske-Nielsen et al., 1966), no definitive study of 
neuroinflammation in diabetic humans has been conducted. Thus, in the clinical setting, 
future research is needed to investigate whether inflammation in cardiovascular centres of the 
brain occurs in humans with diabetes. If neuroinflammation is proven, the inhibition of 
microglial activation will provide an exciting new strategy for treating and preventing 
diabetic complications and therefore be beneficial for future generations.  
This thesis not only provides insights into the mechanisms underlying the development of 
diabetic complications, it also provides potential therapeutic interventions that differ from the 
current therapies. We have shown that 1% NaCl intake in the short term increases blood 
pressure in STZ diabetic rats. It is possible that there is no extreme salt depletion at 2 weeks 
in STZ diabetic rats, and these rats obtain more salt than they need. Consequently, a high salt 
intake contributes to an increase in blood pressure. In contrast, drinking 1% NaCl for a longer 
period produces beneficial effects on the cardiovascular system of STZ diabetic rats. It would 
be expected that at 6 weeks, STZ diabetic rats excrete larger amounts of salt in their urine 
than at earlier stages and that drinking 1% NaCl will normalise salt balance and thereby 
inhibit neuroinflammation and improve the function of the cardiovascular system in these 
diabetic animals. Such data suggest that both high and low salt intake may be associated with 
adverse outcomes in diabetes, supporting the complex effects of salt that are evident from 
epidemiological studies. For example, several studies have shown convincing evidence of the 
beneficial effect of low salt intake in terms of the reduction in blood pressure and 
cardiovascular diseases. In the context of type 1 diabetes, dietary salt restriction has also been 
recommended via many international guidelines (Franz, 2008). This recommendation has 
been obtained from a clinical study showing that dietary salt restriction reduced hypertension 
in some but not all patients with type 1 diabetes (Gerdts et al., 1996); however, other clinical 
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studies have demonstrated that low salt intake enhanced the risk of the development of 
cardiovascular disease in diabetic patients (Ekinci et al., 2011; Thomas et al., 2011). 
Consequently, consistent with this data, the beneficial effects of drinking 1% NaCl obtained 
here and in other studies suggest that dietary sodium restriction, which is usually 
recommended in the clinical setting, may not be the best treatment strategy for diabetic 
patients. Therefore, the current recommendation may put diabetic patients at risk for the 
development of cardiovascular disease and other diabetic complications associated with 
increased sympathetic nerve activity. More studies are needed to evaluate the most 
efficacious range of salt intake in these patients. In addition, whether the correction of salt 
intake may also be effective in preventing cardiovascular complications and CNS 
inflammation in individual diabetic humans awaits further investigation. 
 Future directions  9.5
In this thesis, we have demonstrated that microglial activation in the PVN is a major 
contributing factor in the development of cardiovascular complications in STZ diabetic rats. 
The data from chapters 6 and 7 indicated that activated microglia may be in part responsible 
for increased activity of PVN neurons. Studies have shown that when microglia become 
activated, they can release many factors, including proinflammatory cytokines, reactive 
oxygen species, ATP and BDNF, all of which can induce neuronal activity; however, 
determining which specific stimulus from microglia is generating the results presented in this 
study requires future experiments.  
The data from chapters 4 and 6 indicated that microglial activation also occurs in the NTS 
and RVLM, which are involved in cardiovascular regulation and particularly in baroreflex 
receptor responses. There is evidence that inflammation in the RVLM participates in the 
development of hypertension in other diseases (Koga et al., 2008; Braga, 2010; Nunes & 
Braga, 2011; Wu et al., 2012). Furthermore, the microinjection of proinflammatory cytokines 
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(IL-6) into the NTS caused a marked decrease in the baroreceptor sensitivity, which is 
believed to precede hypertension (Takagishi et al., 2010); however, the role of activated 
microglia in the NTS and RVLM in the pathology of the cardiovascular complications in 
diabetic animals is not clear, and further research is required to demonstrate the effect of 
microglial inhibition in these regions. 
As discussed previously, a deficiency in the levels of H2S is reported in diabetic humans (Jain 
et al., 2010), and this deficiency contributes to the development of diabetic complications, 
including diabetic cardiomyopathy and nephropathy (Lefer, 2008; Szabo, 2012). The data 
from chapter 8 provided evidence that the systemic infusion of H2S reduces neuronal 
activation in the PVN in STZ diabetic animals; however, in this study, the consequences of 
H2S on PVN inflammation were not tested due to the lack of microglial activation in short-
term STZ diabetic mice. Thus, future experiments should investigate the effect of H2S 
treatment on microglial activation as well as cardiovascular changes in long-term STZ 
diabetic animals.  
The data from this thesis has provided evidence that an imbalance of salt intake and excretion 
in diabetes can have a negative impact on the cardiovascular system via causing CNS 
inflammation. Due to enhanced urinary excretion in diabetic humans and animals, deficiency 
in other minerals, such as magnesium, may also occur. Magnesium has received substantial 
attention for its roles in the pathogenesis of cardiovascular diseases (Kolte et al., 2014). The 
depletion of magnesium has been reported in patients with type I diabetes (Mooradian & 
Morley, 1987) and STZ diabetic animals (Soltani et al., 2005). Several studies on STZ 
diabetic rats have documented that diabetic complications, including hypertension and 
nephropathy, are improved by treatment with magnesium (Soltani et al., 2005; Parvizi et al., 
2014); however, the possibility that increased dietary magnesium could improve cardiac 
functions in STZ diabetic rats has not been previously investigated. Hence, future 
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experiments could explore whether dietary magnesium can reduce cardiac dysfunction and 
help prevent neuroinflammation in animal models of diabetes.  
 Conclusion  9.6
The impact of diabetic complications, such as cardiovascular disease and diabetic kidney 
disease, on the health and survival of human populations is considerable and is growing 
worldwide, as the number of people with diabetes is increasing at an alarming rate; however, 
protecting diabetic patients from these complications remains a challenge in the field, as the 
exact nature and mechanisms contributing to diabetic complications have not been well 
defined. This thesis provided convincing evidence that neuroinflammation is a potential 
mechanism underling the development of diabetic complications. This thesis also improved 
our understanding of the complex role of salt intake in diabetic complications, providing 
novel knowledge about the mechanisms by which salt intake contributes to the pathogenesis 
of cardiovascular complications in diabetes. Indeed, the data presented here may lead to the 
development of new and better approaches to treating diabetes and its complications.  
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